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Heart failure (HF) is the pathologic inability of the heart to supply the body with sufficient 
amounts of oxygen-rich blood. This increasingly common, life-threatening condition occurs in 
the final stage of various cardiac pathologies that reduce heart function. Common 
pharmacotherapies of HF aim to inhibit the renin-angiotensin system and adrenergic receptors 
that are activated in response to the reduced pumping function and have been available for 
over 20 years. However, the morbidity and mortality rates of affected patients remain high. To 
this day the development of new, more effective therapies poses a major challenge in medical 
research. 
The new therapeutic strategy investigated in this work is based on increasing evidence that 
epigenetics play an important role in the pathogenesis of HF. The rationale behind targeting 
epigenetic processes to treat the development of HF is that they modulate multiple 
transcriptional networks simultaneously. For instance, the small molecule JQ1 was shown to 
displace the bromodomain and extraterminal domain (BET) reader proteins BRD2, BRD3, and 
BRD4 from chromatin, preventing re-expression of the fetal gene program, pathologic 
hypertrophy, and fibrosis after pressure overload (PO). To allow effective and safe application 
of BET inhibition as treatment for HF, it is necessary to assess if targeting BET proteins has 
added benefits in comparison to current pharmacotherapies such as improved survival and to 
elucidate functions of individual BET members specifically in cardiac cells. However, previous 
studies miss to report mortality rates for JQ1 treated animals and do not consider that JQ1 acts 
systemically and inhibits all four BET family members alike. Thus, the mechanisms underlying 
BET-mediated cardio protection remain elusive. 
First, to characterize and validate cardiac BET expression at baseline and in response to PO 
I performed gene expression analysis and immunoblotting using hearts of adult wildtype mice. 
I identified Brd2 as the highest expressed BET family member in the heart with four times 
higher mRNA levels compared to Brd3/Brd4 and revealed TAC-induced expression of the long 
BRD4 isoform. 
Second, to describe the effect of BET inhibition on life expectancy after PO induction I 
monitored the survival of JQ1-treated wildtype mice for up to 2 months after TAC and analyzed 
the hearts using echocardiography as well as histological and molecular methods. I found PO-
dependent mortality unchanged with JQ1-mediated BET inhibition and observed pathologic 
changes such as expression of cardiac stress markers, cardiomegaly, cardiomyocyte 
hypertrophy, interstitial fibrosis, and systolic dysfunction, which were comparable to vehicle-
treated animals after TAC. This contradicts previous reports on cardio-protective features of 
JQ1 in a mouse PO model (Anand et al. 2013). As experimental differences such as sex, age, 
mouse strain, TAC-performance, and JQ1-batch cannot be excluded as explanations for the 
discrepant results, future studies should take these possible confounding factors into account. 
 
VIII 
Moreover, a reliable cardiac-specific biomarker of BET-inhibition should be explored to allow 
successful therapy monitoring. 
Third, using conditional alleles I generated mice expressing a truncated BRD2 protein lacking 
the first bromodomain, Brd2∆BDI, and mice with a cardiomyocyte-specific Brd4-knockout, Brd4 
KO, to investigate whether these gene deletions alter the response to PO. Homozygous 
Brd2∆BDI mice were viable and their hearts and cardiac functions were not significantly 
different from Cre-positive control mice at baseline and after PO induction. In contrast, 
cardiomyocyte-specific homozygous deletion of Brd4 during early embryonic development was 
lethal suggesting that BRD4 is essential during cardiogenesis. For further examination Brd4 
KO was induced at postnatal week five and resulted in animals that were viable for over 12 
months. Adult Brd4 KO mice showed basal concentric hypertrophy, preserved ejection fraction, 
mild interstitial fibrosis, and cardiac stress marker expression. These features are 
characteristic for hypertrophic cardiomyopathy (HCM) and were further supported by 
transcriptome analysis that revealed differential expression of genes involved in extracellular 
matrix remodeling, energy metabolism, sarcomere composition, and cardiac muscle 
contraction. Moreover, Brd4 KO mice subjected to TAC showed significantly higher mortality 
within the first month after surgery, which might be attributed to diastolic dysfunction or 
arrythmias. Nevertheless, no significant wall thickening or left ventricular mass increase, 
despite the basal hypertrophy was observed in Brd4 KO mice after TAC. This lack of stress 
response was confirmed by mRNA sequencing as no relevant changes were detected in Brd4 
KO animals after TAC compared to Sham. However, Brd4 KO mice that survived the acute 
phase of PO showed better heart function in comparison to TAC control. 
My findings suggest that the function of BRD2 in cardiomyocytes is either independent from 
its first bromodomain, substituted by another protein upon disruption, or not essential and 
therefore needs further investigation. Furthermore, beside the established function of BRD4 
as co-activator of cardiac stress response, my findings lead to the conclusion that BRD4 has 
a second function as co-repressor of e.g. pro-hypertrophic genes in the healthy heart. I further 
propose that the shift between both cardiac functions might be mediated by a stress-induced 
switch from the short to the long Brd4 isoform and a respective interaction with e.g. an inactive 
or active P-TEFb complex (Schröder et al. 2012). 
My thesis provides the first functional insight into cardiomyocyte-specific loss of Brd4 in vivo, 
links it to the development of HCM, establishes basal BRD4-mediated negative regulation of 
transcription, and provides evidence for its depletion to blunt stress-response. These findings 
could contribute to the development of more selective therapeutic approaches for HF as 






1.1 Heart failure 
Cardiovascular diseases are the major cause of death worldwide, accounting for over 17 
million deaths per year (WHO 2018). This number is expected to rise by 35% to 23 million 
deaths by 2030 due to increased life expectancies (Heidenreich et al. 2013). The subclass of 
cardiovascular diseases with the strongest increase in incidents is heart failure (HF). 
Prevalence of HF is estimated between 2 and 3% of the population with a strong increase in 
elders with a prevalence between 10 and 20% in 70- to 80-year-old people (Dickstein et al. 
2008). Projections estimate an increase of 46% in HF prevalence from 2012 to 2030 (Benjamin 
et al. 2018). The prognosis for chronic heart failure is poor, with a 5-year mortality rate of about 
50% after initial diagnosis (Dickstein et al. 2008; Heidenreich et al. 2013). Furthermore, HF as 
the leading cause of hospitalization and healthcare expenditures poses a socioeconomic 
challenge for the ageing population (Hill and Olson 2008). In the United States, the total costs 
of all cardiovascular diseases are expected to double by 2030 to about 1 000 billion US dollars 
(Figure 1.1) (Heidenreich et al. 2011). 
 
 
Figure 1.1: Projected total costs of all cardiovascular diseases by age. 
In the US, the total (direct and indirect) costs p.a. for cardiovascular diseases are estimated to double 
by the year 2030 with highest increase for elderly patients at the age of 65-79 years (red) and over 80 
years (blue). Adapted from Heidenreich and colleagues (Heidenreich et al. 2011). 
 
Various pathological conditions such as ischemic heart disease, mitral regurgitation, aortic 
stenosis, congenital cardiomyopathy or alcohol excess have been described to cause HF. 
They all have in common to reduce ventricular function. As a consequence, the heart is not 

































excessive tiredness, multi-organ dysfunction, and premature death (Benjamin et al. 2018). The 
underlying molecular, cellular, and interstitial changes that lead to changed morphology and 
function after heart injury are referred to as cardiac remodeling (Hill and Olson 2008; Azevedo 
et al. 2016). 
1.1.1 Cardiac remodeling 
During the progression to HF, the heart is subject to hemodynamic stress. The ventricular wall 
can either be stretched during diastole by increased blood volume (volume overload) or must 
contract against an increased pressure during systole (pressure overload) (Toischer et al. 
2010; Mohamed et al. 2016). A prominent trigger of pressure overload (PO) is aortic stenosis 
(Rockman et al. 1991; Burchfield et al. 2013; Merino et al. 2018), which is mainly caused by 
calcification of the aortic valve and leads to the narrowing of the ventricle’s outflow tract 
(Rogers 2013). In order to adapt to such altered workload and normalize the reduced 
ventricular function, the heart undergoes cardiac remodeling (Hill and Olson 2008; Azevedo et 
al. 2016; Nakamura and Sadoshima 2018). 
Activation of neuroendocrine stimulation normalizes the output by vasoconstriction and 
increased contractility, whereas cardiomyocyte hypertrophy increases the number of 
contractile units. Initially, this leads to reduction in ventricular chamber dimensions and 
increased wall thickness (concentric hypertrophy), where cardiomyocytes incorporate 
additional sarcomeres, resulting in increased cellular diameters. At this compensated state the 
contractile function is largely preserved. However, persistent stress and prolonged activation 
of those compensatory processes become maladaptive and lead to decompensation with 
contractile dysfunction and finally HF (Figure 1.2). The involved pathological changes include 
dilatation of the ventricular chamber, increased apoptosis, interstitial fibrosis, impaired Ca2+ 
handling, mitochondrial dysfunction, reactivation of the fetal gene program, and altered 
sarcomere structure (Hill and Olson 2008; Toischer et al. 2010; van Berlo et al. 2013; 
Nakamura and Sadoshima 2018). This small set of cellular responses is activated by a 






Figure 1.2: Overview of pathological hypertrophy. 
The heart undergoes remodeling in order to preserve contractility and reduce wall stress in response 
to pathological stimuli. Adaptive changes include the reduction of ventricular diameter and ventricular 
wall thickening (concentric hypertrophy) through increased thickness of individual cardiomyocytes. 
Thus, the heart compensates higher workload and preserves contractility. With persistent stress these 
changes become maladaptive and lead to ventricular dilatation and loss of wall thickness (eccentric 
hypertrophy) with lengthening of cardiomyocytes. This decompensation is accompanied by increased 
apoptosis, interstitial fibrosis, and impaired contractility, finally leading to heart failure. Adapted from 
Nakamura and Sadoshima (Nakamura and Sadoshima 2018). 
 
1.1.2 Molecular mechanisms of cardiac remodeling 
Stress induced proximal signals such as neuroendocrine hormones and mechanical forces 
trigger various signaling pathways (Figure 1.3) that drive cardiac remodeling and progression 
to HF (Hill and Olson 2008; van Berlo et al. 2013). The neuroendocrine hormones angiotensin 
II, endothelin 1, and catecholamines are secreted upon cardiac stress. They bind the G protein 
coupled receptors (GPCRs) angiotensin II receptor, endothelin 1 receptor, and β-adrenergic 
receptors, respectively. These GPCRs indirectly activate second messengers which in turn 
activate effector kinases and phosphatases that influence contractility and gene expression of 
the cardiomyocytes. Catecholamines activate protein kinase A (PKA) via cyclic AMP (cAMP). 
Angiotensin II and endothelin 1 lead to the induction of protein kinase Cα (PKCα), 
calcium/calmodulin-dependent protein kinase type II (CaMKII), and Calcineurin via the Ca2+ 
calmodulin complex. PKA, PKCα, and CaMKII increase contractility by regulating the Ca2+ 
handling proteins ryanodine receptor 2 (RYR2), sarcoplasmic reticulum Ca2+ ATPase 
(SERCA), and phospholamban (PLN) (Zhang 2003; van Berlo et al. 2013; Zhang et al. 2013; 
Newton et al. 2016; Nakamura and Sadoshima 2018). 
Further, CaMKII induces the nuclear export of class II histone deacetylase 4 (HDAC4). Class 
II HDACs 4, 5, and 9 were shown to repress cardiac hypertrophy, whereas class I HDACs 1, 
2, and 3 induce hypertrophy (Backs and Olson 2006; Backs et al. 2009). The Ca2+-activated 
serine/threonine protein phosphatase Calcineurin dephosphorylates nuclear factor of activated 
T-cells (NFAT) and leads to its translocation into the nucleus (Molkentin et al. 1998; Nakamura 
and Sadoshima 2018). The MAPK signaling cascade is induced by activated G proteins in 
cardiomyocytes upon binding of the neuroendocrine hormones. JUN N-terminal kinases 



















(JNKs), p38 kinases, and extracellular regulated kinases 1/2 (ERK1/2) comprise the MAPK 
cascade and are activated by the mitogen-activated protein kinase kinases MEK3/6, MEK4/7, 
and MEK1/2, respectively. JNK and p38 kinases phosphorylate and activate myocyte-specific 
enhancer factor 2 (MEF2) and GATA binding protein 4 (GATA4) (ROSE et al. 2010; Nakamura 
and Sadoshima 2018). In the nucleus, the transcription factors NFAT, MEF2, and GATA4 
induce the expression of pro-hypertrophic genes (van Berlo et al. 2013; Nakamura and 
Sadoshima 2018). 
Furthermore, angiotensin II, endothelin 1, and catecholamines induce mitochondrial 
dysfunction, fibrosis and cell death by increasing levels of reactive oxygen species (ROS) and 
metabolic intermediates. Additionally, the peptide hormones atrial natriuretic peptide (ANP, 
gene Nppa) and brain natriuretic peptide (BNP, gene Nppb) are secreted by cardiomyocytes 
in response to stretching. These hormones act in an autocrine or paracrine manner, lead to 
increased levels of cyclic GMP (cGMP), and thus activate protein kinase G (PKG). PKG inhibits 
cell growth, but the natriuretic peptide receptor (NPR) is desensitized during cardiac 
remodeling and HF (Nakamura and Sadoshima 2018). Existing and experimental 
pharmaceuticals target single components of this complex signaling network to treat pathologic 
remodeling and HF. 
 
 





















































Simplified scheme of signaling pathways activated during cardiac remodeling. Furthermore, current 
treatments (red), FDA-approved drugs that could potentially be used for cardiovascular indications 
(orange), and druggable targets identified in preclinical animal models (blue) are depicted. 
AC= adenylyl cyclase, ACE= angiotensin-converting enzyme, ANP= atrial natriuretic peptide, 
β-AR= β-adrenergic receptor, ARB= angiotensin receptor blocker, ATR= angiotensin II receptor, 
BNP= brain natriuretic peptide, CaMKII= calcium/calmodulin-dependent protein kinase type II, 
ERK1/2= extracellular regulated kinases 1/2, GATA4= GATA binding protein 4, GC= guanylate 
cyclase, HDAC= histone deacetylase, JNK= JUN N-terminal kinase, MAPKKK= MAP kinase kinase 
kinases, MEF2= myocyte-specific enhancer factor 2, MEK= mitogen-activated protein kinase kinase, 
NFAT= nuclear factor of activated T-cells, NPR= natriuretic peptide receptor, p38= p38 kinases, 
PKA/Cα/G= protein kinase A/Cα/G, PLC= phospholipase C, PLN= phospholamban, RYR2= ryanodine 
receptor 2, SERCA= sarcoplasmic reticulum Ca2+ ATPase. (adapted from (Nakamura and Sadoshima 
2018), (van Berlo et al. 2013)). 
 
1.1.3 Pharmacotherapies 
Available pharmacotherapies of HF patients target neurohormonal signaling pathways by 
inhibiting the renin-angiotensin system (angiotensin-converting enzyme inhibitors, 
angiotensin receptor blockers) or antagonizing beta-adrenergic receptors (β-blockers) 
(Figure 1.3) and have been shown to improve survival in HF patients. However, the 
therapeutic efficacy of this approach is limited, as morbidity and mortality remain high 
(Benjamin et al. 2018). Therefore, it is necessary to identify new therapies for this common, 
costly, and potentially fatal condition. Various preclinical and clinical studies pursuing this 
goal focus on the inhibition of single targets such as different MAPK kinases, PKCα, or 
CaMKII (Figure 1.3) (van Berlo et al. 2013). Some of these strategies seem promising but 
they have in common to target only single components of the complex signaling network 
activated during cardiac remodeling. This might be disadvantageous, especially because of 
the redundancy of different signaling cascades in activation of few transcription factors (e.g. 
NFAT, MEF2, GATA4), which induce pathologic gene expression (Hill and Olson 2008; van 
Berlo et al. 2013).  
Nevertheless, cellular responses do not result from the activation of transcription factors alone. 
It is rather the interplay of DNA-binding regulators with the chromatin structure and the 
epigenetic landscape in general that drive changes in cell state (Anand et al. 2013). In the 
heart, chromatin remodeling mechanisms such as post-transcriptional histone modifications 
and DNA methylation were shown to associate with stress-induced pathways of pathological 
hypertrophy and HF (McKinsey and Olson 2005; Gilsbach et al. 2014). As changes in 
chromatin structure modulate multiple transcriptional networks simultaneously, chromatin-
dependent gene regulatory mechanisms constitute potent therapeutic targets to suppress 
pathologic gene expression associated with cardiac remodeling and development of HF 




1.2 Epigenetics and gene regulation 
Epigenetic mechanisms not only organize genetic information but enable the implementation 
of external input into genomic instructions. This allows dynamic and contextual regulation of 
the transcriptome (McKinsey and Olson 2005; Duygu et al. 2013). Genetic information is 
packaged as a complex between DNA, histone and nuclear non-histone proteins. The smallest 
organizational units that are used to package DNA are nucleosomes. A nucleosome consists 
of 147 base pairs (bp) of DNA wrapped around a histone octamer that consists of two copies 
of the four core histones (H2A, H2B, H3, and H4) (Tonna et al. 2010; Duygu et al. 2013; 
Mahmoud and Poizat 2013; Khalil 2014). The resulting “bead on a string”-like DNA fiber is 
further condensed to chromatin (Figure 1.4) (Tonna et al. 2010). Based on the DNA-
accessibility, chromatin is further classified into the highly condensed and mostly inactive 
heterochromatin or the more accessible and transcriptionally active euchromatin. To allow 
transcription, packaged DNA is dynamically modified by ATP-dependent nucleosome 
remodelers (Tonna et al. 2010; Bell et al. 2011; Blakey and Litt 2015a). 
The three major epigenetic mechanisms are expression of non-coding RNA species, DNA 
methylation, and post-translational modifications (PTMs) of the unstructured amino-terminal 
tail of histones (“histone tail”). Non-coding RNAs represent the largest part of the transcriptome 
and are divided into subgroups of long non-coding RNAs, small interfering RNAs and micro 
RNAs (miRNAs) (Duygu et al. 2013; Mahmoud and Poizat 2013; Khalil 2014). The best studied 
non-coding RNAs are miRNAs. They are about 22 nucleotides long and were shown to 
catalyze gene silencing by binding to messenger RNA (mRNA) (Ambros 2004). DNA 
methylation is a process by which a methyl group is transferred to a cytosine that precedes a 
guanine nucleotide (CpG) catalyzed by DNA methyl-transferases (DNMTs). DNA methylation 
is an essential process during development and is typically associated with transcriptional 
repression (Gilsbach et al. 2014). Common PTMs of histone tails include acetylation, 
methylation, phosphorylation, and ubiquitination. These modifications are enzymatically added 
or removed, alter chromatin structure, thus, modulate DNA accessibility, and regulate gene 
expression (Mahmoud and Poizat 2013; Blakey and Litt 2015a; Blakey and Litt 2015a). 
The various cellular mechanisms controlling expression or repression of specific gene products 
(RNA or protein) can be summarized by the term “gene regulation”. There are three levels of 
gene regulation: transcriptional, post-transcriptional, and post-translational gene regulation 
(Harrison and Shanahan 2014). Figure 1.4 shows a schematic overview of gene regulatory 
mechanisms. On a global scale, chromatin structure and remodeling play an important role in 
transcriptional regulation by maintaining the overall accessibility to the DNA (Bell et al. 2011; 
Keung et al. 2015). Chromatin structure can be changed by DNA modifications, such as 
methylation or hydroxy-methylation of cytosine residues, and by post translational 




(Mahmoud and Poizat 2013). On a single gene scale, transcription factors regulate gene 
expression by binding regulatory DNA elements (enhancers) and recruiting transcriptional 
complexes to the promoter close to the transcriptional start sites of target genes (Spitz and 
Furlong 2012). Beside classical DNA-binding transcription factors, proteins recognizing 
specific histone tail modifications, so called chromatin readers, were shown to regulate gene 
expression by several interactions with the general transcriptional machinery (Jiang et al. 1998; 
Jang et al. 2005; Yang et al. 2005). 
Post-transcriptional regulation occurs on the mRNA level during transcription, transcript 
processing, or translation. Processing of mRNA (e.g. alternative splicing, poly-adenylation, and 
capping) regulates the exon-composition, translation rate, and transcript stability. RNA 
methylation by specific methyl-transferases has been shown to reduce mRNA half-life (Wang 
et al. 2014) but increase translation efficacy (Wang et al. 2015). Non-coding RNAs were shown 
to directly regulate transcription (Holoch and Moazed 2015; Catalanotto et al. 2016), to 
catalyze mRNA degradation, or inhibit translation via various mechanisms (Fabian et al. 2010). 
Post-translational mechanisms involve proteolytic processing or degradation, translocation, 
and diverse modifications of proteins (e.g. methylation, acetylation or phosphorylation) (Karve 
and Cheema 2011). Histone acetyl transferases, for example, acetylate histone tails which are 
then recognized by specialized reader proteins that, in turn, recruit co-activators to regulate 
the transcription of target genes (Gillette and Hill 2015). This example shows the complexity 







Figure 1.4: Organization of chromatin and gene regulatory mechanisms. 
Genetic information is organized as chromatin which is a highly condensed form of a complex between 
DNA and histone proteins. The smallest organizational units of chromatin are nucleosomes that are 
used to package DNA. A nucleosome consists of 147 bp of DNA wrapped around dimers of the four 
core histones, the histone octamer. Various cellular mechanisms regulate gene expression. Both, DNA 
modifications (methylation or hydroxy-methylation) and post-translational modifications of histone tails 
can change chromatin structure to be more accessible (active) or condensed (repressed). Transcription 
can be activated or blocked at a specific position by either DNA-binding proteins (transcription factors) 
that recognize specific promotors, or by specialized “readers” of chromatin modifications. Post-
transcriptional mechanisms include alternative splicing, RNA methylation or silencing by non-coding 
RNAs. Non-coding RNAs can directly regulate transcription or inhibit translation via various 
mechanisms. Post-translational mechanisms involve proteolytic processing or degradation, 
translocation, and diverse modifications (e.g. methylation, acetylation or phosphorylation) of proteins. 
HAT= histone acetyl transferase, HDAC= histone deacetylase, Tcf= transcription factor, Ac= acetyl 
group, Me= methyl group, P= phosphoryl group, nm= nanometer. Adapted from Tonna and colleagues 


















































1.2.1 Histone code: of writers, erasers and readers 
The possible combinations of methyl, acetyl, and phosphoryl groups on different histone 
residues are referred to as the histone code (Jenuwein 2001). Three protein classes, writers, 
erasers and readers, are involved in the establishment and translation of the histone code 
(Jenuwein 2001; Gillette and Hill 2015). Writers like histone methyl transferases add 
modifications to histone tails. Erasers like histone demethylases remove those modifications. 
Chromatin readers recognize various modification patterns on histone tails and for example 
recruit transcriptional regulators (Gillette and Hill 2015). The histone code with its dynamic 
PTMs, together with the combinatorial pattern recognition of chromatin readers enables a high 
level of chromatin plasticity and, thus, selective spatiotemporal transcriptional regulation 
(Jenuwein 2001; Blakey and Litt 2015a; Blakey and Litt 2015b). 
N-ε-acetylation of lysine residues is the most frequent PTM of histones and is regulated by 
histone acetyl transferases (HATs) and histone deacetylases (HDACs). HATs are writers and 
add acetyl groups, whereas, HDACs act as erasers and remove acetyl marks. Histone 
acetylation is an important process in general development and various diseases. For 
instance, aberrant expression of HDACs and altered histone acetylation patterns deregulate 
transcription and contribute to the development of cardiomyopathies (Backs and Olson 2006; 
Mahmoud and Poizat 2013). Generally, acetylated chromatin is associated with open 
chromatin and transcriptional activation but also DNA repair (Bell et al. 2011). Chromatin 
readers with one or more bromodomains selectively recognize acetylated lysine residues and 
recruit chromatin remodelers and other effector complexes to target sites in the chromatin 
(Filippakopoulos et al. 2012), thus, promoting gene transcription (Jiang et al. 1998; Jang et al. 
2005; Yang et al. 2005). The bromodomain is an evolutionary conserved protein domain 
comprised of about 110 amino acids. There are 61 bromodomain-containing proteins in 
human, which can be classified in eight families by structure similarity. These include various 
nuclear proteins like HATs (PCAF), transcriptional co-activators (TAFs, TRIM/TIF1), and the 
bromodomain and extra-terminal domain (BET) proteins (Filippakopoulos et al. 2010; 
Filippakopoulos et al. 2012). 
1.2.2 BET protein family members 
Members of the BET protein family (Figure 1.5A) include the ubiquitously expressed BRD2, 
BRD3, BRD4, and the testis specific BRDT, all of which have two tandem N-terminal 
bromodomains (BDI and BDII) and an extra-terminal (ET) domain (Figure 1.5B) (Houzelstein 
et al. 2002; Shang et al. 2007; Shang et al. 2009; Filippakopoulos et al. 2010). BET chromatin 
readers were shown to specifically bind acetylated lysine residues of histone tails 




transcriptional complexes like mediator (Jiang et al. 1998) and the positive transcription 
elongation factor b (P-TEFb) (Jang et al. 2005; Yang et al. 2005) to acetylated chromatin. 
BET proteins have been shown to be essential for embryonic development and differentiation 
in the mouse model. Both, Brd2 (Shang et al. 2007; Gyuris et al. 2009; Shang et al. 2009; 
WANG et al. 2009) and Brd4 (Houzelstein et al. 2002) homozygous for the respective null 
allele are embryonic lethal. 
Brd4-/- embryos die shortly after implantation at about embryonic day 5.5 (E5.5) and explanted 
blastocyst are not able to maintain the inner cell mass. Brd4+/- animals display pre- and 
postnatal growth defects, significant mortality in the first two weeks of postnatal life, and various 
anatomical abnormalities like abnormal head shape, abnormally thick epidermis, reduced 
subcutaneous fat, abnormal liver cells, and cataracts. Isolated Brd4+/- fibroblasts show reduced 
proliferation rates and increased sensitivity to the DNA-damaging agent methyl methane 
sulfate (Houzelstein et al. 2002). 
In comparison, Brd2-/- embryos survive until E12.5 and show reduced growth, defects in neural 
tube closure, and an increase in cell death, before they get resorbed. Isolated fibroblasts from 
these embryos do also proliferate more slowly than fibroblasts from wildtype embryos (Shang 
et al. 2007; Gyuris et al. 2009; Shang et al. 2009; WANG et al. 2009).  
Consistent with these findings, BET proteins have been shown to play an important role in the 
cell cycle (Dey et al. 2009; Zhao et al. 2011). For instance, BRD4 stays at H4K5ac during 
mitosis, marks the start sites of many M/G1 genes, accelerates the expression of G1 genes, 
and promotes the progression to S phase (Dey et al. 2009; Filippakopoulos et al. 2010). Due 
to their involvement in cell cycle and gene regulation, BET proteins have been proposed as 
promising therapeutic targets in cancer (Filippakopoulos et al. 2010; Helin and Dhanak 2013), 
which led to the development of various small molecules like I-BET, I-BET-151, RVX-208, PFI-
1 and JQ1 that specifically block the BET bromodomains (Filippakopoulos et al. 2010; Fu et 
al. 2015; Pérez-Salvia and Esteller 2017).  
JQ1 was the first-in-class potent and highly selective BET inhibitor available and was shown 
to displace BET bromodomains from acetylated chromatin by competitive binding and, thus to 
suppress transcription of downstream targets (Filippakopoulos et al. 2010; Delmore et al. 
2011). BET inhibition by JQ1 was used to investigate BET function in pathologic conditions 
such as cancer (Filippakopoulos et al. 2010; Delmore et al. 2011), HIV infection (Banerjee et 






Figure 1.5: Phylogenetic tree of bromodomain-containing proteins and structure of BET proteins. 
Phylogenetic tree showing the eight families (I-VIII) of human bromodomain-containing proteins 
(adapted from (Filippakopoulos et al. 2012)) (A). Main features of BET proteins (adapted from (Fu et 
al. 2015)) (B). BDI/II= bromodomain 1/2, BET= bromodomain and extraterminal domain proteins, 
CTD= C-terminal domain, ET= extraterminal domain. 
 
1.2.3 The role of BET proteins in the heart 
The potential of BET inhibition in the heart has first been discovered in a high throughput assay 
of cardiomyocyte hypertrophy. Using phenylephrine-stimulated primary neonatal rat ventricular 
myocytes (NRVMs), an in vitro model for adrenergic activation, JQ1 was found to block 
hypertrophy and suppress expression of ANP, BNP, and SERCA2 mRNA (Anand et al. 2013; 
BRD2 BDI
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Spiltoir et al. 2013). BET inhibition by JQ1 was further investigated in vivo in mice that were 
subjected to transverse aortic constriction (TAC), a murine pressure overload model. TAC 
induces cardiac remodeling, hypertrophy and left ventricular systolic dysfunction (Rockman et 
al. 1991). Daily administration of JQ1 for 4 weeks, however, was shown to block pathologic 
cardiac hypertrophy, to preserve cardiac function, and to attenuate cardinal histopathologic 
features of HF in mice subjected to TAC (Anand et al. 2013; Spiltoir et al. 2013).  
In particular, morphometric and echocardiographic analyses revealed that JQ1 protects the 
heart from left ventricular wall thickening and dilatation, preserves the left ventricular mass, 
and protects the animals from systolic dysfunction after TAC. Furthermore, JQ1 was shown to 
normalize cardiomyocyte size, attenuate apoptosis, and reduce interstitial fibrosis after TAC, 
as demonstrated by histologic staining. As shown by quantitative real time PCR, JQ1 inhibits 
the expression of hypertrophic marker genes like Nppa and Nppb (Anand et al. 2013; Spiltoir 
et al. 2013). Moreover, global gene expression analysis revealed that JQ1-treatment reverses 
the expression of TAC-induced genes to levels of Sham-treated hearts, and that these genes 
show an enrichment for biological processes described for cardiac remodeling and 
development of HF like cell cycle regulation, cytoskeleton assembly, response to wounding, 
growth, and extracellular matrix organization. Gene set enrichment analysis (GSEA) of the 
TAC-induced genes showed a positive enrichment for HF gene sets that result from 
Calcineurin, NFΚB and GATA4 activation, which were negatively enriched with JQ1-treatment 
after TAC (Anand et al. 2013). 
These cardio protective effects of BET inhibition have mostly been brought into context of 
BRD4, which was shown to be the highest expressed BET protein in the heart that gets further 
activated by hypertrophy (Anand et al. 2013; Spiltoir et al. 2013). Chromatin 
immunoprecipitation (ChIP) sequencing showed strong enrichment of BRD4 at active 
transcriptional start sites and at the majority of active enhancers in the murine heart (Anand et 
al. 2013). Thus, BRD4 was shown to promote the expression of the pro-hypertrophic ANP, and 
the connective tissue growth factor (CTGF) after TAC. Mechanistically BET proteins have been 
proposed to mediate transcriptional pause release through activation of the P-TEFb complex, 
which phosphorylates the C-terminal domain of RNA polymerase II (Anand et al. 2013).  
These data show that BRD4 is induced in response to hypertrophic stimuli, enriches at 
transcriptional start sites and enhancers of a specific gene set, and plays a crucial role in the 
integration of pro-hypertrophic transcription factors like NFAT and GATA4. Therefore, BRD4 
was proposed as co-activator of hypertrophic gene expression (Haldar and McKinsey 2014). 
These studies demonstrate that BET proteins are promising therapeutic targets for HF. Indeed, 
BET inhibition is being established in human in the clinical trials with RVX-208 as therapeutic 
approach to reduce major adverse cardiac events in high-risk cardiovascular disease patients 




BRD3 although they were detected in the heart as well (Anand et al. 2013; Spiltoir et al. 2013; 
Duan et al. 2017) and are also affected by BET inhibitors like JQ1 (Filippakopoulos et al. 2010). 
1.3 Objectives 
To ensure safety and efficacy of BET inhibitors as treatment of HF and to support the 
development of novel compounds, it is important to first identify the exact functions of individual 
BET members in cardiac cells: This would help to understand how BET inhibition directly 
affects the heart and could potentially help to refine this therapeutic approach. Therefore, 
further investigation on the roles of BET proteins in the heart are necessary and should answer 
the following questions: (i) what are the functions of the individual BET proteins in the heart? 
(ii) do the cardio protective effects of BET inhibition improve the prognosis of established 
pressure overload? and (iii) can the depletion of individual BET proteins in cardiac cells 
replicate the cardio protective properties of BET inhibition by JQ1? 
Haldar and McKinsey suggested that the generation of conditional BET alleles is essential to 
allow the detailed examination of particular BET proteins and their individual functions in 
cardiac cells (Haldar and McKinsey 2014). In order to elucidate the cardio protective properties 
of BET inhibition and the contribution of BET chromatin readers to cardiac remodeling and the 
development of heart failure, the aims of my thesis are to: 
 
1. Measure BET mRNA and protein levels in the healthy and diseased murine heart 
I will describe cardiac BET expression by mRNA sequencing, quantitative PCR, 
immunoblotting, and immunocytochemistry in healthy adult mice and in mice with TAC-
induced PO. 
2. Analyze the impact of JQ1-mediated BET inhibition on the survival of mice in the first two 
months after TAC 
To investigate if BET inhibition influences PO-mediated mortality, I will monitor the survival 
of JQ1-treated mice for eight weeks after TAC. Further, I will compare the effects of JQ1 
and vehicle on pathogenesis four and eight weeks after PO-induction using histological, 
molecular, and echocardiographic methods. 
3. Generate and validate mice with a cardiomyocyte-specific disruption of Brd2 and Brd4  
To enable in vivo analysis of loss-of-function for particular BET members in specific tissues, 
conditional Brd2 and Brd4 alleles were previously generated in our group. My aim is to 
generate mice with a cardiomyocyte-specific disruption of Brd2 and Brd4, respectively, by 
using our conditional alleles. To validate the Cre-mediated gene disruption, I will analyze 
cardiac DNA, mRNA, and protein levels in the resulting mice via PCR and immunoblotting. 
4. Examine the influence of Brd2 and Brd4 disruption on heart morphology and function in 




My aim is to phenotype the hearts of the newly generated mice with a cardiomyocyte-
specific disruption of Brd2 or Brd4 by histological, morphometric, and echocardiographic 
measurements. 
5. Investigate if loss of Brd2 or loss of Brd4 function in cardiomyocytes can protect the heart 
from TAC-mediated pathologic changes 
Data from BET inhibition by JQ1 suggest that BET proteins activate pro-hypertrophic genes 
upon induction of cardiac stress. In the final part of my thesis I investigate in vivo if and 
how the disruption of Brd2 and Brd4 in cardiomyocytes affects the heart’s response to 
pressure overload. To identify changes in mortality, morphology, histopathology, stress 
signaling, and heart function I monitor the survival of the animals for over 4 months after 
PO-induction and perform morphometric, histological, molecular, and echocardiographic 
analyses 5 weeks after TAC. 
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2 Materials and Methods 
2.1 Animals 
2.1.1 Animal welfare 
All animal experiments were approved and conducted in accordance with institutional and 
governmental guidelines. All animals in context of this thesis were maintained under standard 
laboratory conditions with 12 hours light/dark cycling and access to food and water ad libitum. 
C57BL/6N mice were delivered from Charles River, all other animals were bred in-house. 
Animals were kept in groups of 5 and were allowed to habituate for 1-2 weeks prior to 
interventions. 
2.1.2 Generation of mouse strains 
Two conditional knockout (KO) mouse lines were used in this study. In the Brd2 conditional 
KO mouse line (Brd2fl/fl, C57BL/6N and C57BL/6J mixed background), the coding exons 3 and 
4 of Brd2 gene were flanked by loxP sites (Benito et al. unpublished). The Brd2 alleles were 
genotyped using primers Brd2-KO-F and Brd2-KO-R. PCR amplified 210 bp from the wildtype 
and 320 bp from the floxed allele. Male Brd2fl/fl mice were crossed with αMHC-Cre females 
(Jackson no. 011038, C57BL/6N and C57BL/6J mixed background) (Agah et al. 1997) to 
generate αMHC-Cre;Brd2fl/fl mice.  
In the Brd4 conditional KO mouse line (Brd4fl/fl, C57BL/6N and C57BL/6J mixed background), 
the exons 6 and 7 of the Brd4 gene were flanked by loxP sites (Benito et al. unpublished). The 
Brd4 alleles were genotyped using primers Brd4-GT-F and Brd4-GT-R. PCR amplified 251 bp 
from the wildtype and 362 bp from the floxed allele. Male Brd4fl/fl mice were crossed with 
αMHC-Cre (Jackson no. 011038, C57BL/6N and C57BL/6J mixed background) or αMHC-
MerCreMer (C57BL/6J background) females to generate αMHC-Cre;Brd4fl/fl or αMHC-
MerCreMer;Brd4fl/fl mice. αMHC-MerCreMer mice were a gift from Dr. Laura Zelerayan and 
originally generated by Dr. Jeffrey Molkentin (Sohal et al. 2001). 
2.1.3 JQ1 treatment 
JQ1 was a kind gift from Dr. Jun Qi and James Bradner, MD, from the Dana-Farber Cancer 
Institute (Boston, Massachusetts). The compound was dissolved in dimethyl sulfoxide (DMSO) 
(Sigma, #D2650-5X10ML) to produce a concentrated stock at a concentration of 50 mg/ml and 
stored in aliquots at -20°C. Before application, appropriate amounts of the JQ1 stock were 
thawed and diluted in 9 parts of 10% 2-Hydroxypropyl-β-cyclodextrin (10% HP-β-CD) (Sigma, 
C0926-5G) to obtain a JQ1 working solution. The JQ1 working solution was delivered daily for 
28 consecutive days by intraperitoneal injection at concentration of 50 mg/kg/day starting one 
day after surgery. As control, half of the animals received DMSO in 10% HP-β-CD (vehicle). 
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The experiments were conducted in C57BL/6N female mice, which were randomly assigned 
to either the JQ1- or the vehicle treatment group. 
2.1.4 Tamoxifen application 
In order to activate Cre-recombinase in αMHC-MerCreMer positive mice Tamoxifen was 
applied. To prepare Tamoxifen working solution at a concentration of 10 mg/ml, 50 mg 
Tamoxifen (Sigma, T5648) were suspended in 100% ethanol and subsequently dissolved in 
4.5 ml Miglyol (Caelo, #3274) by vigorous shaking. The Tamoxifen solution was delivered to 
5-week-old animals by intraperitoneal injection at a dosage of 30 mg/kg/day for three 
consecutive days (Bersell et al. 2013). 
2.1.5 Echocardiography 
The heart function and dimensions of untreated, Sham, and TAC operated mice were 
examined by transthoracic echocardiography using a Vevo 2100 system equipped with a MS-
400 30 MHz transducer (Visualsonics) as previously described (Pistner et al. 2010). Fractional 
flow reserve was calculated from pressure gradients across the transverse aorta, which were 
measured by Doppler echocardiography with a 20 MHz transducer (MS-250). Therefore, the 
animals were first anesthetized with isoflurane (1-2 %) using a respiratory mask and their 
thorax depilated with hair removal cream. Short sequences of the beating hearts were recorded 
in B-mode in the long axis or the short axis view and M-Mode in mid papillary view, respectively. 
During the recordings vital parameters were monitored to stay in the defined range (body 
temperature, heart rate, respiration). 
Using the LV-trace function of the VevoLab software (version 3.1.0), echocardiographic M-
Mode images were analyzed to determine heart dimensions: anterior wall thickness 
(AWThd/s), posterior wall thickness (PWThd/s), left ventricular enddiastolic diameter (LV-
EDD), left ventricular endsystolic diameter (LV-ESD), and heart rate. These parameters were 
used to calculate characteristic variables (Appendix Table 5.1) such as ejection fraction (EF), 
fractional shortening (FS), left ventricular mass, and left ventricular weight to body weight ratio. 
Echocardiography was performed by the SFB1002 service team Marcel Zoremba and Roland 
Blume (Cardiology and Pneumology, University Medical Center Göttingen). The data was 
analyzed in a blind test with respect to genotype and treatment. GraphPad Prism (v. 7.03) was 
used to plot and analyze data. Two-way ANOVA with Tukey post-hoc test (p<0.05), if not stated 
otherwise, was used to determine statistical significance among groups. 
2.1.6 Transverse aortic constriction (TAC) 
Transverse aortic constriction has been previously described (Rockman et al. 1991; Hu et al. 
2003; deAlmeida et al. 2010). The aim of this surgical procedure is to reduce the diameter of 
the transverse aorta. Mice aged 8-10 weeks were randomized into Sham or TAC groups. Right 
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before surgery, mice were anesthetized by intraperitoneal injection of 50 µl 0.9% sodium 
chloride solution containing Medetomidin (0.5 mg/kg), Midazolam (5 mg/kg) and Fentanyl (0.05 
mg/kg).  
A 1-1,5 cm long suprasternal incision was made, and the aortic arch was visualized using a 
binocular operating stereoscope. The thymus and fat tissue were gently separated from the 
aortic arch. After identification of the transverse aorta, a 6-0 polyviolene suture was placed 
between the first and second trunk of the aortic arch and two loose knots were tied. To 
standardize the constriction, a 27 gauge blunt needle was placed parallel to the transverse 
aorta, the knots fastened and the needle removed. For the Sham control surgery, the 
procedure is identical except for the constriction of the aorta. The mouse is closed using a 6-0 
prolene suture. 
After surgery the anesthesia was antagonized by subcutaneous injection of 50 µl 0.9% sodium 
chloride solution containing Atipamezol (2.5 mg/kg) and Flumazenil (0.1 mg/kg). 
Subcutaneous injection of Buprenorphin in the common dose of 0.05-0.1 mg/kg was used for 
analgesia. The mouse was allowed to recover on a heating pad. 
3 days later, Doppler velocity was measured using a 20 MHz probe to quantify the pressure 
gradient across the TAC/Sham region by transthoracic echocardiography. During 3 days after 
surgery, mice received analgesic therapy with carprofen (subcutaneous) and animal health 
status was checked every day. 1, 4 and 8 weeks after surgery, mice were analyzed by 
echocardiography and hearts were harvested for molecular characterization or histology. 
Surgeries were performed by Sarah Zafar (AG Zimmermann, Pharmacology and Toxicology, 
University Medical Center Göttingen), Sabrina Koszewa and Alessya Kretzschmar (AG 
Toischer, Cardiology and Pneumology, University Medical Center Göttingen). Power 
calculation using G*Power (v.3.1.9.2) (Faul et al. 2007) was performed to determine sample 
sizes based on mean ejection fractions of animals subjected to Sham and TAC in previous 
studies from our group (Appendix Figure 5.1).  
2.1.7 Heart dissections 
Mice were anesthetized with isoflurane and sacrificed by cervical dislocation. The body weight 
was determined before dissection. Next, the thorax was cut open and the heart excised at the 
aorta and transferred into a petri dish filled with sterile saline. A 21 gauge blunt needle was 
carefully placed into the aorta and fixed with fine forceps allowing a retrograde perfusion with 
sterile saline to remove residual blood. The heart was weighted, atria and the right ventricle 
removed, and the left ventricle weighted again before it was snap frozen in liquid nitrogen. The 
tibia was dissected and measured using an electronic gauge. 
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2.2 Molecular analysis 
2.2.1 In-silico oligonucleotide design 
Oligonucleotides for legacy PCRs were designed with DNADynamo (BluetractorSoftware), 
whereas RT-qPCR primers were designed using Primer-BLAST 
(https://www.ncbi.nlm.nih.gov/tools/primer-blast/). Primer-BLAST was operated with the 
following settings, product size: 100-200 bp; exon junction span: may not span exon-exon 
junction; intron inclusion: yes (if possible); organism: Mus musculus (taxid:10090); allow splice 
variants: yes. Melting temperatures were calculated using the Thermo Fisher Tm Calculator 
(https://www.thermofisher.com/de/de/home/brands/thermo-scientific/molecular-
biology/molecular-biology-learning-center/molecular-biology-resource-library/thermo-
scientific-web-tools/tm-calculator.html). All oligonucleotides were synthesized by Eurofins 
Genomics. 
2.2.2 Genotyping 
The genotypes of genetically modified mice were analyzed by legacy PCR using primers 
depicted in Table 2.1 and MangoTaqTM Polymerase (Bioline, BIO-21078). To isolate genomic 
DNA (gDNA), tail biopsies were digested overnight in 200 µl DirectPCR-Tail lysis buffer 
(Viagen Biotech, #102-T) including 200 µg/ml Proteinase K at 55°C and 400 rpm on a heating 
block. Proteinase K was heat inactivated for 45 min at 85°C prior to the assembly (Table 2.2) 
and run (Table 2.3) of the PCR reaction. 
Table 2.1: Genotyping primer 
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Table 2.2: Standard genotyping reaction  Table 2.3: Standard genotyping protocol 
Reagents Volume (µl)  Step Temp. (°C) Time 
5x reaction buffer (colored) 4.0  Denaturation 95 3 min 
MgCl2 (50 mM) 1.5  Amplification 
(x30) 
95 30 sec 
dNTPs (100 mM) 0.5  58-60 30 sec 
Forward primer (10 pmol/µl) 1.0  72 30 sec 
Reverse primer (10 pmol/µl) 1.0  Elongation 72 5 min 
gDNA 1.5     
H2O (to 20 µl) 10.3     
Mango-Taq polymerase  0.2     
 
The PCR reactions, together with a 100 bp DNA ladder (Thermo Fischer, SM1153), were 
separated by gel electrophoresis for 45 min at 120 V in a TBE (45 mM Tris-borate, 1 mM 
EDTA) buffered 2 % agarose gel. The ethidium bromide (0.2-0.5 µg/ ml gel) stained DNA was 
imaged using the Alpha Imager gel documentation system (Protein Simple). 
2.2.3 RNA isolation 
In order to reproducibly obtain high quality RNA from heart samples or isolated cardiomyocytes 
the RNeasy Fibrous tissue Mini kit (Qiagen, 74704) was used according to the manufacturer’s 
manual. 
In short, up to 30 mg of snap frozen heart tissue or 10-25 µl pellet of isolated cardiomyocytes 
was placed into a 2ml tube containing a 7 mm stainless steel bead (Qiagen, 69990) and 300 
µl RLT buffer with 40 mM DTT and homogenized for 5 min and 50 Hz using a Tissue Lyser LT 
(Qiagen, 85600). After addition of 590 µl RNase-free water and 10 µl Proteinase K, the lysate 
was incubated for 10 min at 55°C and spun for 3 min at 10,000 x g. The clear supernatant was 
transferred into a fresh 1.5 ml tube and mixed with 0.5 vol of 100% ethanol. The precipitated 
RNA was transferred to a spin column and bound to the silica membrane spinning for 15 sec 
at 10,000 x g. After washing with 350 µl buffer RW1 and spinning for 15 sec at 10,000 x g the 
membrane was incubated for 15 min at room temperature with 10 µl DNase I in 70 µl RDD 
buffer followed by a second wash with buffer RW1. Next, the membrane was washed twice 
with 500 µl buffer RPM (supplemented with 100% ethanol) and first spun for 15 sec at 10,000 
x g and second for 1 min at 10,000 x g. After incubating with 30 µl elution buffer for 1 min at 
room temperature, the RNA was eluted into a fresh RNase-free 1.5 ml tube by spinning for 1 
min at 10,000 x g and immediately placed on ice. All isolation steps were carried out at room 
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temperature. Based on the absorbance at 260nm, the RNA concentrations were 
photometrically determined using a Nanodrop 2000 (Thermo Fisher). The RNA was 
subsequently used for reverse transcription (RT) or stored at -80°C. 
2.2.4 cDNA synthesis 
For gene expression studies, total RNA was reverse transcribed into complementary DNA 
(cDNA) using the iScript™ cDNA Synthesis Kit (Bio-Rad, 1708891). 
To allow for cloning of the complete coding region of a gene of interest, total RNA was reverse 
transcribed using the Superscript IV reverse transcriptase (Thermo Fischer, 18090010) 
together with Oligo (dT) primers (Thermo Fischer, 18418012) according to the manufacturer’s 
instructions. 
2.2.5 Molecular cloning 
To analyze the Brd2 mRNA sequence of Brd2∆BDI mice, total left ventricular RNA (2.2.3) was 
reverse transcribed using Superscript IV reverse transcriptase and Oligo (dT) primers (2.2.4). 
Brd2 was amplified from cDNA using custom made primers annealing upstream of the start 
codon (5’-GCTGAGCGGCGGCGGTTCC-3’) and downstream of the stop codon 
(5’-GAGCCTTCCTGCCCCATCTGGCC-3’), respectively, using Phusion® High Fidelity DNA 
Polymerase (New England Biolabs, M0530S) according to the manufacturer’s protocol. The 
PCR product was purified by 1% agar (Peqlab) gel-electrophoresis in TAE-buffer (40 mM Tris, 
20 mM acetic acid, 1 mM EDTA), extracted with Monarch® DNA Gel Extraction Kit (New 
England Biolabs, T1020S), and ligated into pMiniTTM 2.0 vector with NEB® PCR Cloning Kit 
(New England Biolabs, E1202S). The resulting plasmid was transformed into NEB® 10-beta 
Competent E. coli (New England Biolabs, C3019H), amplified, purified with Nucleospin 
Plasmid EasyPure (Macherey-Nagel, #740727.50), and validated by Sanger sequencing with 
Sp6-20 (5’-CTATTTAGGTGACACTATAG-3’) and T7prom (5’-TAATACGACTCACTATAGGG-
3’) standard primers (LGC Genomics, FlexiRun). The sequencing results were aligned to Brd2 
cDNA sequence (CCDS28641.1) and analyzed using DNADynamo (BluetractorSoftware). 
2.2.6 Quantitative real time PCR 
To analyze gene expression levels reverse transcription quantitative real-time PCR (RT-qPCR) 
was performed. Primers (Table 2.4) were designed using Primer-BLAST 
(https://www.ncbi.nlm.nih.gov/tools/primer-blast/) as described in “nucleotide design”. The 
SsoAdvanced Universal SYBR Green Supermix (Bio-Rad, #1725272) was diluted with 
nuclease-free water, supplemented with primers according to Table 2.5 and transferred into 
ice-cooled 96 well plates (Bio-Rad, #2239441) where cDNA or nuclease-free water (no 
template control) were added. The reaction plates were covered with adhesive sealing film 
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(Bio-Rad, #MSB1001), spun at 1000xg for 1 min and measured using settings according to 
Table 2.6 with the IQ5 Real Time PCR System (Bio-Rad). 
Table 2.4: qPCR primer 
























Table 2.5: qPCR reaction  Table 2.6: qPCR protocol 
Reagents Volume (µl)  Step Temp. (°C) Time 
Nuclease-free H2O 7.8  Denaturation 95 3 min 
Forward primer (10 pmol/µl) 0.6  Amplification 
(x45) 
95 10 sec 
Reverse primer (10 pmol/µl) 0.6  60 30 sec 
SsoAdvanced SYBR Green Mix 10  Meltcurve 
(x81) 
55-95 6 sec/step 
cDNA (2.5 ng) 1  
 
2.2.7 Total protein extraction 
For downstream applications like western blotting or mass spectrometry heart tissue or cells 
were mechanically homogenized and lysed using RIPA buffer. In short, about 30 mg of snap 
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frozen heart tissue was placed in RNase-free 2 ml tubes containing a 5 mm stainless steel 
bead (Qiagen, 69989) that were precooled on dry ice for at least 15 min and incubated for 
another 15 min on dry ice. To prevent the lysis buffer from freezing, the samples were 
incubated on room temperature for 2 min before Pierce RIPA buffer (Thermo Fischer, 89900) 
supplemented with cOmpleteTM protease inhibitors (Sigma, 000000011873580001) was 
added. The samples were then immediately placed in the Tissue Lyser LT (Qiagen, 85600) 
and homogenized for 5 min with 50 Hz. The lysates were briefly spun in a precooled centrifuge 
to remove the foam and placed on an overhead rotor at 4°C for at least 30 min before they 
were cleared for 15 min at 16,000 x g and transferred into a fresh 1.5 ml tube. Based on the 
absorbance at 562nm, the protein concentrations were photometrically determined using a 
Pierce™ BCA Protein Assay Kit (Thermo Fischer, 23225) and a 96-well plate reader (Biotek). 
For longtime storage the protein was kept at -80°C. 
2.2.8 Subcellular fractionation 
To examine protein localization and to especially enrich nuclear and chromatin-bound proteins 
from tissue and cells, the Subcellular Protein Fractionation Kit for tissue (Thermo Fischer, # 
87790) was used according to the manufacturer’s protocol. When handling cardiomyocytes, 
the cell strainer was omitted, and lysis buffer volumes adjusted according to the protocol of the 
Subcellular Protein Fractionation Kit for cultured cells (Thermo Fischer, # 78840). 
2.2.9 Immunoblotting 
Protein levels were detected after separation by SDS-PAGE, subsequent transfer onto 
nitrocellulose membrane following immunostaining (“Western blot”). Protein samples (10-30 
µg) containing protease inhibitors (Sigma, 000000011873580001) were denatured for 10 min 
at 95°C in 4x Laemmli buffer (Bio-Rad, #1610747) and 0.2M DTT and separated using stain-
free 4-15% TGX Gels (Bio-Rad; #) by applying a constant Voltage of 200 V for 35 min. The 
polyacrylamide gel was UV-activated (1 min) for subsequent stain-free imaging. Separated 
proteins were then transferred onto 0.2 µm nitrocellulose membrane (Bio-Rad, #1704270) 
using the Trans-Blot® TurboTM System (Bio-Rad, #170-4155) at a constant current of 2.5 A. To 
check transfer efficiency and for later normalization, the membrane was imaged using the 
stain-free system with a ChemiDoc XRS+ (Bio-Rad, #1708265). Membranes were then cut as 
required and blocked in 5% milk (Roth, #T145.3) in TBS-T (20 mM Tris-base, 50 mM NaCl, 
0.1% Tween 20, pH=7.5) for one hour at room temperature. After blocking, membranes were 
incubated with primary antibodies (Table 2.7) in 1% milk in TBS-T at 4°C overnight. Next, 
membranes were washed three times in TBS-T and incubated with horseradish peroxidase 
conjugated secondary antibodies ECL anti-Rabbit IgG and ECL anti-Mouse IgG (Table 2.7) for 
one hour on room temperature. Afterwards membranes were washed trice in TBS-T before the 
SuperSignal™ West Femto Maximum Sensitivity Substrate (Thermo Fisher, #34095) was 
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added. Chemiluminescence signal was detected with a Chemidoc XRS+ imager. Band 
intensities were quantified with Image Lab using backround subtraction, normalized to total 
protein in Microsoft Excel 2016, plotted and analyzed in GraphPad using two-tailed t-test. 
Table 2.7: Antibodies used for immunoblotting   
Antibody Dilution Source Antibody ID 
Rabbit-anti-BRD2 1:1000 CST, #5848S AB_10835146 
Rabbit-anti-BRD4 1:1000 Abcam, ab128874 AB_11145462 
Rabbit-anti-BRD4 1:1000 CST, #13440 AB_2687578 
Mouse anti-GAPDH 1:10000 Merck Millipore, MAB374 AB_2107445 
Donkey anti-Rabbit IgG HRP-conjugated 1:10000 GE Healthcare, NA934 AB_772206 
Sheep anti-Mouse IgG HRP-conjugated 1:10000 GE Healthcare, NA931 AB_772210 
 
2.3 Histological and immunocytochemical analyses 
2.3.1 Langendorff CM isolation 
Adult ventricular cardiomyocytes were isolated via the Langendorff perfusion as previously 
described (Toischer et al. 2017). Mice were anesthetized and sacrificed by cervical dislocation. 
The heart was dissected by cutting the aorta and then quickly transferred into a petri dish filled 
with ice-cold Ca-free Tyrode (Table 2.8). Next, the aorta was connected to a 20G cannula, the 
heart mounted on a Langendorff apparatus, and retrogradely perfused with Tyrode (flow rate 
3.5 ml/min) for 3 min at 37°C. Thereafter, perfusion was continued for 7 min with 20 mL Tyrode 
supplemented with LiberaseTM TM (Sigma, LIBTM-RO), trypsin, and CaCl2 (Table 2.9) until the 
heart became soft. Afterwards, the atria were carefully excised and discarded, whereas the 
digested ventricles were dissected for 30 sec in 2.5 mL digestion buffer. To stop the digestion, 
2.5 mL Stop solution (Table 2.10) were added to the cell suspension, which was then 
homogenized using a 1 mL syringe without a needle for 3 min. After 10 min of sedimentation 
the supernatant was removed, and the cardiomyocyte pellet washed twice with Tyrode. Freshly 
isolated cardiomyocytes were either directly used for immunocytochemistry or the pellet snap 
frozen on liquid nitrogen and stored at -80°C for later protein or RNA isolation. 
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Table 2.8: Tyrode solution 




Na2HPO4 x 2 H2O 0.6 





2,3-butanedione monoxime (BDM) 10 
glucose 5.5 
phenol red 0.032 
 
Table 2.9: Digestion buffer  Table 2.10: Stop solution 
Reagents volume  Reagents volume 
Tyrode 20 ml  Tyrode 2.25 ml 
LiberaseTM TM 300 µl  Bovine calf serum 250 µl 
Trypsin 10-fold, 2.5% 111.2 µl  10 mM CaCl2 3.125 µl 
10 mM CaCl2 25 µl    
2.3.2 Immunocytochemistry 
Directly after isolation, 200 µl of suspended cardiomyocytes were plated for 30 min on laminin-
coated Ø 18 mm coverslips (10 µl laminin [2 mg/ml] 1:10 in Tyrode per coverslip) placed in a 
12-well-plate. The buffer was replaced by 4% paraformaldehyde and cells fixed for 10 min. 
After a quick washing step with blocking buffer (10% bovine calf serum, 0.2% Triton X-100 in 
PBS), the cells were blocked and permeabilized in blocking buffer for one hour at room 
temperature. After blocking, cells were incubated with primary antibodies (Table 2.11) in 
blocking buffer at 4°C overnight. Next, the cells were washed trice with blocking buffer and 
incubated with secondary antibodies (Table 2.11) in blocking buffer overnight at 4°C in a dark 
chamber. Afterwards, the cells were washed three times with PBS and mounted on slides 
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using ProLong® Gold antifade with DAPI (Thermo Fischer, P36935) which was allowed to 
harden overnight at room temperature and in the dark. 
Table 2.11: Antibodies used for immunocytochemistry 
Antibody Dilution Source Antibody ID 
Rabbit-anti-BRD2 1:500 Bethyl, A302-583A AB_2034829 
Rabbit-anti-BRD2 1:500 CST, #5848S AB_10835146 
Rabbit-anti-BRD4 1:500 Abcam, ab128874 AB_11145462 
Mouse anti-Actinin 1:500 Sigma, A7811 AB_476766 
Alexa Fluor® 633 Goat anti-Rabbit IgG (H+L) 1:1000 Thermo, A-21070 AB_2535731 
Alexa Fluor® 514 Goat anti-Mouse IgG (H+L) 1:1000 Thermo, A-31555  AB_2536171 
2.3.3 Confocal microscopy 
Confocal microscopy was performed using Zeiss LSM 710 (Zeiss) microscope equipped with 
a Plan-Apochromat x63/1.40 oil-immersion objective. Images were acquired for Alexa Fluor 
514 (514 nm diode laser excitation) and Alexa Fluor 633 (633 nm diode laser excitation) with 
a resolution of 2048 x 2048 pixels, at a speed of 31 seconds per frame and 16-fold line 
averaging. ZEN 2010 software was used for image analysis. 
2.3.4 Paraffin embedding, dewaxing and rehydration 
Dissected hearts were fixed in 4% paraformaldehyde (PFA) at 4°C overnight. The fixed hearts 
were dehydrated in an ethanol series, and infiltrated in paraffin for sectioning using a dip and 
dunk tissue processor (Leica, TP1020) by incubating in 60% ethanol, 2x 75% ethanol, 2x 96% 
ethanol, 2x 100% ethanol, 2x xylol, and 3x paraffin, each for 90 min. Paraffin blocks were 
prepared using an embedding station (Leica, EG1150H) and 5 μm thick heart cross sections 
were generated at a Microtom (Leica RM 2165). For downstream applications, paraffin cross 
sections were incubated at 65°C for one hour, dewaxed in xylol (5 min twice) and rehydrated 
in a decreasing ethanol series (2x 100 % - 95% - 70% - 50%- 30 %, 5 min each step) and in 
distilled water. 
2.3.5 Masson’s trichrome staining 
After dewaxing, the 5 µm paraffin sections were post-fixed with Bouin’s solution (Sigma, HT10-
1-32) overnight at room temperature and stained using Masson’s trichrome staining kit (Sigma, 
HT15-1KT) according to the manufacturer’s instructions. In short, Bouin’s solution was 
removed and slides rinsed with tap water until colorless, incubated with Hematoxylin QS 
(Vectorlabs) for 40 sec and rinsed with tap water for 5 min. After washing with distilled water, 
the slides were stained with Biebrich Scarlet-acid Fuchsin solution for 2 min and immediately 
placed in phosphotungstic/phosphomolybdic acid solution and incubated for 30 min. Next, the 
slides were immersed in aniline blue solution for 10 min, de-stained for 1 min in 1% acetic acid 
and washed in distilled water. The slides were then dehydrated in an increasing ethanol series 
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(30% - 50% - 70% - 95% - 100%) and xylol, each for 1 min. The slides were mounted using 
Permount medium (Fischer Scientific, SP15-100). Nuclei are stained blue/violet, cytoplasm 
red, muscle fibers red and collagen blue. 
2.3.6 Picro Sirius Red staining 
Connective tissue of dewaxed and rehydrated 5 µm paraffin section was stained using the 
Picro-Sirius Red Stain Kit (Abcam, ab150681) according to the manufacturer’s instructions. In 
short, dewaxed and rehydrated slides were covered with Picro-Sirius Red solution and 
incubated for 60 min at room temperature. The slides were then quickly rinsed twice in acetic 
acid solution and once in absolute alcohol. After dehydration in two changes of absolute 
alcohol, the slides were cleared and mounted with Permount (Fischer Scientific, SP15-100) 
medium. Cytoplasm and muscle fibers are stained yellow, whereas collagen is stained red. 
2.3.7 Wheat germ Agglutinin staining 
To visualize cell borders, dewaxed and rehydrated heart sections were washed twice with 
Hank’s balanced salt solution (HBSS) without phenol (life technologies #14025-092) and 
labeled for 15 min at room temperature with a wheat germ agglutinin (WGA) conjugate 
(Invitrogen, W11262) in HBSS at a concentration of 10 µg/ml. After two consecutive washes 
with PBS, the slides were mounted using ProLong® Gold antifade with DAPI (Thermo Fischer, 
P36935) which was allowed to harden overnight at room temperature and in the dark. 
2.3.8 Quantification of histological stainings 
Images of histological stainings were analyzed using the ImageJ distribution Fiji (Schindelin et 
al. 2012; Rueden et al. 2017). To determine the minimal fiber diameters (MFD) of heart cells, 
5 images (200x magnification) from one WGA-stained heart section per mouse were captured, 
digitized and analyzed using semi-automated segmentation (macro: Appendix Table 5.2). In 
brief, grey-scale images underwent smoothening, background subtraction, and contrast 
adjustments before they were transformed to binary images (black-and-white) using regional 
gradient thresholding to allow identification and analysis of the particles (cell lumen). MFDs 
from >1200 cells per mouse were analyzed and plotted with GraphPad using two-way ANOVA. 
To determine the percentage of fibrous area from Picro-Sirius Red stained heart sections, 
images of one section per mouse were captured at a 100x magnification and analyzed with a 
custom-made ImageJ macro (Appendix Table 5.3). Therefore, brightfield images were split in 
the red-green-blue (RGB) channels and the area of the whole section as well as of the fibrotic 
regions measured using automated thresholds. The amount of fibrosis was calculated in 
Microsoft Excel 2016 and plotted and analyzed with GraphPad using two-way ANOVA with 
Tukey correction for multiple comparisons. 
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2.4 Next Generation Sequencing 
2.4.1 mRNA library preparation 
Sequencing of RNA-seq samples and basic analysis (2.4.2 – 2.4.4) was conducted at the 
Microarray and Deep-Sequencing Facility Göttingen (Transcriptome and Genome Analysis 
Laboratory, TAL, headed by Gabriela Salinas) by Orr Shomroni. RNA-seq libraries were 
generated using the TruSeq RNA Library Preparation Kit v2, Set A (48 samples, 12 indexes) 
RS-122-2001 protocol from Illumina starting with 500 ng of total RNA. Quality and integrity of 
RNA was assessed with the Fragment Analyzer from Advanced Analytical by using the 
standard sensitivity RNA Analysis Kit (DNF-471). All samples selected for sequencing 
exhibited an RNA integrity number over 8. The ligation step was optimized by diluting the 
adapters concentration to increase ligation efficiency (>94%), and finally the number of PCR 
cycles was reduced to avoid PCR duplication artifacts as well as primer dimers in the final 
library product. For accurate quantitation of cDNA libraries, a fluorometric based system, the 
QuantiFluor™ dsDNA System from Promega, was used. The size of final cDNA libraries was 
determined by using the dsDNA 905 Reagent Kit (Fragment Analyzer from Advanced 
Bioanalytical) exhibiting a sizing of 300 bp in average. Libraries were pooled and and 
sequenced on an Illumina HiSeq 4000 (Illumina) generating 50 bp single-end reads (30-40 Mio 
reads/sample). 
2.4.2 Raw read and Quality check 
Sequence images were transformed with Illumina software BaseCaller to BCL files, which was 
demultiplexed to fastq files with bcl2fastq v2.17.1.14. The sequencing quality was asserted 
using FastQC (Andrews 2010). 
2.4.3 Mapping and Normalization 
Sequences were aligned to the reference genome Mus musculus (mm10 version 89, 
https://www.ensembl.org/Mus_musculus/Info/Index) using the STAR aligner (Dobin et al. 
2013) (version 2.5.2a) allowing for 2 mismatches within 50 bases. Subsequently, read counting 
was performed using featureCounts (Liao et al. 2014). 
2.4.4 Differential expression analysis 
Read counts were analyzed in the R/Bioconductor environment (version 3.4.2, 
www.bioconductor.org) using the DESeq2 (Love et al. 2014) package version 1.14.1. 
Candidate genes were filtered using an absolute log2 fold-change >0.5 and FDR-corrected p-
value <0.05. Gene annotation was performed using Mus Musculus entries via biomaRt R 
package version 2.32.1 (Durinck et al. 2009). 
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2.4.5 Analysis of differentially expressed genes 
InteractiVenn (http://www.interactivenn.net/) was used to calculate gene set overlaps (Heberle 
et al. 2015). Heatmapper (http://heatmapper.ca/, (Babicki et al. 2016)) was used to generate 
heatmaps. WebGestalt (http://www.webgestalt.org, (Zhang et al. 2005)) was used for Gene 
Ontology (GO) functional analysis with categories being significantly enriched with p<0.05 and 
false discovery rate (FDR)<0.05 if not otherwise indicated. Cytoscape 3.6.1 plugin ClueGO 
2.5.2 (Bindea et al. 2009) (Bonferroni adjusted p-value<0.05, κ -score=0.4) GO term fusion 
was used for gene network visualization using ontology for molecular function, biological 
process and cellular compartment if not otherwise indicated. 
2.4.6 Gene set enrichment analysis 
Gene set enrichment was analyzed using GSEA (Mootha et al. 2003; Subramanian et al. 
2005). Mouse gene symbols (uppercase letters) and Reads Per Kilobase Million (RPKM) were 
converted to a tab delimited text file (.txt) and a categorical class file format (.cls) was 
generated. Data were not ranked and analyzed with following settings, number of 
permutations: 1000; permutation type: phenotype, max size: 1000, number of markers: 1000. 
2.4.7 Microarray analysis 
Quality control and differential expression analysis of the microarray data was performed at 
the Microarray and Deep-Sequencing Facility Göttingen (Transcriptome and Genome Analysis 
Laboratory, TAL, headed by Gabriela Salinas) by Orr Shomroni. The data analysed was 
previously published data GSE48110 (Anand et al. 2013). The complete analysis was done in 
the R/bioconductor environment (version 3.5.1). Quality control for the data was performed 
using arrayQualityMetrics (version 3.36.0) (Kauffmann et al. 2009), generating plots for 
between array comparisons, array intensity distributions, variance mean dependence and 
individual array quality. Differential expression analysis between the different conditions was 
performed using R package limma (version 3.36.2) (Ritchie et al. 2015) using annotation 
package mogene10sttranscriptcluster.db (version 8.7.0) (MacDonald 2017), where samples 
from the 3 conditions (TAC, TAC_JQ1 and Sham) were tested against each other, while 





3.1 BET protein family members in the mouse heart 
3.1.1 BETs are expressed in the heart and localized in nuclei 
Anand and colleagues previously described that the BET protein family members Brd2, Brd3, 
and Brd4 are expressed in the murine heart, with significantly higher levels of Brd4. 
Furthermore, they showed that BRD4 is localized in cardiomyocyte nuclei (Anand et al. 2013). 
Transcriptome analysis of adult mice of the FVB/N inbred strain by mRNA sequencing 
(Khadjeh et al. unpublished) showed Brd2, Brd3, and Brd4 expression in the left ventricle. The 
comparison of the gene length normalized counts (RPKMs) revealed a 4-fold higher 
expression of Brd2 in the heart than Brd3 and Brd4 (p<0.0001, one-way ANOVA with Tukey 
post-hoc test, n=5). (Figure 3.1A). Immunocytochemistry of isolated cardiomyocytes from 3-
month-old wildtype mice revealed co-localized fluorescent signals for BRD2 or BRD4 with 
DAPI indicating nuclear localization (Figure 3.1B). In all following experiments I focused on 
Brd2 as the highest expressed BET member in the heart, and Brd4 as the most intensively 
studied one. 
Immunoblotting with left ventricular total protein from 3 months old FVB/N mice detected BRD2 
at about 110 kDa (Figure 1.1C left), whereas BRD4 showed only very weak signal (data not 
shown). Therefore, further BRD4 immunoblots were performed using subcellular protein 
fractions from left ventricle. In a direct comparison, BRD4 was only detectable in the nuclear 
and chromatin-bound protein but not in the cytosolic and membrane-bound fractions (Figure 
3.1C right). Interestingly in the BRD4 blot, a protein band at 100 kDa was observed in the 
nuclear fraction that was replaced by a signal at approximately 125 kDa in the chromatin-bound 
protein fraction. Additionally, a protein band at 150 kDa was detected in both fractions but was 
identified as unspecific signal in vitro using siBrd4 (Appendix Figure 5.2) (Ana Kutschat and 






Figure 3.1: BRD2 and BRD4 are expressed in the heart and localized in the nucleus. 
Transcriptome analysis showed Brd2, Brd3, and Brd4 expression in the left ventricle. Comparison of 
length normalized read counts (RPKM) revealed significantly higher expression levels for Brd2 
(p<0.0001, one-way ANOVA with Tukey post hoc, n=5). Shown as fold change expression to Brd2. Error 
bars indicate SD (A). BRD2 and BRD4 (red) can be detected by immunocytochemistry in isolated 
cardiomyocytes and co-localizes with DAPI (blue), ACTN1 (green) visualizes the sarcomere structure 
(bar=20µm) (B). Western Blot showed BRD2 and Brd4 are predominantly present in the nuclear and 
chromatin-bound protein fraction (C).  
 
3.1.2 Particular BETs are differently regulated after pressure overload 
Spiltoir and colleagues previously suggested that BRD2 protein levels are decreased, BRD3 
levels remain unchanged, and BRD4 levels are increased after TAC-induced PO (Spiltoir et al. 
2013). After validation of BET expression in the murine heart, I wanted to test whether 
particular BET proteins are altered after PO under our laboratory conditions. Therefore, the 
expression of Brd2, Brd3, and Brd4 was analyzed using previous mRNA sequencing data from 
our group (Khadjeh et al. unpublished) obtained from left ventricular RNA of wildtype animals 
(FVB/N strain) one and eight weeks after TAC or Sham (control) surgery. Regardless of the 
time point or treatment, all samples showed much higher expression of Brd2 in the heart than 
of Brd3 or Brd4 (p<0.0001, two-way ANOVA with Tukey post-hoc test, n=5). Adjusted p-values 
showed no significant difference in BET expression between TAC and Sham operated animals 
in none of the timepoints. RT-qPCR analysis confirmed that Brd2 and Brd4 are not regulated 














































































and BRD4 protein levels in left ventricles of animals 8 weeks after TAC or Sham surgery using 
immunoblotting showed that BRD2 levels were unchanged, whereas an additional BRD4 
protein band at about 200 kDa (arrow) was detectable only after TAC (Figure 3.2 B-C). As this 
suggested a potential change towards the long isoform of Brd4 after stress induction, an 
additional RT-qPCR was performed using primers spanning the exons three to four (exon 3-4) 
and five to six (exon 5-6), which detect both the short and long isoform, as well as primers 
targeting exons 15 to 16 (exon 15-16) that are exclusive to the long isoform. Relative Brd4 
expression was compared to that of exon 3-4 Sham and overall showed a significantly lower 
expression of the long isoform (p<0.0001 to exon3-4 Sham and exon5-6 Sham/TAC, p>0.01 
to exon3-4 TAC, two-way ANOVA). After TAC, however, decreased expression of the 5’ coding 




Figure 3.2: BET genes are differently regulated after pressure overload. 
Gene length normalized counts (RPKM) from RNA sequencing revealed an overall significantly higher 
expression of Brd2 in the heart compared to Brd3 and Brd4 (p<0.0001, two-way ANOVA with Tukey 
post-hoc, n=5). Data shown as mean RPKM +SD. (A). Western blot with total protein from left ventricle 
showed BRD2 and BRD4 were present 8 weeks after control (Sham) or TAC surgery (B) and that an 
additional BRD4 band appeared at 200 kDa after TAC when quantified and normalized to total protein 
(p<0.05, unpaired two-tailed t-test, n=4-8) (C). Brd2, Brd3 and Brd4 mRNA was not significantly changed 
8 weeks after TAC (RT-qPCR, n=5-6) (D). Detailed expression analysis of Brd4 showed an overall 
significantly lower expression of the long isoform ($= p<0.0001 to exon3-4 Sham) and a significantly 
decreased expression of the 5’ coding region 8 weeks after TAC (RT-qPCR, n=5-6, normalized to 
exon3-4 Sham) (E). If not stated otherwise unpaired two-tailed t-test was used. Error bars indicate SEM 
if not stated otherwise, *= p<0.05, ****= p<0.0001, ns= not significant. (A) Normalized counts were kindly 





































































































































3.2 Effects of JQ1-mediated BET inhibition after pressure overload 
3.2.1 JQ1 administration does not improve survival after TAC 
BET-inhibition with the small molecule JQ1 has previously been reported to prevent TAC-
induced cardiac remodeling and HF (Anand et al. 2013) but no effect on the overall survival 
after TAC was described. BET-inhibition with JQ1 in PO was performed in order to verify the 
previous findings and to analyze its impact on TAC-dependent mortality (Figure 3.3). Therefore, 
8 weeks old female wildtype mice (C57BL/6N) underwent TAC or Sham surgery. Half of TAC-
animals were randomly chosen to receive daily intraperitoneal injections of JQ1 in a 
concentration of 50mg/kg/d for 28 days and starting 24 hours after surgery. The remaining 
TAC animals and the Sham group received daily intraperitoneal injections of DMSO in the 
vehicle solution. The animals were analyzed by echocardiography 4 weeks after TAC and 
sacrificed for molecular testing 3 days later (group1). Animals were treated as in group 1 but 
additionally 50% of Sham-animals received JQ1. After treatment all animals were analyzed by 
echocardiography 4 and 8 weeks after surgery before being sacrificed for molecular testing 3 
days after the second echo (group2). 
 
 
Figure 3.3: Experimental design for BET inhibition with JQ1 after TAC. 
8 weeks old female C57BL/6N mice underwent TAC or Sham surgery. 50% of TAC-animals were 
randomly chosen to receive daily intraperitoneal injections of JQ1 in a concentration of 50mg/kg/d for 
28 days and starting 24 hours after surgery. The remaining TAC animals and the Sham group received 
daily intraperitoneal injections of DMSO in the vehicle solution. The animals were analyzed by 
echocardiography 4 weeks after TAC and sacrificed for molecular testing 3 days later (group1). Animals 
were treated as in group 1 but additionally 50% of Sham-animals received JQ1. After treatment all 
animals were analyzed by echocardiography 4 and 8 weeks after surgery before being sacrificed for 
molecular testing 3 days after the second echo (group2). 
 
To ensure consistent constrictions in all animals, the pressure gradients across the transverse 
aorta were determined after TAC. The average fractional flow reserve values were comparable 
and showed a more than 14-fold TAC-dependent increase (p<0.0001, Sham n=7-17, TAC 
n=29-39) from about 4.5 mmHG at baseline (Sham) to 73 mmHG (±18SD) in the vehicle group 
and 70 mmHG (±25SD) in JQ1 treated animals (Figure 3.4A). Significant and comparable TAC-
mediated mortality was observed in vehicle (p<0.0001, Log-rank Mantel-Cox test, n=24-29) 
and in JQ1 treated animals (p=0.0006, Log-rank Mantel-Cox test, n=24-40), whereas no Sham 
mouse died within the time frame of the observation (Figure 3.4B). 
 
JQ1 50 mg/kg/d IP vs. vehicle
TAC/Sham echo
sacrifice
JQ1 50 mg/kg/d IP vs. vehicle











Figure 3.4: The survival after TAC showed no difference between vehicle and JQ1 treated 
animals. 
The successful TAC was ensured by measurement of the fractional flow reserve 24 to 72 hours after 
surgery which was comparably increased in both groups after TAC (data presented as mean +SD, each 
point represents the measurement for one animal, ****= p<0.0001, two-way ANOVA with Tukey test) 
(A). Kaplan-Meier curve showing the percent of living animals for the time after TAC or Sham without 
the first 48 hours after surgery (Log-rank Mantel-Cox test, numbers in brackets represent animals 
examined, dotted lines indicate median survival) (B). 
 
3.2.2 TAC-induced cardiac remodeling is unaffected by JQ1 
Despite the expected cardio-protective effects of BET inhibition, TAC-dependent mortality was 
not decreased by JQ1. To confirm the previously reported beneficial effects of JQ1, the 
collected hearts of vehicle or JQ1 treated animals four and eight weeks after surgeries were 
examined by histologic staining and gene expression analysis. 
As demonstrated by Masson’s trichrome stain and the comparison of left ventricle to body 
weight ratios (Figure 3.5 A-B), JQ1 and vehicle treated animals showed equally enlarged left 
ventricles 4 and 8 weeks after TAC (p<0.0001, two-way ANOVA with Tukey post hoc). 
Moreover, both treatment groups showed the same significant increase of Nppa and Nppb 












































Figure 3.5: JQ1 and vehicle treated mice show comparable cardiac remodeling and cardiac 
stress marker expression 4 and 8 weeks after TAC. 
Masson’s trichrome stain showed increase in size of the left ventricle after TAC in the JQ1 and vehicle 
group, respectively (bar=2 mm) (A). Both treatment groups showed the same extremely significant 
increase of left ventricular weight 4 and 8 weeks after TAC in comparison to Sham (error bars 
2 mm
vehicle JQ1 vehicle



















































































































































indicate SD) (B). Expression levels of Nppa mRNA (C), and Nppb mRNA were increased in both groups 
after TAC (RT-qPCR, n=5-6) (D). Two-way ANOVA together with Tukey correction for multiple 
comparisons was used. Error bars indicate SEM if not stated otherwise, *= p<0.05, **= p<0.01, ***= 
p<0.001. 
 
WGA-stained heart cross sections were used to determine the diameter of individual 
cardiomyocytes (Figure 3.6A). Four and eight weeks after TAC, mean MFDs of vehicle and 
JQ1 treated animals were significantly higher than in the Sham groups (Figure 3.6B) 
demonstrating TAC-dependent hypertrophy regardless treatment. The comparison of MFD 
frequencies in hearts after Sham or TAC surgeries showed a shift to increased cell diameters 
after TAC in vehicle and JQ1 treated animals alike (Figure 3.6C). JQ1-treated mice showed 
slightly smaller cell diameters 4 weeks after TAC than 8 weeks after TAC (Figure 3.6C right) 
but such difference was not observed in vehicle treated animals (data not shown). Thus, in our 
hands JQ1 had no effect on TAC-induced cardiac remodeling. 
 
Figure 3.6: Hearts from JQ1 and vehicle treated animals show comparable cardiomyocyte 
hypertrophy after TAC. 
Representative pictures of Wheat Germ Agglutinin staining (bar=100 µm) (A), analysis of the minimal 
fiber diameter (MFD) 4 weeks after TAC (one-way ANOVA with Fischer’s LSD test, n=3) (B, top) and 8 
weeks after TAC (two-way ANOVA with Fischer’s LSD test, n=3) (B, bottom) and its distribution showed 
cardiomyocyte hypertrophy in JQ1 and vehicle treated animals 4 and 8 weeks after TAC. Note that 
cardiomyocyte hypertrophy is milder in JQ1 treated animals 4 weeks after TAC compared to 8 weeks 













































































3.2.3 JQ1-treated animals show less wall thickening but reduced contractility 
Independent from treatment with vehicle or JQ1, TAC-induced PO led to an significant 
decrease of ejection fraction 4 and 8 weeks After surgery (Figure 3.7A), left ventricular dilatation 
8 weeks after surgery (Figure 3.7B) and an extremely significant increase of left ventricular wall 
thickness at both examination time points (Figure 3.7C). However, JQ1 treated mice showed a 
reduced wall thickening in comparison to vehicle treated 4 weeks after TAC (p=0.0017, n=21-
24, two-way ANOVA with Tukey post hoc). In contrast to previous reports, these data do not 
support cardio protective effects of JQ1 after PO. 
 
Figure 3.7: Echocardiographic phenotyping showed an overall comparable systolic dysfunction, 
left ventricular dilation and wall thickening in both groups after TAC. 
Echocardiographic phenotyping of JQ1 and vehicle treated mice showed in both groups a significant 
decrease of ejection fraction 4 and 8 weeks after TAC (A), an increase of left ventricular diameter 8 
weeks after TAC (B) and an extremely significant increase of left ventricular wall thickness, although 
JQ1 treated mice showed a reduced wall thickening in comparison to vehicle treated 4 weeks after TAC 
(C). Two-way ANOVA together with Tukey correction for multiple comparisons was used. Error bars 
indicate SD, *= p<0.05, **= p<0.01, ***= p<0.001, ****= p<0.0001, each point represents the 































































3.2.4 JQ1 modulates the immune response, cell cycle, and muscle contraction 
So far, the previously reported JQ1-mediated cardio-protection from hemodynamic stress 
could not be reproduced in this work. To detect subtle JQ1 effects, a molecular characterization 
of the left ventricular transcriptome in animals used for the previous analyses was performed. 
Mice of group 1 were allowed to rest for three days after echocardiographic assessment four 
weeks after surgery prior to sacrifice and heart dissection to avoid acute transcriptional 
artefacts due to handling, stress, or anesthesia. The retrograde perfused left ventricles of 
Sham vehicle, TAC vehicle, and TAC JQ1 were used for next-generation mRNA sequencing. 
In comparison to Sham vehicle, 892 differentially expressed genes (DEGs) were detected for 
TAC vehicle and 961 DEGs for TAC JQ1 at an adjusted p-value (padj) less than 0.05 and a 
log2FC cutoff of 0.5 (Figure 3.8). The DEGs of TAC vehicle were used for an 
overrepresentation analysis (ORA) for gene ontology (GO) terms of biological processes and 
showed enrichment for genes associated with tissue development, ion transport, and ECM 
organization (padj<0.05, false discovery rate (FDR)<0.05) (Figure 3.8A-B). To allow analysis 
of potentially BET-regulated genes after TAC, genes differentially expressed in TAC vehicle 
were removed from GO analysis (Figure 3.8C, intersect) and only TAC JQ1 specific DEGs were 
analyzed. ORA of these 418 DEGs showed strongest enrichment for immune cell activation 
and cell division (padj<0.05, FDR<0.05, Top10 sorted according to ratio of enrichment) (Figure 
3.8C). However, a direct comparison of expression data from TAC vehicle and TAC JQ1 
revealed only 19 DEGs (padj<0.05, log2FC±0.5) that after ORA with a less stringent cutoff 
showed an enrichment for processes involved in immune response and metabolic processes 
(padj<0.05, FDR<0.11, sorted according to log10 ratio of enrichment) (Figure 3.8D) as no 
biological processes was overrepresented at a FDR less than 0.05. A heatmap of RPKMs of 
these 19 DEGs showed clusters of genes that were only induced or repressed in TAC JQ1 
hearts and a cluster of genes induced in TAC vehicle and unaffected in TAC JQ1 (Figure 3.8E). 
Among these genes detected were Zfp948 and Zfp185 (zink finger proteins possibly involved 
in cell proliferation and differentiation), Tfrc (receptor for iron uptake), Asb4 and Asb5 (involved 
in vascularization), Bach2 (transcription factor regulating apoptosis), Ccl2 (chemotactic factor 
recruiting monocytes and basophils), Cd74 (critical for antigen processing), H2.Ab1 and 
H2.Eb1 and H2.Aa (atypical histones). To detected functional groups of slightly differentially 
regulated genes that individually are discarded by cutoffs during differential expression 
analysis, gene set enrichment analysis (GSEA) was performed. GSEA of TAC vehicle versus 
TAC JQ1 revealed 49 positively enriched GO gene sets (padj<0.05, FDR<0.25). The GO 
categories were manually clustered into ‘Transport’, ‘Translation initiation’, ‘Splicing’, ‘RNA 





Figure 3.8: Four weeks after TAC hearts show wide gene expression changes and mild reaction 
to JQ1-dependent BET inhibition. 
Differential expression analysis after mRNAseq of left ventricles 4 weeks after TAC and vehicle 
treatment versus Sham and vehicle showed 1990 differentially expressed genes (DEGs) in TAC vehicle 
(padj<0.05; 1065 up, red; 925 down, blue) of which 892 were significant at padj<0.05 and log2FC±0.5 
(568 up, dark red; 324 down, dark blue). White numbers indicate number of DEGs and x-axis the percent 
of total DEGs (A). Overrepresentation analysis (ORA) of gene ontology (GO) terms of biological 
processes for 892 significantly regulated genes in (A) showed enrichment in regulation of tissue 
development, ion transport, and ECM organization (padj<0.05, FDR<0.05, Top10 sorted according to 
ratio of enrichment) (B). Overlap for DEGs (padj<0.05, log2FC±0.5) in TAC vehicle (892 genes) and 
TAC JQ1 (961 genes), both versus Sham vehicle. 418 TAC JQ1 exclusive DEGs were identified and 
used for ORA of GO biological processes. This showed an enrichment of GO terms for immune cell 
activation and cell division (padj<0.05, FDR<0.05, Top10 sorted according to ratio of enrichment) (C). 
mRNA sequencing revealed 43 DEGs (20 up, red; 23 down, blue) between TAC JQ1 and TAC vehicle 
with padj<0.05. A subsequent cutoff at log2FC±0.5 resulted in 19 DEGs (8 up, dark red; 11 down, dark 
blue) which were used for ORA GO biological processes. Enriched GO categories (padj<0.05, 
FDR<0.11, sorted according to log10 ratio of enrichment) in TAC JQ1 hearts included immune response 
and metabolic processes (D). A heatmap of the 19 TAC JQ1 DEGs was clustered via centroid linkage 
with Pearson method and revealed 3 clusters, JQ1 induced genes, JQ1 repressed genes, and TAC-
dependent gene induction that is reversed by JQ1 (E). 
 



































negative regulation of multicellular organismal process
anatomical structure formation involved in morphogenesis
tissue development
positive regulation of multicellular organismal process
ion transport
biological adhesion
regulation of multicellular organismal development
GO biological process
0 5 10 15
ratio of enrichment
positive regulation of cell adhesion
mitotic nuclear division
cell division
mitotic cell cycle process
mitotic cell cycle
hemopoiesis
hematopoietic or lymphoid organ development
cell activation
immune system development
movement of cell or subcellular component
GO biological process



































































































positive regulation of T cell activation














To describe the effects of JQ1 on the stressed heart in more detail, 418 genes differentially 
expressed (padj<0.05, log2FC±0.5) in TAC JQ1 but not in TAC vehicle mice in comparison to 
Sham vehicle (Figure 3.9A) were further analyzed. Pathway analysis showed significant 
clusters (padj<0.05) associated with T cell activation, antigen processing and cell cycle but 
also with sarcolemma, calcium regulation in cardiac cells, and muscle contraction (Figure 
3.9B). Plotting of the normalized gene counts (RPKM) of the 418 DEGs in a heatmap revealed 
one cluster of genes up-regulated and another down-regulated after TAC for both treatments, 
although TAC JQ1 showed stronger difference to Sham vehicle (Figure 3.9C). These data 
demonstrate that JQ1-mediated BET inhibition has only mild effects on gene expression after 




Figure 3.9: JQ1 modulates multiple biological pathways such as immune response, cell cycle, 
and muscle contraction. 
Overlap for DEGs (padj<0.05, log2FC±0.5) in TAC vehicle (892 genes) and TAC JQ1 (961 genes), both 
versus Sham vehicle. 418 TAC JQ1 exclusive DEGs were identified (A). ClueGO pathway analysis of 
418 DEGs from (A) (padj<0.05, log2FC±0.5) revealed enrichment for immune response, cell cycle, and 
cardiac muscle contraction (padj<0.05, Kappa=0.4). Nodes have been rearranged for better readability. 
Circle size represents padj (B). Heatmap of the 418 TAC JQ1 DEGs, clustered via centroid linkage with 





3.2.5 JQ1 does not reverse stress-induced gene expression 
The findings from this study contradict previous reports on JQ1-mediated protection of hearts 
after TAC (Anand et al. 2013; Spiltoir et al. 2013; Haldar and McKinsey 2014). Therefore, the 
previously published microarray data from Anand and colleagues (Anand et al. 2013) was 
reanalyzed. Differential expression analysis of ‘TAC vehicle 28d’ or ‘TAC JQ1 28d’ versus 
‘Sham vehicle 28d’ (Anand et al. 2013) resulted in 979 DEGs (716 up, 264 down) for TAC 
vehicle and 1066 DEGs (118 up, 948 down) for TAC JQ1 (padj<0.05, log2FC±0.5). From the 
408 DEGs common for both groups 391 genes were differentially regulated (Figure 3.10A). The 
comparison of these differentially regulated genes to DEGs of TAC vehicle and TAC JQ1 
(4 weeks) from this study (padj<0.05, log2FC±0.5) identified 142 common DEGs (Figure 
3.10B). As demonstrated by the heatmap for length normalized read counts, none of the 142 
common DEG was differentially regulated in mice from this study upon vehicle or JQ1 
treatment (Figure 3.10C). Moreover, after TAC both treatment groups of this study showed 
almost identical significant increase of cardiac stress marker expression such as genes 
encoding for natriuretic peptides (Nppa, Nppb), for embryonal isoforms of sarcomere proteins 
(Acta1, Myh7), for an inhibitor of calcineurin-dependent transcriptional respons (Rcan), for the 
connective tissue growth factor (Ctgf) expressed by vascular endothelial cells, and for a typical 
cytokine (Il6) (Figure 3.10D). Altogether, the previously reported cardio-protection of JQ1 
administration after TAC (Anand et al. 2013; Spiltoir et al. 2013; Haldar and McKinsey 2014; 
Duan et al. 2017) could not be reproduced in this study. 
As the quality and delivery of JQ1 was not monitored throughout this study, cardiac delivery 
and function is hard to prove. Therefore, I have analyzed the expression of Hexim1, Serpini1, 
Zcchc24, Zmynd8 (Lin et al. 2017), Myc, Ccr2, Cd180 (Yeh et al. 2017), and Bcl2 (Hogg et al. 
2016), which were previously described as BET inhibition biomarkers. However, transcriptome 
data from TAC JQ1 four weeks after surgery showed no differential expression for these genes 





Figure 3.10: JQ1 does not reverse TAC-induced genes. 
Reanalysis of previously published microarray data of TAC vehicle or TAC JQ1 versus Sham vehicle 
(28 days) (Anand et al. 2013) resulted in 979 DEGs for TAC vehicle and 1066 DEGs for TAC JQ1 
(padj<0.05, log2FC±0.5). From the overall 408 intersecting DEGs 391 were up-regulated in TAC vehicle 
and down-regulated in TAC JQ1 (A). Overlap of 391 TAC-induced and JQ1-reversed DEGs from (A) 
with DEGs of TAC vehicle and TAC JQ1 (4 weeks) from this study (padj<0.05, log2FC±0.5). 142 
intersecting DEGs were identified (B). Heatmap of expression data from this study for the 142 DEGs 
common with the differentially regulated DEGs from (A), clustered via centroid linkage with Pearson 
method (C). Relative expression of cardiac stress and remodeling markers. No significant differences 
between TAC vehicle and TAC JQ1 were observed. Based on RPKM normalized to Sham vehicle. Error 





 291  408
 249


























 716 118 0
 247  931 17


































3.3 The role of Brd2 in the healthy and diseased mouse heart 
3.3.1 Generation and validation of Brd2 knockout mice 
BET-inhibition by JQ1 has been previously shown to prevent pathologic remodeling and 
preserve contractile function of the heart in a mouse PO model. Therefore, BET inhibitors have 
been proposed as potential pharmaceuticals for HF (Anand et al. 2013; Spiltoir et al. 2013; 
Duan et al. 2017). Under our laboratory conditions these findings could not be confirmed as 
JQ1 treated animals developed pathologic hypertrophy, showed decreased heart function, and 
died prematurely after TAC (3.2). It cannot be excluded that experimental differences between 
the studies such as age, sex, and genetic background of the examined mice might lead to 
these controversial results. To clarify the inconsistencies, to overcome the limits of systemic 
BET inhibition, and to evaluate the potential of BET proteins as targets for HF treatment, it is 
necessary to further dissect the functions of particular BET proteins specifically in cardiac cells. 
Therefore, it is essential to generate and to use conditional BET alleles (Haldar and McKinsey 
2014). 
Although Brd2 shows the highest expression level of all BET members in the heart, its role in 
cardiac cells is unknown. To allow functional analyses a conditional Brd2 allele was used, 
which was previously generated in our group (Benito et al. unpublished) by introduction of two 
loxP sites at the Brd2 locus, one upstream of exon 3 and the other downstream of exon 4, to 
induce a frameshift and premature Stop after Cre-mediated recombination (Figure 3.11A). 
Homozygous male mice of this line (Brd2 fl/fl) were crossed to female mice of the 
cardiomyocyte-specific Cre-line αMHC-Cre to obtain Cre-positive mice homozygous for the 
conditional allele (Cre+;Brd2 fl/fl) in the F2 generation (Figure 3.11B). Mice homozygous for the 
recombined allele were viable and bred normally. DNA from tail biopsies was used to control 
the genetic identity of the mice (Figure 3.11C). All crossings produced offspring with genotypes 






Figure 3.11: Generation of cardiomyocyte-specific Brd2 knockout mice. 
Illustration of the floxed Brd2 allele. Boxes with numbers represent exons, blue filling represents coding 
region, red indicates target region excised after Cre-mediated recombination. The exon/intron 
proportions were maintained (bar=1 kb) (A). Paternal Brd2fl/fl (Brd2 fl/fl) were mated to maternal 
αMHC-Cre+ (Cre +) resulting in either Cre- ; Brd2fl/+ or Cre+ ; Brd2fl/+ (orange box). Female Cre+ ; Brd2fl/+ 
were backcrossed to male Brd2fl/fl to obtain Cre+ ; Brd2fl/fl (red box) (B). Representative genotyping PCR 
from tail biopsies. Brd2 primers bind to endogenous region flanking the loxP site between exons 4 and 
5 and result in a PCR product of 210 bp for the wildtype allele and 320 bp for the floxed allele. In the 
Cre-PCR an internal control primer pair yields a smaller product of 200 bp and the Cre-primer a product 
of ~300 bp. H2O served as negative control. bp=basepairs (C). 
 
To validate the desired Brd2 knockout in the heart, PCR-based analysis on genome and 
transcriptome level was performed on Cre- ; Brd2fl/fl (cre-) and Cre+ ; Brd2fl/fl (cre+) animals 
using primer pairs annealing outside or at the target site (Figure 3.12B). Standard PCR with 
DNA from left ventricles and primers flanking the target site at the Brd2 locus confirmed 
successful Cre-mediated deletion of Brd2 exons 3 and 4 (Figure 3.12A). The deletion led to a 
significant reduction of Brd2 mRNA levels containing exons 3 and 4 in left ventricle (p<0.05) 
and isolated cardiomyocytes (p<0.001). But interestingly, Brd2 mRNA levels downstream of 
the target site remained unchanged in total RNA from left ventricle and isolated cardiomyocytes 
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Figure 3.12: The Cre-mediated recombination in the Brd2 locus leads to the expression of a Brd2 
mRNA with a deletion of the target exons 3 and 4. 
Representative genotyping PCRs from heart biopsies. Brd2 recombination primers result in a ~ 380 bp 
PCR product after successful recombination whereas the control PCR yields a ~ 350 bp product for the 
floxed allele regardless recombination. H2O served as negative control (A). Illustration of the floxed Brd2 
allele with target sites of recombination and RT-qPCR primers. Dashed lines are not amplified during 
PCR. Boxes with numbers represent exons, blue filling represents coding region, red indicates target 
region excised after Cre-mediated recombination. The exon/intron proportions were maintained 
(bar=1 kb) (B). After recombination, the expression of the targeted Brd2 exons 3 and 4 was significantly 
decreased but downstream exons showed no expression changes when analyzing total RNA from left 
ventricle (C, left) and from isolated cardiomyocytes (RT-qPCR, n=5-6) (C, right). Unpaired two-tailed 
t-test was used. Error bars indicate SEM, *= p<0.05, ****= p<0.0001. 
 
Western blotting was used to check if the truncated Brd2 mRNA leads to the translation of a 
residual protein. Using total protein extracts from left ventricle, the full-length BRD2 (~110 kDa) 
was detected in both, Cre+ ; Brd2fl/fl animals and the Cre-negative littermates (Figure 3.13A left) 
at comparable levels (quantification not shown). But only in the Cre+ ; Brd2fl/fl samples an 
additional protein band at approximately 90 kDa was detected (Figure 3.13A right). The αMHC-
Cre mice express Cre-recombinase exclusively in cardiomyocytes, that is why other cells in 
the heart of Cre+ ; Brd2fl/fl still express full-length BRD2. Therefore, the analysis was repeated 
with total protein from isolated cardiomyocytes to exclude non-cardiomyocyte protein. Western 
blot analysis of these samples revealed that the full-length BRD2 was only detectable in 
samples from cre-negative mice, whereas in Cre+ ; Brd2fl/fl only a shorter protein at about 90 
kDa was observed (Figure 3.13A right). The specificity of the antibody against BRD2 was 
assured in vitro using siBrd2 (Appendix Figure 5.2) (Ana Kutschat and Feda Hamdan, 
unpublished). Immunocytochemistry of isolated Brd2∆BDI cardiomyocytes (data not shown) 
showed no difference to wildtype (Figure 3.1). Neither wildtype BRD2 nor a truncated BRD2 
were detectable in protein samples from left ventricle and isolated cardiomyocytes from 
Brd2∆BDI and control mice using Orbitrap liquid chromatography-mass spectrometry after 
excision from polyacrylamide gel at the respective molecular weights (data not shown) 
(Christian Schiffmann, personal correspondence). To analyze the identity of the transcript and 
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check if it could yield a truncated protein, the mutant mRNA was reverse transcribed and 
resulting cDNA sequenced. Alignment of the sequencing results to the annotated full-length 
Brd2 cDNA (Appendix Table 5.4) revealed that the Cre-mediated recombination in the Brd2 
locus leads to a transcript that is alternatively spliced from exon 2 to exon 5 (Figure 3.13B). An 
in-frame ATG in the beginning of exon 5 could be used as alternative start codon (Figure 
3.13B). Thus, the mutant Brd2 mRNA could potentially be translated and result in a truncated 
BRD2 protein, which lacks the first bromodomain (BDI) but contains the inter-bromodomain 
region, the second bromodomain, and the whole C-terminus. In the following the Cre+ ; Brd2fl/fl 
mice will be referred to as Brd2∆BDI. 
 
 
Figure 3.13: The deletion of Brd2 exons 3 to 4 results in the expression of a truncated protein.  
Western blot analysis revealed the expression of a truncated protein after deletion of Brd2 exons 3-4 in 
total protein from left ventricle (A, left) and isolated cardiomyocytes (A, right). Splicing of the mutant 
Brd2 mRNA and the predicted protein. cDNA of the mutant mRNA was generated and sequenced to 
elucidate the identity of the transcript and the putative truncated protein. The original translation start 
codon (ATG) is located in exon 2 (not depicted) but yields no protein due to a frameshift and premature 
stop in exon 5 (underscored). The sequence encoding BDI is highlighted in light blue. Exon 5 contains 
an in-frame ATG (red). The mutant allele is referred to as Brd2∆BDI (B). WT= wild type 
 
3.3.2 Characterization of Brd2∆BDI mutant mice 
Distinct functions of the two bromodomains of BET proteins have previously been 
demonstrated using BET inhibitors with higher specificity for the first (Gacias et al. 2014; 
Cheung et al. 2017a) or the second bromodomain (Picaud et al. 2013; Gilham et al. 2016) and 
by expression of mutant BET proteins lacking one of the bromodomains in vitro (Gamsjaeger 
et al. 2011; Shi et al. 2014) and in vivo (Shang et al. 2007). Therefore, I decided to continue 
with the characterization of the newly generated Brd2∆BDI mice to examine the phenotypic 











































Mice of the αMHC-Cre line positive for the Cre recombinase (cre control) and our newly 
generated Brd2∆BDI animals were compared in context of heart morphology, function and 
physiology to identify possible alterations in animals lacking the first bromodomain of BRD2 in 
cardiomyocytes. Cre control and Brd2∆BDI hearts showed no signs of fibrosis and no 
differences in Masson’s trichrome stainings at the age of three months. Notably, Cre-
dependent degenerative vacuoles in cardiomyocytes were observed in 6 month old animals of 
both groups (Figure 3.14 A-B). Furthermore, no alterations in LV-weight-to-body-weight (LV-
W/BW) ratio were observed at the age of 3 and 6 months (Figure 3.14 C). Likewise, 
cardiomyocyte dimensions of WGA-stained cre control and Brd2∆BDI heart cross sections also 
did not show any differences in mean minimal fiber diameters (MFD) and their distributions 
(Figure 3.14 D-F). To analyze in vivo heart dimensions and function, echocardiography of cre 
control and Brd2∆BDI animals was performed. No significant alterations in ejection fraction 
(EF), left ventricular end-diastolic diameter (LV-EDD), and wall thickness were revealed 
between both groups (Figure 3.14 G-I). However, mice of both groups that were used for basal 






























































































































































Figure 3.14: Morphometric characterization and echocardiographic analysis of Brd2∆BDI mice 
showed no differences to cre control mice. 
Masson’s trichrome stain shows no difference in heart dimension (bar=2 mm) (A) and no fibrosis in 3 
and 6 months old Brd2∆BDI mutant and cre control mice. Note the degenerative vacuoles (white spots) 
in 6 months old animals (both groups) (bar=100 µm) (B). Basal left ventricular weight was not changed 
upon Brd2 exon 3-4 deletion (C). Representative pictures of Wheat Germ Agglutinin staining (D), 
analysis of the minimal fiber diameter (error bars indicate SEM, n=2-6) (E) and its distribution analysis 
showed no changes of cardiomyocyte dimensions in Brd2∆BDI mutant mice (F). Echocardiographic 
phenotyping of cre control vs. Brd2∆BDI mutant mice at 3 and 6 months of age showed no changes in 
ejection fraction (G) a slight increase of left ventricular diameter in Brd2∆BDI from 3 to 6 months of age 
(H) and a comparable increase of left ventricular wall thickness in 6 months old animals of both groups 
(I).Two-way ANOVA together with Tukey correction for multiple comparisons was used. Error bars 
indicate SD if not stated otherwise, *= p<0.05, **= p<0.01, ****= p<0.0001. Each point represents the 
measurement for one animal. 
 
3.3.3 The survival of Brd2∆BDI mice is slightly reduced after TAC 
To examine the impact of BRD2∆BDI on cardiac remodeling and development of HF, 
Cre- ; Brd2fl/fl (control), Cre+ ; Brd2fl/fl (Brd2∆BDI) and αMHC-Cre+ (cre control) mice were bred 
as depicted in Figure 3.15 A. The animals of all three groups underwent TAC or Sham surgery 
at the age of 8 weeks. To monitor heart function and dimensions, the animals were analyzed 
by echocardiography one and five weeks after TAC or Sham surgery and either sacrificed 
afterwards for histological and molecular analyses or monitored regarding their survival after 
TAC for up to 4 months (Figure 3.15B). 
 
 
Figure 3.15: Brd2∆BDI mating scheme and experimental design. 
Mating scheme of parental transgenic mouse lines and resulting offspring genotypes, Cre- ; Brd2fl/fl 
(control), Cre+ ; Brd2fl/fl (Brd2∆BDI) and αMHC-Cre+ (cre control) mice. The animals underwent TAC or 
Sham surgery at the age of 8 weeks (A). Experimental design: the animals were analyzed by 
echocardiography 1 and 5 weeks after TAC or Sham surgery and either sacrificed afterwards for 
molecular testing or monitored regarding their survival after TAC for up to 4 months (B). 
 
To ensure that the TAC was successful and comparable between groups the pressure gradient 
across the constriction was measured 24 to 72 hours after surgery by Doppler 
echocardiography. The average fractional flow reserve values were comparable and showed 
an almost 14-fold TAC-dependent increase (p<0.0001, two-way ANOVA with Tukey test) from 
about 5 mmHG at baseline (Sham) to 70 mmHG (±20SD) in the control group and 68 mmHG 



















molecular testing 5 weeks after TAC were monitored for their survival and analyzed using a 
Kaplan-Meier curve. Despite comparable fractional flow reserves, Brd2∆BDI animals showed 
a significantly higher mortality after TAC in comparison to control (p=0.0129, n=34) but not to 
cre control, which showed an ‘intermediate’ mortality. 
 
 
Figure 3.16: The survival after TAC is reduced in Brd2∆BDI mutant mice compared to control but 
not to cre control. 
The successful TAC was ensured by measurement of the fractional flow reserve 24 to 72 hours after 
surgery which was comparably increased in Brd2∆BDI and controls after TAC (data presented as mean 
+SD, each point represents the measurement for one animal, ****= p<0.0001, two-way ANOVA with 
Tukey test) (A). Kaplan-Meier curve showing the percent of living animals for the time after TAC or Sham 
without first 48 hours after surgery (Log-rank Mantel-Cox test, *= p<0.05, numbers in brackets represent 
animals examined, dotted lines indicate median survival) (B). 
 
3.3.4 Brd2∆BDI and control mice show comparable cardiac remodeling 
Masson’s trichrome stain and LV-W/BW ratio showed left ventricular enlargement 5 weeks 
after TAC in Brd2∆BDI and control mice, respectively (Figure 3.17 A-B). The mRNA levels of 
the cardiac stress markers Nppa and Nppb were increased 5 weeks after TAC in comparison 
to Sham in both groups (Figure 3.17C-D). Notably, Brd2∆BDI hearts showed 5.5-fold higher 
Nppa levels than control (Figure 3.17C, p<0.01, two-way ANOVA). The data suggest that the 
expression of BRD2∆BDI does not alter the response to TAC-induced PO. 
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Figure 3.17: Brd2∆BDI and controls show comparable cardiac remodeling and cardiac stress 
marker expression 5 weeks after TAC. 
Masson’s trichrome stain showed increase in size of the left ventricle after TAC in Brd2∆BDI and control 
mice, respectively (bar=2 mm) (A). Control groups and Brd2∆BDI showed a comparable increase of left 
ventricular weight 5 weeks after TAC in comparison to Sham (error bars indicate SD) (B). Nppa mRNA 
expression levels were increased 5 weeks after TAC in comparison to Sham for control (F(1,14) = 9,718, 
p=0,0076) and significantly stronger for Brd2∆BDI mice (#= p<0.001 to Sham Brd2∆BDI, $= p<0.01 to 
TAC control) (C), whereas Nppb mRNA expression was comparably increased for both groups after 
TAC (RT-qPCR, n=3-5) (D). Two-way ANOVA together with Tukey correction for multiple comparisons 
was used. Error bars indicate SEM if not stated otherwise, *= p<0.05, **= p<0.01, ***= p<0.001. 
 
Echocardiographic phenotyping of control and Brd2∆BDI mutant mice 5 weeks after surgery 
showed an extremely significant decrease of ejection fraction after TAC across all groups 
(Figure 3.18A), no significant change of left ventricular diameter, although some individuals had 
dilated ventricles, (Figure 3.18B) and a comparable increase of left ventricular wall thickness in 
all groups (Figure 3.18C). Consequently, Brd2∆BDI does not influence heart dimensions and 

























































































Figure 3.18: Echocardiographic phenotyping shows no significant differences between 
Brd2∆BDI, control and cre control mice 5 weeks after TAC. 
Echocardiographic phenotyping of control and Brd2∆BDI mutant mice 5 weeks after surgery showed an 
extremely significant decrease of ejection fraction after TAC across all groups (A) no significant change 
of left ventricular diameter (B) and a comparable increase of left ventricular wall thickness in all groups 
(C). Two-way ANOVA together with Tukey correction for multiple comparisons was used. Error bars 
indicate SEM if not stated otherwise, *= p<0.05, ***= p<0.001, ****= p<0.0001, each point represents 
the measurement for one animal. 
 
3.4 The role of Brd4 in the healthy and diseased mouse heart 
3.4.1 Generation and validation of Brd4 knockout mice 
Once a conditional Brd4 allele was available in our group (Benito et al. unpublished), which 
contained two loxP sites at the Brd4 locus, one upstream of exon 6 and the other downstream 
of exon 7 (Figure 3.19A), matings with the cardiomyocyte-specific Cre-line were set up. 
Therefore, male mice heterozygous for the floxed Brd4 allele (Brd4 fl/+) were crossed to female 
mice of the αMHC-Cre (Cre +). DNA from tail biopsies was used to control the genetic identity 
of the mice (Figure 3.19C). Genotypes of the F1 generation showed a Mendelian distribution 
and mice heterozygous for the recombined allele were viable and dissected hearts showed no 
obvious abnormalities (data not shown). Next, female Cre+;Brd4fl/+ mice were backcrossed to 
male Brd4fl/+ mice to produce homozygous Brd4 knockout mice (Figure 3.19B). Five of these 
matings produced 17 litters with 94 pups in total but only one Cre-positive mouse was identified 
as homozygous for the conditional Brd4 allele (Cre+;Brd4fl/fl) (Figure 3.19D). This female died 






















































3.19D) were not Mendelian (Figure 3.19B) and suggested embryonic lethality of mice 
homozygous for the recombined Brd4 allele. 
 
Figure 3.19: Generation of cardiomyocyte-specific Brd4 knockout mice. 
Illustration of the floxed Brd4 allele. Boxes with numbers represent exons, green filling represents coding 
region, red indicates target region excised after Cre-mediated recombination. The exon/intron 
proportions were maintained (bar=1 kb) (A). Paternal Brd4fl/+ were mated to maternal αMHC-Cre+ 
(Cre +) resulting in either Cre- ; Brd4fl/+ or Cre+ ; Brd4fl/+ (orange box). Female Cre+ ; Brd4fl/+ were 
backcrossed to male Brd4fl/+ to obtain Cre+ ; Brd4fl/fl (red box). Expected Mendelian genotype frequencies 
of F2 genotypes are presented in % (B). Representative genotyping PCR from tail biopsies. Brd4 
primers bind to endogenous region flanking the loxP site between exons 7 and 8 and result in a PCR 
product of 250 bp for the wildtype allele and 360 bp for the floxed allele. In the Cre-PCR an internal 
control primer pair yields a smaller product of 200 bp and the Cre-primer a product of ~300 bp. H2O 
served as negative control. bp=basepairs (C). Genotype distribution for matings of female Cre+ ; Brd4fl/+ 
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It was previously reported that the αMHC-Cre mice might transiently express the Cre-
recombinase during early embryonic development in the heart and, depending on the target 
gene, could lead to developmental defects and lethality (Davis et al. 2012). My findings support 
this report. To overcome this limitation, the Tamoxifen-inducible αMHC-MerCreMer mice were 
used in a second approach. These mice express a fusion protein of Cre-recombinase with two 
copies of a modified estrogen-receptor ligand-binding domain (MerCreMer) in cardiomyocytes. 
Only upon application of Tamoxifen, the fusion-Cre-recombinase is translocated from cytosol 
into the nucleus enabling loxP-site-specific recombination (Sohal et al. 2001; Lexow et al. 
2013). Therefore, male Brd4fl/fl (Brd4 fl/fl) were mated to female MerCreMer+ mice resulting in 
either MerCreMer- ; Brd4fl/+ or MerCreMer+ ; Brd4fl/+ pups. Female MerCreMer+ ; Brd4fl/+ 
animals were further backcrossed to male Brd4fl/fl to obtain MerCreMer+ ; Brd4fl/fl (Figure 3.20A). 
DNA from tail biopsies was used to control the genetic identity of the mice (Figure 3.20B) and 
showed a Mendelian distribution of genotypes with 1:1 female to male ratio. All Cre-positive 
mice hetero- or homozygous for the floxed Brd4 allele were viable and bred normally. 
 
 
Figure 3.20: Generation of inducible cardiomyocyte-specific Brd4 knockout mice. 
Paternal Brd4fl/fl were mated to maternal αMHC-MerCreMer+ (MerCreMer +) resulting in either 
MerCreMer- ; Brd4fl/+ or MerCreMer+ ; Brd4fl/+ (orange box). Female MerCreMer+ ; Brd4fl/+ were 
backcrossed to male Brd4fl/fl to obtain MerCreMer+ ; Brd4fl/fl (red box) (A). Representative genotyping 
PCR from tail biopsies. Brd4 primers bind to endogenous region flanking the loxP site between exons 7 
and 8 and result in a PCR product of 250 bp for the wildtype allele and 360 bp for the floxed allele. In 
the MerCreMer-PCR the MerCreMer-primer result in a product of ~120 bp. H2O served as negative 
control. bp=basepairs (B). 
 
For further validation, 5 weeks old MerCreMer+;Brd4fl/fl mice either received Tamoxifen (2.1.4) 
on three consecutive days at the dosage of 30 mg/kg/day by intraperitoneal injection (Brd4 
KO), or were not treated (control). Administration of 3 x 30 mg/kg tamoxifen caused 10-20% 
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previous findings (Bersell et al. 2013), but the remaining Brd4 KO mice lived for over one year 
without incidents or unusual observations (data not shown).  
The successful Brd4 knockout was validated by standard PCR on the genome and by RT-
qPCR on the transcriptome level using primer pairs specific for the target site or transcript 
variants (Figure 3.21A). Standard PCR, with DNA from left ventricles and primers flanking the 
target site at the Brd4 locus, confirmed successful Cre-mediated deletion of Brd4 exons 6 and 
7 (Figure 3.21B). As demonstrated by RT-qPCR, the deletion led to an extremely significant 
reduction of total Brd4 mRNA levels in left ventricle (p<0.0001, unpaired two-tailed t-test, n=8-
9) and even stronger in isolated cardiomyocytes (p<0.0001, unpaired two-tailed t-test, n=3-6) 
(Figure 3.21C). This means that the Cre-mediated deletion of exons 6 and 7 of Brd4 leads to a 
complete depletion of the full-length Brd4 short and long isoforms in cardiomyocytes. 
 
 
Figure 3.21: Tamoxifen-induced deletion of exons 6 and 7 in the Brd4 locus via MerCreMer leads 
to decreased Brd4 expression in the heart. 
Illustration of the floxed Brd4 allele with target sites of recombination and RT-qPCR primers. Dashed 
lines are not amplified during PCR. Boxes with numbers represent exons, green filling represents coding 
region, red indicates target region excised after MerCreMer-mediated recombination. Long introns were 
discontinued (bar=1 kb) (A). Representative genotyping PCRs from heart biopsies. Brd4 recombination 
primers result in a ~ 250 bp PCR product after successful recombination whereas the control PCR yields 
a ~ 320 bp product for the floxed allele regardless recombination. H2O served as negative control (B). 
After recombination, the overall expression of Brd4 was significantly decreased when analyzing total 
RNA from left ventricle (RT-qPCR, n=8-9) (C, top) and from isolated cardiomyocytes (RT-qPCR, n=3-6) 
(C, bottom). Unpaired two-tailed t-test was used. Error bars indicate SEM, ****= p<0.0001. 
 
Western blot analysis of nuclear and chromatin-bound protein fractions from left ventricles of 
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3.22A). But a slight but not significant reduction in the nuclear fraction from isolated 
cardiomyocytes was observed in Brd4 KO samples (Figure 3.22B-C). Immunocytochemistry of 
isolated Brd4 KO cardiomyocytes (data not shown) showed no difference to wildtype (Figure 
3.1). Despite various efforts, the absence of BRD4 after knockout could not be clearly verified 
by immunoblotting. This might be due to residual fibroblasts and 10-20% of not recombined 
cardiomyocytes, which still express BRD4. The western blot conditions might be further 
improved in future studies but the slight reduction of BRD4 levels in Brd4 KO cardiomyocytes 




Figure 3.22: Successful Brd4 knockout could not be clearly validated by immunoblotting. 
Western blot showed that BRD4 was present in subcellular fractions for nuclear and chromatin-bound 
protein from left ventricles of 3 months old control and Brd4 KO mice (A) but slightly reduced in the 
nuclear fraction from isolated cardiomyocytes using anti-BRD4 (ab128874) (B). Quantification of BRD4 
intensities normalized to total protein (not significant, unpaired two-tailed t-test, n=3) (C). Data presented 
as mean +SEM. 
 
3.4.2 Brd4 knockout mice show basal concentric hypertrophy 
Morphometric and echocardiographic characterization was performed to investigate the basal 
effect of Brd4 depletion from cardiomyocytes. Therefore, MerCreMer+;Brd4fl/fl mice that were 
not induced (control) or that received Tamoxifen (Brd4 KO) as previously described (2.1.4) 
were compared in context of heart morphology, function and physiology in 3 and 6 month old 
animals. At both timepoints, Brd4 KO hearts showed slightly enlarged ventricular walls in 
Masson’s trichrome stainings (Figure 3.23A), which led to increased left ventricular to body 
weight ratios in three month old animals in comparison to control (p=0.0005, two-way ANOVA 
with Tukey post-hoc, n=16-19) (Figure 3.23B). Six months old control animals showed a 
significant increase compared to three month old control (p=0.0002, two-way ANOVA with 
Tukey post hoc, n=16-18) but not to Brd4 KO as their left ventricles did not change with age 
αBRD4
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(Figure 3.23B). WGA-stained heart cross sections showed increased mean MFDs (F(1,13) = 
6.711, p=0.0224, two-way ANOVA, n=4-5) and a distribution shift towards larger 
cardiomyocytes in Brd4 KO compared to control mice (Figure 3.23 C-E).  
 
 
Figure 3.23: Mormphometric characterization of Brd4 knockout mice showed concentric 
hypertrophy in comparison to control mice. 
Masson’s trichrome stain showed slightly enlarged hearts in 3 and 6 months old Brd4 KO vs. control 
mice (bar=2 mm) (A) Basal left ventricular weight to body weight ratio was not changed upon Brd4 
knockout (each point represents the measurement for one animal, error bars indicate SD, two-way 
ANOVA with Tukey) (B). Representative pictures of Wheat Germ Agglutinin staining (C), analysis of the 
minimal fiber diameter (error bars indicate SEM) (two-way ANOVA with Tukey, F(1,13) = 6.711, 
p=0.0224, n=4-5) (D) and its distribution analysis showed cardiomyocyte hypertrophy in Brd4 knockout 
mice (E). Two-way ANOVA together with Tukey correction for multiple comparisons was used. Error 
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3.4.3 Brd4 KO mice show thicker ventricular walls but normal cardiac function 
To challenge these findings, additional basal echocardiographic phenotyping was performed 
including Tamoxifen-induced αMHC-MerCreMer positive mice (MerCreMer+) to rule out 
possible Tamoxifen or Cre activity related effects. MerCreMer+, control and Brd4 KO mice at 3 
and 6 months of age showed no significant differences in ejection fraction, although Brd4 KO 
mice had slightly higher ejection fractions with 3 months that significantly decreased to control 
levels with 6 months (p=0.0002, two-way ANOVA, n=16-19) (Figure 3.24A). No left ventricular 
dilation was observed (Figure 3.24B) but with 3 months left ventricular wall thickness was 
significantly increased in Brd4 KO to control (p<0.0001, two-way ANOVA with Tukey post hoc, 
n=14-17) and to MerCreMer+ (p=0.0013, two-way ANOVA with Tukey post hoc, n=7-14). With 
6 months left ventricular wall thickness of MerCreMer+ animals slightly increased (p=0.0103, 
two-way ANOVA with Tukey post hoc, n=7) and stayed stable in Brd4 KO mice but was still 
significantly thicker compared to control (p<0.0001, two-way ANOVA with Tukey post hoc, 
n=16-18) (Figure 3.24C). 
These data showed that with induction at postnatal week 5, Brd4 KO mice are viable and 
develop basal concentric hypertrophy, which had no adverse effects on heart function nor on 
survival. Furthermore, echocardiographic examination of MerCreMer+ control animals 
demonstrated that the Brd4 KO effects were not attributed to Tamoxifen application or Cre-
activity in 3- and 6-months old animals. Therefore, MerCreMer+ animals were not included in 
the following experiments. 
 
 
Figure 3.24: Basal echocardiographic phenotyping showed increased left ventricular wall 
thickness in Brd4 KO mice. 
Echocardiographic phenotyping of MerCreMer+, control and Brd4 KO mice at 3 and 6 months of age 
showed no significant differences in ejection fraction between groups, although Brd4 KO mice show 
slightly higher ejection fraction with 3 months that significantly decreases to control levels with 6 months 
(A). No difference in left ventricular diameter was observed (B). Left ventricular wall thickness was 
significantly increased in Brd4 KO to both controls in 3 months old animals. With 6 months left ventricular 
wall thickness of MerCreMer+ animals slightly increased and stayed stable in Brd4 KO mice but was still 
significantly thicker compared to control (C). Two-way ANOVA together with Tukey correction for 
multiple comparisons was used. Error bars indicate SD, *= p<0.05, **= p<0.01, ***= p<0.001, 
****= p<0.0001. Each point represents the measurement for one animal. 
 



















































3.4.4 Brd4 KO mice show higher mortality after TAC 
To examine Brd4 KO mice for cardiac phenotypes after TAC-induced PO, female 
MerCreMer+ ; Brd4 fl/fl mice were crossed with male Brd4fl/fl mice. Only MerCreMer-positive 
offspring was used for further examination. With 5 weeks 50% of animals received 30mg/kg/d 
Tamoxifen on three consecutive days via intraperitoneal injection (Brd4 KO), whereas the other 
half was not induced (control) (Figure 3.25A). It was previously described that transient cardiac 
phenotypes can occur in MerCreMer+ animals shortly after Tamoxifen-application but are 
normalized within one to three weeks after the last dosage (Hougen et al. 2010). For that 
reason, I decided to induce MerCreMer-mediated recombination by applying Tamoxifen at the 
age of 5 weeks, 3 weeks before TAC or Sham surgery. Animals of the control and Brd4 KO 
group underwent TAC or Sham at the age of 8-10 weeks and were analyzed by 
echocardiography 1 and 5 weeks after surgery. Afterwards, the animals were either sacrificed 
for molecular testing or received an additional echo 10 weeks after surgery and were monitored 
regarding their survival after TAC for up to 6 months (Figure 3.25B). 
 
 
Figure 3.25: Brd4 KO mating scheme and experimental design. 
Mating scheme of parental transgenic mouse lines. Only MerCreMer+ ; Brd4 fl/fl offspring was used for 
further examination. With 5 weeks 50% of animals received 30mg/kg/d Tamoxifen on three consecutive 
days via intraperitoneal injection (Brd4 KO). The other half was not induced (control). The animals 
underwent TAC or Sham surgery at the age of 8-10 weeks (A). Experimental design: the animals were 
analyzed by echocardiography 1 and 5 weeks after TAC or Sham surgery and either sacrificed 
afterwards for molecular testing or received additional echo 10 weeks after surgery and were monitored 
regarding their survival after TAC for up to 6 months (B). 
 
After surgeries the pressure gradients across the transverse aorta were controlled by Doppler 
echocardiography, to ensure the consistency of constrictions. Both, control and Brd4 KO 
animals showed normally distributed 10- to 20-fold higher (p<0.0001, two-way ANOVA with 
Tukey post hoc) fractional flow reserve after TAC than after Sham (Figure 3.26A). In total, 78 
mice that underwent surgical intervention were monitored for the outcome of the surgeries.All 
death events were documented in a Kaplan-Meier curve. No Sham mouse of either group died 
within the time frame of the observation. Brd4 KO mice showed a significantly increased 
mortality after TAC, especially within the first 40 days. The median survival of Brd4 KO mice 
was 36.5 days and, thus 3.6 times lower than that of the control group (p=0.0188, Grehan-























Figure 3.26: The survival after TAC is reduced in Brd4 KO mice compared to control with the 
strongest mortality in the early phase after TAC. 
The successful TAC was ensured by measurement of the fractional flow reserve 24 to 72 hours after 
surgery which was comparably increased in Brd4 KO and control after TAC (data presented as mean 
+SD, each point represents the measurement for one animal, ****= p<0.0001, two-way ANOVA with 
Tukey test) (A). Kaplan-Meier curve (without the first 48 hours after surgery) showing a significantly 
increased mortality of Brd4 KO mice, especially within the first 40 days after TAC. Median survival in the 
Brd4 KO group was 36.5 days and 132 days in the control group (Gehan-Breslow-Wilcoxon test, * 
p=0.0188, numbers in brackets represent animals examined, dotted lines indicate median survival) (B). 
 
3.4.5 Brd4 KO attenuates cardiac remodeling after TAC 
Morphometric characterization confirmed that left ventricles of Brd4 KO mice showed 
moderate concentric hypertrophy at baseline (Sham) and revealed that left ventricular mass 
did not significantly increase within 5 weeks after TAC in these animals. In contrast, left 
ventricles of control animals were dramatically enlarged 5 weeks after TAC and were 
significantly larger than left ventricles of TAC-operated Brd4 KO mice (p<0.01, two-way 
ANOVA with Tukey post hoc test) (Figure 3.27 A-B). RT-qPCR was performed to determine 
mRNA levels of Nppa and Nppb and showed an extremely significant increase of both stress 
markers (p<0.0001, two-way ANOVA with Tukey post hoc test) in control and Brd4 KO hearts 
5 weeks after TAC (Figure 3.27 C-D). Notably, Brd4 KO animals that underwent Sham surgery 
had already significantly higher cardiac Nppa levels than the control animals after Sham 











































Figure 3.27: Brd4 KO and control mice show increased cardiac stress marker expression 5 weeks 
after TAC, but Brd4 KO mice do not develop cardiomegaly. 
Masson’s trichrome stain showed increase in size of the left ventricle after TAC in control but not in Brd4 
KO mice (bar=2 mm) (A). The left ventricular weight to body weight ratios were increased 5 weeks after 
TAC in both groups but significantly higher in control animals (error bars indicate SD) (B). Nppa mRNA 
expression was significantly increased in Brd4 KO Sham and both TAC groups (C), whereas Nppb 
mRNA expression was only significantly increased after TAC in Brd4 KO and control hearts (RT-qPCR, 
n=4-6) (D). Two-way ANOVA together with Tukey correction for multiple comparisons was used. Error 
bars indicate SEM if not stated otherwise, **= p<0.01, ***= p<0.001, ****= p<0.0001. 
 
Next, the size of cardiomyocytes was determined as MFD from histological WGA staining of 
heart cross sections (Figure 3.28). The comparison of the average MFDs and their distributions 
showed a significant enlargement of cardiomyocytes in control animals after TAC in 
comparison to Sham control (p<0.05, two-way ANOVA with Fischer’s LSD test, n=4-6), 
whereas the size of larger Brd4 KO cardiomyocytes at baseline did not further increase after 































































































Figure 3.28: The basal cardiomyocyte hypertrophy in Brd4 KO animals does not change after 
TAC. 
Representative pictures of Wheat Germ Agglutinin staining (A), analysis of the minimal fiber diameter 
(error bars indicate SEM) (two-way ANOVA with Fischer’s LSD test, *= p<0.05, n=4-6) (B) and its 
distribution confirmed basal cardiomyocyte hypertrophy in Brd4 KO animals and showed that cell size 
does not further increase after TAC (C).  
 
3.4.6 Brd4 KO hearts show basal fibrosis that increases after TAC 
Picro Sirius Red staining was used to visualize collagen type I and III in heart sections from 
control and Brd4 KO mice following Sham or TAC surgery allowing to measure interstitial 
fibrosis (Figure 3.29A). Semi-automated analysis revealed that in control 18%±3.4SEM and in 
Brd4 KO hearts 19%±3.8SEM of the cross-sectional area were fibrotic five weeks after TAC, 
which was almost 5-fold higher compared to Sham control hearts (p<0.05, two-way ANOVA 
with Tukey post hoc testing, n=4-6). However, Brd4 KO mice that underwent Sham surgery 
already showed mild fibrosis of about 12% in a direct comparison to Sham-control (p=0.0442, 
two-way ANOVA Fischer’s LSD test, n=4-6) (Figure 3.29B). These data suggest a basal 
activation of cardiac remodeling in Brd4 KO animals, leading to hypertrophy, expression of 
cardiac stress markers and mild fibrosis. After TAC, Brd4 KO and control mice showed 
































































animals were significantly larger. Moreover, Brd4KO mice showed significantly higher mortality 
within the first 40 days after TAC. This further suggests a limited capacity for cardiac 
remodeling after PO as well as a decreased compensatory potential in the acute phase after 
TAC in Brd4 KO animals. 
 
Figure 3.29: Brd4 KO hearts showed mild fibrosis after Sham that increased after TAC. 
Representative heart sections stained with Picro Sirius Red from a control and Brd4 KO mouse following 
Sham or TAC surgery (bars: overview=2 mm, detailed=200 µm) (A). Quantification of myocardial fibrosis 
in control and Brd4 KO hearts 5 weeks after Sham or TAC surgery. (B). Two-way ANOVA together with 
Tukey correction for multiple comparisons was used. Error bars indicate SEM. #= p<0.01 to Sham 
control, n=4-6. 
 
3.4.7 Brd4 KO mice show partially preserved heart function after TAC 
Analysis of echocardiographic images revealed differences in heart function and dimensions 
between control and Brd4 KO mice after pressure overload. Control animals showed a typical 
decrease of a basal ejection fraction of 52.5% (±6.2SD) to 41.1% (±10.4SD) (p=0.0018, two-
way ANOVA with Tukey, n=11-36) 5 weeks and 30.4% (±9.1SD) (p<0.0001, two-way ANOVA 
with Tukey, n=5-19) 10 weeks after TAC. In contrast, Brd4 KO animals showed a milder 
reduction of the heart function starting at an ejection fraction of 58% (±7.7SD), it decreased to 
46.9% (±8.1SD) (p=0.0247, two-way ANOVA with Tukey, n=12-20) 5 weeks and to 42.3% 
(±5.4SD) (p=0.0102, two-way ANOVA with Tukey, n=5-10) 10 weeks after TAC. Interestingly, 
Brd4 KO mice had significantly higher ejection fraction 10 weeks after TAC compared to TAC 
control (p=0.0018, two-way ANOVA with Tukey, n=10-19) (Figure 3.30A). Furthermore, left 

































animals (p<0.01, two-way ANOVA with Tukey, n=4-26) and stayed significantly lower in Brd4 
KO compared to control animals at all three time points after TAC (Figure 3.30B). Brd4 KO 
mice showed slightly thicker ventricular walls at baseline and almost no further wall thickening 
after TAC. Control animals, on the other hand, showed significant wall thickening one week 
after TAC (p=0.0061, two-way ANOVA with Tukey, n=4-20), which further increased with the 
duration of pressure overload (p<0.0001, two-way ANOVA with Tukey) (Figure 3.30C). The 
echocardiographic phenotyping confirms a basal concentric hypertrophy that leads to a slightly 
increased basal ejection fraction in Brd4 KO mice and suggests that those animals have a 
limited remodeling capacity as demonstrated by no to little wall thickening and dilatation. 
Nevertheless, after pressure overload heart function seems to be somehow preserved in Brd4 
KO animals or progression of HF slowed as ejection fraction decrease was not as dramatic as 
















































































Figure 3.30: Brd4 KO animals show limited remodeling capacity after TAC and slightly preserved 
ejection fraction. 
Echocardiographic phenotyping showed a mild ejection fraction reduction after TAC in Brd4 KO animals 
with significantly higher ejection fraction 10 weeks after TAC compared to TAC control (A). After TAC, 
left ventricular inner diameter was significantly lower in Brd4 KO compared to control animals (B). Brd4 
KO mice showed less wall thickening after TAC compared to control (C). Two-way ANOVA together with 
Tukey correction for multiple comparisons was used. Error bars indicate SD, *= p<0.05, **= p<0.01, 
***= p<0.001, ****= p<0.0001, each point represents the measurement for one animal. grey triangles= 
control, green dots= Brd4 KO. 
 
3.4.8 Brd4 KO induces differential expression of genes involved in ECM 
organization, energy metabolism, and cardiac muscle contraction 
The cardiomyocyte-specific knockout of Brd4 in adolescent murine hearts led to the 
development of concentric hypertrophy, fibrosis, and the expression of cardiac stress markers 
but ventricular diameter, ejection fraction, and viability remained unchanged. After TAC, 
however, Brd4 KO mice showed increased mortality but otherwise little changes in response 
to cardiac stress. And although the ejection fraction of Brd4 KO mice decreased, it remained 
higher than that of TAC control animals. To understand the effects of BRD4 absence in 
cardiomyocytes at baseline and after stress-induction hearts of Brd4 KO and control animals 
were allowed to rest for three days after the echocardiographic examination five weeks after 
Sham or TAC surgery before they were sacrificed, and their hearts dissected. The so obtained 
hearts were retrogradely perfused to remove residual blood and left ventricles of all four 
experimental groups used for subsequent mRNA sequencing. 
First, the basal impact of Brd4 deletion on transcription was analyzed. Differential expression 
analysis of Sham Brd4 KO to Sham control revealed 2902 DEGs (1317 up, dark red; 1585 
down, dark blue) (padj<0.05, log2FC±0.5) (Figure 3.31A). The RPKMs of the 2902 DEGs were 
plotted on a heatmap and showed 4 main gene clusters, Brd4 KO induced, Brd4 KO repressed, 
TAC and Brd4 KO induced, and TAC and Brd4 KO repressed (Figure 3.31B). Pathway analysis 
of the 1317 up-regulated genes in Sham Brd4 KO (padj<0.05, log2FC±0.5) showed an 
enrichment of genes involved in ECM organization, dilated cardiomyopathy, and AGE-RAGE 
signaling pathway (padj<0.05, Kappa=0.4) (Figure 3.31C). However, the 1585 down-regulated 
genes showed enrichment for GO terms associated with energy metabolism, oxidative 
phosphorylation, and cardiac muscle contraction (padj<0.05, Kappa=0.4) (Figure 3.31D). 
Moreover, left ventricles of Sham Brd4 KO mice showed significantly increased expression of 
cardiac stress markers (padj<0.05, log2FC±0.5) in comparison to Sham control (Figure 3.31E). 
Consequently, transcriptome analysis provides a link between the phenotypic and functional 
observations and Brd4 KO mediated differential expression of genes associated with cardiac 






Figure 3.31: Depletion of Brd4 from cardiomyocytes induces cardiac remodeling, alters ECM 
organization, energy metabolism, and cardiac muscle contraction. 
mRNA sequencing revealed 5621 DEGs (2645 up, red; 2976 down, blue) between Sham control and 
Sham Brd4 KO with padj<0.05. A subsequent cutoff at log2FC±0.5 resulted in 2902 DEGs (1317 up, 
dark red; 1585 down, dark blue). X-axis indicates number and percent of total DEG (A). A heatmap of 
the 2902 Sham Brd4 KO DEGs was clustered via centroid linkage with Pearson method and revealed 4 
clusters (B). ClueGO pathway analysis of 2902 DEGs from (A) (padj<0.05, log2FC±0.5) showed GO 
terms enriched for ECM organization, dilated cardiomyopathy, and AGE-RAGE signaling pathway for 
up-regulated genes (C) and enrichment of GO terms for energy metabolism, oxidative phosphorylation, 
and cardiac muscle contraction for down-regulated genes (padj<0.05, Kappa=0.4). Circle size 
represents padj (D). Relative expression of cardiac stress and remodeling markers is increased for 




The basal Brd4 KO effects resemble main features of hypertrophic cardiomyopathy (HCM) 
(Marian and Braunwald 2017). For validation, DEGs for Sham Brd4 KO versus Sham control 
were mapped to the according KEGG HCM pathway (red= up-regulated, blue= down-
regulated) (Figure 3.32). Upon Brd4 deletion, the expression of sarcomere genes (Myh7, 
Mybpc3, Tnnt2, Tnni3, Actc1) and of genes encoding ion channels involved in membrane 
repolarization (RyR2, SERCA2a) is modulated. The absence of BRD4 further led to increased 
expression of integrins, intermediate filaments (Dystrophin and Desmin) as well as the 
induction of factors like IGF-1, TGF-ß, TNF-α, and IL-6. The underlying gene expression 
changes provide a causal link to the observed basal Brd4 KO effects. 
 
 
Figure 3.32: Brd4 KO animals show gene expression changes associated with HCM. 
Schematic view of a cardiomyocyte with key proteins associated with the KEGG pathway map (05410) 
for hypertrophic cardiomyopathy (HCM). Differentially expressed genes for Sham Brd4 KO versus Sham 
control are highlighted (red= up-regulated, blue= down-regulated). Upon Brd4 deletion, sarcomere 
composition and Ca2+ handling is modulated which leads to activation of signaling pathways associated 
with cardiac remodeling such as hypertrophy, fibrosis, and heart failure. ACE1= angiotensin I-converting 
enzyme; ACTC1= actin; ACTG1= actin beta/gamma 1; DAG= dystroglycan 1; DHPR= voltage-
dependent calcium channel; DMD= dystrophin; IGF-1= insulin-like growth factor 1; IL6= interleukin 6; 
ITG= integrin; MYBPC3= myosin-binding protein C; MYH6= myosin heavy chain 6; MYH7= myosin 
heavy chain 7; Myl2= myosin regulatory light chain 2; Myl3= myosin light chain 3; NCX= solute carrier 
family 8 (sodium/calcium exchanger); PRKA= AMP-activated protein kinase; RyR= ryanodine receptor 
2; SERCA2a= ATPase sarcoplasmic/endoplasmic reticulum Ca2+ transporting 2; SGC= sarcoglycan; 
TGF-β= transforming growth factor beta-1; TnC= troponin C; TNF-α= tumor necrosis factor superfamily, 





















































































3.4.9 BRD4 depletion blunts the response to TAC-induced cardiac stress 
The basal effects of in vivo Brd4 depletion from cardiomyocytes as well as underlying biological 
processes have already been elaborated and revealed wide expression changes mainly 
associated with energy metabolism and cardiac muscle contraction that in turn most likely lead 
to the development of HCM. Subsequently, the impact of Brd4 KO on stress response was 
analyzed using our mRNA sequencing data. 
The comparison of DEGs for TAC control (2063 genes), TAC Brd4 KO (3882 genes), and 
Sham Brd4 KO (2901 genes) all versus Sham control (padj<0.05, log2FC±0.5) showed 1011 
genes common for all three groups (Figure 3.33A). This intersect included e.g. cardiac stress 
and remodeling markers such as Nppa, Nppb, Acta1, Rcan1, Ctgf, Il6, and Myh7, which were 
significantly increased in all three groups in comparison to Sham control (padj<0.05, 
log2FC±0.5), although Sham Brd4 KO showed slightly lower expression than the TAC groups 
(Figure 3.33B). Additional differential expression analyses were performed to enable the 
identification of genes differently regulated in TAC control and TAC Brd4 KO animals as well 
as to describe transcriptional changes in Brd4 KO mic in response to cardiac stress. For TAC 
control versus TAC Brd4 KO 2121 DEGs (926 up, dark red; 1195 down, dark blue) were 
detected (Figure 3.33C), whereas for Sham Brd4 KO and TAC Brd4 KO only 34 DEGs (19 up, 
dark red; 15 down, dark blue) were identified (padj<0.05, log2FC±0.5) (Figure 3.33D). KEGG 
pathway analysis of the 2121 DEGs between both TAC groups identified 42 enriched pathways 
that were manually assigned to the respective KEGG orthology categories. Thus, 21 metabolic 
pathways (blue), 10 pathways associated with organismal systems (green), 8 associated with 
human diseases (orange), and 3 associated with other KEGG categories (black) (padj<0.05, 
FDR<0.05) were detected. In contrast, the 34 DEGs from the comparison of Brd4 KO mice 
after Sham versus TAC showed no enrichment (Figure 3.33E).These analyses showed only 
marginal transcriptional changes after TAC in Brd4 KO hearts, but a wide range of differentially 
expressed genes mainly associated with metabolism and human diseases between TAC Brd4 






Figure 3.33: Brd4 KO hearts show marginal transcriptional changes after TAC, but a wide range 
of genes associated with metabolism and human diseases is differentially expressed between 
TAC Brd4 KO and TAC control. 
Overlap for DEGs (padj<0.05, log2FC±0.5) in TAC control (2063 genes) and TAC Brd4 KO (3882 genes) 
and Sham Brd4 KO (2901 genes), all versus Sham control (A). Relative expression of cardiac stress 
and remodeling markers is increased after TAC and after Brd4 depletion. Based on RPKM normalized 
to Sham control. Error bars indicate SEM (B). Differential expression analysis revealed 2121 DEGs (926 
up, dark red; 1195 down, dark blue) between TAC control and TAC Brd4 KO (C) and 34 DEGs (19 up, 
dark red; 15 down, dark blue) between Sham Brd4 KO and TAC Brd4 KO at a cutoff of padj<0.05 and 
log2FC±0.5. X-axis indicates number and percent of total DEG (D). KEGG pathway analysis (padj<0.05, 
FDR<0.05) with TAC Brd4 KO DEGs from (C) shows enrichment for 21 metabolic pathways (blue), 10 
pathways associated with organismal systems (green), 8 associated with human diseases (orange), and 
3 associated with other KEGG categories (black). The 34 DEGs from the comparison of Sham Brd4 KO 
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Finally, for a more precise description of Brd4 KO specific gene regulation, the resulting DEGs 
from six differential expression analyses were compared with a Venn diagram to identify 
subsets of genes. For further examination three clusters of genes were picked that are 
regulated only upon Brd4 deletion and independent of the surgery (Cluster #1), differentially 
regulated in Brd4 KO mice in comparison to TAC control (Cluster #2), and regulated in TAC 
control but not affected by Brd4 KO (Cluster #3) (Figure 3.34A). Cluster #3 resulted in 176 
genes regulated only in the TAC control group but did not show significant enrichment for any 
GO terms. I have identified 163 differentially regulated DEGs in Cluster #2, which showed an 
enrichment for biological processes such as ion transport, membrane repolarization, and 
muscle contraction. In Cluster #1 742 Brd4 KO exclusive DEGs were detected that showed an 
enrichment for mitochondrial membrane organization and metabolism (Figure 3.34). A 
subsequent pathway analysis revealed that Brd4 KO altered the energy metabolism, the 
response to mechanical stimulus, and cardiac muscle contraction (Appendix Figure 5.4) 
suggesting that BRD4 is important for the regulation of those processes in cardiomyocytes. 
These results demonstrate that BRD4 mostly affects energy metabolism and membrane 






Figure 3.34: Deletion of Brd4 mostly affects energy metabolism and membrane repolarization. 
Overlap for DEGs (padj<0.05, log2FC±0.5) from all 6 possible comparisons for the 4 sequencing groups 
Sham control, TAC control, Sham Brd4 KO, and TAC Brd4 KO. Three subgroups of DEGs are 
highlighted: Brd4 KO exclusive DEGs (Cluster #1), DEGs differentially regulated in Brd4 KO and TAC 
control (Cluster #2), and TAC-regulated and Brd4 KO reversed DEGs (Cluster #3) (A). A heatmap of 
the three DEG clusters depicted in (A) was clustered via centroid linkage with Pearson method (B). 
Overrepresentation analysis (ORA) of gene ontology (GO) terms of biological processes for 742 
significantly regulated genes in Cluster #1 (A-B) showed enrichment in mitochondrial membrane 
organization and metabolic processes (padj<0.05, FDR<0.05, Top10 sorted according to ratio of 
enrichment) (C). ORA of GO terms of biological processes for 163 significantly regulated genes in 
Cluster #2 (A-B) showed enrichment in ion transport, membrane repolarization, and muscle contraction 
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Heart failure (HF) is a multifactorial disease with a high prevalence and poor prognosis and 
therefore poses a socioeconomic burden for the whole population. It is the leading cause of 
hospitalizations and healthcare expenditures, which are predicted to double by the year 2030 
(Heidenreich et al. 2013). ACE inhibitors and ß-blockers are used for over 20 years to treat 
HF, but novel therapeutic strategies are needed as morbidity and mortality are still 
unacceptably high. Despite classical gene regulation by transcription factors, hemodynamic 
and hormonal stress can be implemented by epigenetic mechanisms like chromatin 
remodeling and acetylation to drive pathologic changes of the heart (Lee et al. 2017). The 
chromatin readers of the Bromo- and extraterminal domain (BET) protein family recognize 
acetylated histone residues associated with active transcription (Filippakopoulos et al. 2010). 
The small molecule JQ1 was shown to displace those readers from chromatin, to prevent 
pathologic cardiac remodeling, and to preserve heart function when applied in a mouse 
transverse aortic constriction (TAC) induced pressure-overload model (PO) (Anand et al. 2013; 
Spiltoir et al. 2013). In conclusion, BET proteins have been reported to control pathological 
cardiac hypertrophy (Spiltoir et al. 2013) by mediating transcriptional pause release in heart 
failure (Anand et al. 2013). But it remains elusive if JQ1 improves the outcome of PO, if it 
directly or indirectly affects the heart and what the individual functions of particular BET 
members are, as JQ1 is administered systemically and was shown to inhibit all proteins of the 
BET family. 
To help elucidate the individual roles of particular BET members in cardiac cells I first described 
their expression in the healthy and diseased adult mouse heart to validate and complement 
previous findings. Second, I examined the survival of JQ1 treated mice after TAC to test if BET 
inhibition does lead to an improved outcome after PO. Next, I used conditional alleles from our 
group to generate mice with cardiomyocyte specific knockout of Brd2 and Brd4, respectively. 
After validation and characterization of the newly generated mice, I investigated how these 
animals respond to TAC-induced PO and if they are protected from maladaptive cardiac 
remodeling as described for BET inhibition by JQ1. 
4.1 Expression of BET members in the healthy and diseased heart 
To characterize the basal expression of BET protein members in the healthy murine heart 
transcriptome analysis and immunoblotting using left ventricles of adult wildtype mice (FVB/N) 
was performed. Cardiac expression of Brd2, Brd3, and Brd4 was confirmed but in contrast to 
literature (Anand et al. 2013), Brd2 showed 4-fold higher mRNA levels than Brd3 and Brd4, 
respectively (Figure 3.1A). Human transcriptome data support these findings (Khadjeh, 




members, Brd2 as the highest expressed member in the heart, and Brd4 as the most 
interesting candidate in non-cardiac analyses. 
Immunocytochemistry confirmed that Brd2 (Spiltoir et al. 2013) and Brd4 (Anand et al. 2013; 
Spiltoir et al. 2013) are translated in cardiomyocytes and the proteins localized in the nucleus 
(Figure 3.1B-C). Using left ventricular total protein from adult mice for immunoblotting, BRD2 
was detected at about 110 kDa. As BRD4 shows low abundance in cardiac total protein (data 
not shown), subcellular protein fractions were obtained from left ventricle (2.2.8). BRD4 was 
detected at 100 kDa in the nuclear fraction and at 125 kDa in chromatin-bound protein (Figure 
3.1C). The higher molecular weight in the chromatin fraction is probably due to phosphorylation 
that has previously been described to act as trigger for the targeting of BRD4 to chromatin (Wu 
et al. 2013; Shu et al. 2016). These results confirm previous reports (Anand et al. 2013; Spiltoir 
et al. 2013) of BET expression in the murine heart as well as the nuclear localization of BRD2 
and BRD4 but in contrast to the literature not Brd4 (Anand et al. 2013) but Brd2 shows 
strongest cardiac expression. 
Moreover, to check if and how BET proteins are regulated upon PO induction, gene expression 
and protein levels were analyzed. Gene expression analyses showed that mRNA levels of 
Brd2, Brd3, and Brd4 are not regulated by TAC-induced hemodynamic stress (Figure 3.2A). 
However, RT-qPCR showed a significant prevalence for the short Brd4 isoform in the Sham 
group but a net shift towards the long isoform after TAC (Figure 3.2E). Immunoblotting supports 
the induction of the presumably long isoform of BRD4 after TAC. BRD2 protein levels, 
however, are not altered after the induction of PO. These results are in contrast to the 
previously reported TAC-mediated decrease of BRD2 and increase of BRD4 protein levels 
(Spiltoir et al. 2013; Haldar and McKinsey 2014), although the published whole blots show 
multiple (>9) unspecific protein bands that compromise the author’s conclusions.  
Nevertheless, there are some experimental differences that make direct comparisons of both 
studies difficult. In this study left ventricle from female FVB/N mice eight weeks after Sham or 
TAC surgery were used, whereas Spiltoir and colleagues examined left ventricles from male 
mice of the BL6/J strain four weeks after surgeries. Possible explanations for the differences 
might be sexual dimorphic gene expression (Isensee et al. 2008) or influence of the genetic 
background (Barnabei et al. 2010). Another explanation might be differential BET expression 
at different stages during disease progression as in my hands mice show advanced pathologic 
remodeling with signs of HF by 4-5 weeks and manifested HF by 8 weeks following TAC. 
However, my finding on the TAC-induced expression of the long Brd4 isoform can be 
complemented with functional data from a previous study. Schröder and colleagues showed 
that the short BRD4 associates with an inactive P-TEFb complex containing HEXIM1 and 7SK 
snRNA and that the long BRD4 can activate P-TEFb by blocking its interaction with HEXIM1-




expression in cardiac remodeling and HF (Anand et al. 2013; Spiltoir et al. 2013; Haldar and 
McKinsey 2014) might be mediated by stress-induced isoform shift from short to long Brd4 
with the according binding of active P-TEFb. Indeed, HEXIM1 has already been suggested as 
endogenous inhibitor of hypertrophy (Haldar and McKinsey 2014) but has not been linked to 
BRD4 isoforms so far. 
4.2 Cardio protective effects of JQ1 could not be reproduced 
BET bromodomain inhibition by JQ1 has been described to protect the murine heart from 
pathologic cardiac remodeling and to preserve ventricular function after TAC (Anand et al. 
2013; Spiltoir et al. 2013) and was described as an effective treatment for preestablished HF, 
more recently (Duan et al. 2017). But it was not reported if BET inhibition does also improve 
the prognosis after PO induction. Beside cardio protective properties, the final proof for an 
effective treatment of HF would be an improved outcome. To investigate if BET inhibition could 
decrease the TAC-mediated mortality, eight weeks old female mice of the C57BL/6N inbred 
strain were subjected to TAC or Sham and treated with JQ1 (50 mg/kg/day vs. vehicle control) 
daily for four weeks, beginning one day after surgery. The consistency of all TAC surgeries 
was demonstrated by comparable pressure gradients across the aortic constriction (Figure 
3.4). Survival analysis revealed that BET inhibition does not improve the outcome of TAC-
induced PO as JQ1 and vehicle treated animals showed comparable mortality after TAC 
(Figure 3.4). JQ1 treated mice showed pathologic cardiomegaly, myocardial expression of 
cardiac stress marker genes (Figure 3.5), and cardiomyocyte hypertrophy (Figure 3.6) after 
TAC. Moreover, echocardiography showed TAC-dependent systolic dysfunction, ventricular 
dilation, and wall thickening in JQ1 treated animals (Figure 3.7). The pathologic changes were 
comparable in JQ1 and vehicle treated mice, four and eight weeks after TAC. The only 
difference between the treatment groups was the significantly lower wall thickness four weeks 
after TAC in the JQ1 group, which was still significantly higher than in Sham control. These 
results contradict previous reports on cardio protective effects of JQ1 in the mouse PO model 
(Anand et al. 2013; Spiltoir et al. 2013; Duan et al. 2017). 
To further evaluate my findings and to validate JQ1-mediated BET inhibition, I analyzed the 
left ventricular gene expression profiles of vehicle or JQ1-treated animals 4 weeks after TAC 
via mRNA sequencing. After differential expression analysis to Sham vehicle and subtraction 
of differentially expressed genes (DEGs) from TAC vehicle, I found JQ1-dependent expression 
of genes involved in biological processes such as immune system development, cell activation, 
mitotic cell cycle, and cell division (Figure 3.8C). Pathway analysis further confirmed the 
influence of JQ1 on the immune response and cell cycle, but in addition revealed an effect on 
ECM, sarcolemma, and muscle contraction (Figure 3.9). Direct comparison of TAC vehicle to 




mostly involved in immune response (Figure 3.8D). These findings are consistent with previous 
reports of BRD4 being involved in cell cycle regulation (Dey et al. 2009; Filippakopoulos et al. 
2010), proliferation (Houzelstein et al. 2002), immune cell differentiation (Cheung et al. 2017a; 
Cheung et al. 2017b), and inflammation (Duan et al. 2017).  
Moreover, gene set enrichment analysis (GSEA) of TAC vehicle and TAC JQ1 showed a 
positive enrichment for ribonucleoprotein complex formation involved in splicing, RNA 
processing, and translation (Appendix Figure 5.3A). This is in line with previous reports of BRD4 
regulating stress-induced splicing (Hussong et al. 2017) and miRNA processing (Suzuki et al. 
2017) and suggests that BRD4 might be important for the response to metabolic and oxidative 
stress in the heart, although in this study no phenotypic or functional differences were observed 
after JQ1-treatment. 
Due to the controversies between this study and findings from Anand and colleagues we re-
analyzed the deposited microarray data of mice that received JQ1 or vehicle for 28 days after 
TAC surgery (Anand et al. 2013) and specifically screened for DEGs, which were differentially 
regulated in the treatment groups. Of the 391 TAC-induced and JQ1-reversed genes from 
Anand’s study 142 were differentially expressed in our data but not differentially regulated upon 
vehicle or JQ1 treatment (Figure 3.10). In addition, typical marker genes of cardiac remodeling 
are expressed in TAC vehicle and TAC JQ1 alike. Overall, these findings are consistent with 
our morphometric and functional data but contradict previous reports of JQ1-mediated cardio-
protection after TAC (Anand et al. 2013; Spiltoir et al. 2013). 
To confirm successful BET inhibition, the expression of BET inhibition biomarkers known from 
cancer research such as Hexim1, Serpini1, Zcchc24, Zmynd8 (Lin et al. 2017), Myc, Ccr2, 
CD180 (Yeh et al. 2017), or Bcl2 (Hogg et al. 2016) was examined but none of the genes were 
differentially expressed in TAC JQ1 animals four weeks after surgery (data not shown). It is 
likely that BET proteins have tissue specific targets, which might explain why none of the 
described biomarkers were regulated in our cardiac samples. Nevertheless, it cannot be fully 
excluded that our batch of JQ1 might have been decomposed despite special attention to 
storage, handling, and preparation according to the instructions from the Bradner lab. Future 
studies could repeatedly analyze the compounds integrity or collect blood samples for serum 
level measurements to ensure the proper quality and delivery of JQ1. 
As this study was not explicitly designed for direct comparison to previous work, the 
experimental setup shows some differences that might partially attribute to the contrary results. 
While I investigated female mice of the inbred strain C57BL/6N, Spiltoir, Anand, Duan and 
colleagues used male mice of the C57BL/6J strain (Anand et al. 2013; Spiltoir et al. 2013; 
Duan et al. 2017). Several studies describe the genetic background of mouse models as 
confounding factor in cardiovascular research (Barnabei et al. 2010; Garcia-Menendez et al. 




pressure and heart weight normalized to tibia length are significantly higher in healthy 
C57BL/6J than in C57BL/6N mice but did not detect any basal structural or functional 
differences by echocardiography (Simon et al. 2013). More importantly in context of this study, 
C57BL/6N mice were reported to show significantly lower survival and cardiac function but 
increased heart weight, lung weight, and Nppb levels after TAC when compared with C57BL/6J 
(Garcia-Menendez et al. 2013). In addition, sex-specific differences in cardiac gene expression 
such as elevated Nppb levels (2.7-fold) in female mice have been described, although older 
animals were examined in that study (Isensee et al. 2008). Furthermore, in this study mice 
were subjected to TAC at the age of 8 to 9 weeks, not at 10-12 (Anand et al. 2013) or 10 to 11 
weeks (Duan et al. 2017). Although age, sex, or genetic background might alter pathogenesis 
or the sensitivity to pharmaceuticals such as BET inhibitors, it seems unlikely that these factors 
could entirely prevent the previously published strong cardioprotective effects of JQ1. 
Another explanation for the conflicting results might be the overall experimental variability of 
TAC, which together with a low number of replicates might lead to statistical artefacts. TAC 
surgeries in this work and previous studies on BET protein members in the heart (Anand et al. 
2013; Spiltoir et al. 2013; Duan et al. 2017) were performed according to the most common 
procedure originally described by Rockman and colleagues. Thus, by tying a ligature around 
the transverse aorta and a 27 G needle as spacer and carefully removing the needle, the aorta 
is constrained to the diameter of the needle and a gaged aortic stenosis is produced (Rockman 
et al. 1991). Following TAC, mice show a significant aortic gradient and develop concentric 
hypertrophy within one to two weeks (Rockman et al. 1991; deAlmeida et al. 2010). However, 
this technique has two major downsides. First, the same spacer (27 G) is used for constriction 
regardless of the sex, body weight and aortic dimensions of the animals, thus, causing 
variability in the degree of constriction among individual animals (Merino et al. 2018). Secondly, 
the tightness of the ligature has an influence on the degree of constriction as well (Merino et 
al. 2018). Both factors introduce a significant variability into resulting pressure gradients and 
the development of cardiac hypertrophy. Therefore, it is crucial to report pressure gradients for 
possibly all animals included in further analysis to assure successful and consistent TACs, 
especially if this could falsify the working hypothesis. This is the major shortcoming of previous 
studies that report cardio protective effects of BET inhibition by JQ1, of which only Anand and 
colleagues (Anand et al. 2013) reported pressure gradients for four animals per group. 
Conversely, in this study I report pressure gradients for all JQ1 or vehicle-treated animals 
following Sham (n=7-17) or TAC (n=29-39) surgery.  
Moreover, beside factors such as anesthesia (Roth et al. 2002), sex, age, and bodyweight, 
echocardiographic analysis is subject to intra- and inter-observer as well as technical variability 
(Donner et al. 2018; Lindsey et al. 2018). Interventions such as TAC further increase this 




individual animals. Using echocardiographic data from our previous studies for power 
calculations, I determined a sample size of fourteen (n=14) animals to allow a sufficient 
statistical power for the mouse PO model (Appendix Figure 5.1). Consequently, I report 
echocardiographic data for 6-17 Sham and 20-24 TAC animals 4 weeks after surgery treated 
either with vehicle or JQ1, whereas previous studies reported data for seven (Duan et al. 2017), 
six to ten (Spiltoir et al. 2013), and ten animals (Anand et al. 2013) after surgeries. 
A future comparative study on BET inhibition by JQ1 after PO in age-matched male and female 
mice of C57BL6/N and C57BL/J strains could address these conflicting results and possibly 
neglect or confirm sex-specific or genetic differences in the cardiac function of BETs. 
4.3 Functional analysis of Brd2 and Brd4 in the murine heart 
The previously reported cardio-protective effects of BET inhibition by JQ1 after PO were not 
confirmed but also not disproved in this study as it cannot be excluded that experimental 
differences such as age, sex, and genetic background might lead to discrepant results. To 
evaluate the potential of BET proteins as targets for HF treatment and to overcome the limits 
of systemic and simultaneous inhibition of all BET members, it is necessary to further dissect 
the functions of particular BET proteins specifically in cardiac cells. In this work, I used two 
murine conditional BET alleles, Brd2flox and Brd4flox, which were previously generated in our 
group (Eva Benito, unpublished), to induce Cre-mediated recombination in cardiomyocytes 
and to analyze the respective loss of Brd2 and Brd4 function in vivo. 
4.3.1 Generation of mice with cardiomyocyte-specific deletion of the first 
bromodomain of BRD2 
Breeding of mice carrying our conditional Brd2 allele with mice of the αMHC-Cre line, which 
express a constitutively active Cre recombinase exclusively in cardiomyocytes (Agah et al. 
1997), resulted in progeny with a genomic deletion of Brd2 exons three and four (Figure 3.11). 
All mice bred normally, and the litters showed Mendelian genotype distribution. Cre-positive 
mice homozygous for the mutant allele are viable. The deletion of exons three and four does 
not lead to the intended nonsense-mediated decay but to the expression of a truncated Brd2 
mRNA (Figure 3.12). Sequence data and immunoblotting strongly suggest that exon 2 of the 
truncated mRNA is omitted leading to in-frame translation from an internal start codon 
downstream of the region encoding for the first bromodomain (Figure 3.13). Therefore, the Cre-
mediated deletion of exons three and four generated a mutant allele of Brd2 that expresses a 
truncated BRD2 protein lacking the first bromodomain (BRD2∆BDI). 
Several studies reported gene targeting approaches using the CRISPR/Cas9 (Kapahnke et al. 
2016; Mou et al. 2017; Sharpe and Cooper 2017) or the Cre/loxP system (Yang et al. 2009) to 




knockout allele. Interestingly, this has also been described for the BET protein member Brdt. 
In the attempt to produce a null allele of the testis specific Brdt in mouse, Shang and colleagues 
deleted exons two, three, and four and generated a mutant allele that expresses a truncated 
BRDT protein lacking the first bromodomain (BDI). This accidental deletion allowed the first 
functional analysis of an individual BET bromodomain in vivo and demonstrated that BRDT-
BDI is necessary for sperm differentiation as male mice homozygous for this mutant Brdt allele 
produce fewer and abnormal sperm, thus, becoming infertile (Shang et al. 2007).  
Distinct functions of the two bromodomains of BET proteins were later reported in various other 
studies. For example, it was shown that BRD3 directly interacts with the acetylated 
hematopoietic transcription factor GATA binding factor 1 (GATA1) via its BDI and that this 
interaction is essential for the recruitment of GATA1 to its target sites on the chromatin as 
demonstrated by BET inhibition via GW841819X (Gamsjaeger et al. 2011; Lamonica et al. 
2011). In a different study, Shi and colleagues reported individual functions for the BRD4 
bromodomains, with BDI binding to acetylated histone 4 residues and BDII linked to di-
acetylated transcription factor Twist. The BRD4-Twist complex controls WNT5A expression in 
breast cancer, and BET inhibitors JQ1 and MS417 were demonstrated to dissociate this 
complex and to suppress tumorigenicity (Shi et al. 2014).  
With the development of more specific molecules that selectively inhibit individual BET 
bromodomains, the therapeutic value of BET inhibition increases. Furthermore, these BET 
inhibitors of the ‘second generation’ help to further establish distinct roles for BDI and BDII. 
Olinone, a BET BDI inhibitor, was described to induce the differentiation of oligodendrocytes, 
whereas inhibition of both BET bromodomains had an opposite effect (Gacias et al. 2014). The 
small molecule RVX-208 selectively inhibits BET BDII (Picaud et al. 2013), is currently in phase 
III clinical trials for treating atherosclerotic cardiovascular disease, and was linked to the 
decrease of major adverse cardiac events (Gilham et al. 2016). 
In contrast to BRD3, BRD4, and BRDT, functional information for BRD2 bromodomains is 
sparse, although BRD2 was described to couple histone acetylation to transcription (LeRoy et 
al. 2008). In particular, BRD2 was shown to recognize acetylated H4 tails via its BDI 
(Nakamura et al. 2007; Filippakopoulos et al. 2010; Umehara et al. 2010; Filippakopoulos et 
al. 2012) and to recruit proteins such as E2F and HDACs to chromatin (Houzelstein et al. 2002; 
Fu et al. 2015). Based on the reported link between BRD2-BDI and transcription, I decided to 
further characterize the newly generated Brd2∆BDI mice to examine morphologic and 
functional consequences upon the loss of the first bromodomain of BRD2 in the healthy adult 




4.3.2 Heart development, function and remodeling are independent from the 
first bromodomain of BRD2 
The newly generated Brd2∆BDI mice were used to examine the functional role of the first 
bromodomain of Brd2 in cardiomyocytes regarding heart development, morphology, function, 
and its response to TAC-induced PO. Homozygous Brd2∆BDI mice are viable, have normal 
sized hearts and cardiomyocytes and do not show any defects or abnormalities of the heart by 
the age of 3 months. Further, echocardiography revealed normal heart dimensions and systolic 
function with three and six months but a slightly increased left ventricular diameter in six 
months old animals (Figure 3.14). These findings suggest that the development of the murine 
heart as well as its size, shape, and function are independent from the first bromodomain of 
BRD2. Conversely, BRD2 might be substituted with BRD2∆BDI or other proteins to maintain 
its possible, if any, functions in cardiomyocytes. Future studies could examine and compare 
the chromatin occupation of BRD2 and BRD2∆BDI by e.g. chromatin immunoprecipitation and 
subsequent sequencing to clarify if the first bromodomain is needed to bind specific BRD2 
target regions in cardiomyocytes. 
However, Brd2∆BDI and cre control mice mostly died by the age of 45 to 50 weeks (data not 
shown). In addition, histology revealed the formation of degenerative vacuoles in 
cardiomyocytes of six months old animals in both groups (Figure 3.14B). Such vacuoles have 
been linked to cardiotoxicity (An et al. 2017) and are probably due to chronic Cre-recombinase 
activity. Cre-dependent cardiotoxicity has been previously described (Davis et al. 2012) and 
was also shown to cause mortality (Bersell et al. 2013). The cardiotoxic effect is dependent on 
Cre recombinase levels in the nucleus as well as on the duration of its nuclear localization 
(Bersell et al. 2013; Lexow et al. 2013), and is probably due to Cre off-target activity at cryptic 
loxP sites in the genome (Loonstra et al. 2001, Semprini et al. 2007).  
I further investigated if the first bromodomain of Brd2 contributes to cardiac remodeling in 
response to PO. Therefore, eight to ten weeks old Brd2∆BDI mice were subjected to TAC, 
analyzed by echocardiography five weeks after surgery, and either sacrificed for subsequent 
histological and molecular testing or monitored for their survival for up to 120 days after 
surgery. Five weeks after PO induction Brd2∆BDI animals showed pathologic hypertrophy and 
systolic dysfunction without any significant differences to the Cre-negative littermates and the 
cre control group (Figure 3.17 and Figure 3.18). Brd2∆BDI mice showed TAC-induced cardiac 
stress marker expression with Nppa levels being significantly higher compared to TAC control 
(Figure 3.17 and Figure 3.18). These findings suggest BRD2-BDI to be dispensable for the 
response to hemodynamic stress and for the according morphologic and functional changes 
of the heart. Based on the elevated Nppa levels one might speculate that Brd2∆BDI possibly 
regulates Nppa expression but this needs further investigation. Furthermore, TAC-dependent 




reports and my own observations discussed before, the increased mortality is likely a Cre-
dependent effect. This is a limitation I did not expect and that could be overcome in future 
studies by using an inducible Cre-line to reduce nuclear Cre levels or by using a CRISPR/Cas9 
mediated gene targeting approach. 
The deletion of the first BRD2 bromodomain did not elicit phenotypic changes neither in the 
healthy heart nor after PO induction, although chromatin acetylation in general has previously 
been shown to play an important role in the development of HF (Backs and Olson 2006) and 
as BRD2 was demonstrated to bind e.g. acetylated lysine 12 on histone 4 (H4K12ac) (Kanno 
et al. 2004). Chromatin binding has been especially linked to the first bromodomain of BRD2 
as it was shown to form homodimers and to recognize H4K12ac in the context of H4K8ac, 
which binds a cavity at the dimer interface of BRD2-BDI (Umehara et al. 2010). In addition, the 
first bromodomain of BRD2 was shown to bind a tetra-acetylated H4 peptide at lysins 5, 8, 12, 
and 16 with a 10-fold higher affinity than the second bromodomain of BRD2 and, thus, Brd2-
BDI was proposed to be responsible for the recognition of H4 tails (Filippakopoulos et al. 2012). 
Consequently, the mutant BRD2∆BDI described in this work is probably unable to recognize 
and bind acetylated chromatin but it might maintain specific functions of the second 
bromodomain such as scaffolding of enhancer complexes. Such function can be derived from 
a recent study in T helper 17 cells. Cheung and colleagues nicely demonstrated that BRD2 
supports enhancer assembly at cis-regulatory elements by binding to acetylated signal 
transducer and activator of transcription 3 (STAT3) via its second bromodomain (Cheung et 
al. 2017b). It is possible that the second bromodomain is sufficient for the heart-specific 
function of BRD2. 
Altogether, my findings suggest that proper heart development, normal heart function, and 
cardiac remodeling in response to hemodynamic stress are independent from the first 
bromodomain of BRD2. This was unexpected as CaMKIIa-Cre-mediated targeting of our 
conditional Brd2 allele and, thus, hippocampal BRD2∆BDI expression was shown to have a 
strong effect on cognition by impairing spatial learning (Eva Benito, unpublished). These 
differences indicate tissue-specific functions for individual BET bromodomains and might have 
therapeutic potential. With the development of novel BET inhibitors, selective targeting of 
particular BET bromodomains became available and could be used specifically in the context 
of a given disease and target tissue. This work suggests that the first bromodomain of BRD2 
might not be a promising therapeutic target for cardiac hypertrophy and HF and, consequently, 
that therapeutic use of BET-BDI inhibitors for non-cardiac diseases possibly has no adverse 
effects on cardiomyocytes, at least in the context of Brd2. To further evaluate Brd2 as potential 
therapeutic target, future studies could investigate its role in more detail by using a null allele 
or by deleting the second bromodomain in cardiac cells. Maybe this would partially resemble 




three-fold higher affinity to the second of the two BRD2 bromodomains (Filippakopoulos et al. 
2010). 
4.3.3 Successful generation of cardiomyocyte-specific Brd4 knockout mice 
JQ1-dependent BET inhibition was described to prevent features of pathologic cardiac 
remodeling such as the activation of stress-induced transcription, pathologic hypertrophy, 
interstitial fibrosis, and systolic dysfunction after pressure overload (PO). This led to the 
hypothesis that BET proteins promote HF by co-activation of target genes in response to 
pathologic stress in the heart (Haldar and McKinsey 2014).  
However, JQ1 acts systemically and simultaneously inhibits all BET members and thus does 
not allow precise conclusions on the function of particular BET members in a certain tissue- or 
cell-type. To challenge the proposed HF promoting function of BET proteins and to overcome 
limitations of previous studies, my aim was to examine the loss-of-function of Brd4 in 
cardiomyocytes in vivo and especially after induction of PO using a genetic approach. This 
work presents the first in vivo insight into the function of Brd4 in cardiomyocytes and its 
consequences on heart development, function, and on pathologic cardiac remodeling. 
At the beginning of this thesis, no conditional Brd4 allele was available, but recently two groups 
reported independent generation of such alleles in mouse. Lee and colleagues generated two 
conditional Brd4 alleles by flanking exon three or exon five with two loxP sites, respectively, 
and used the resulting mice to disrupt Brd4 in adipocytes and myocytes. Brd4 deficient mice 
died after birth and showed severe reduction of brown adipose tissue and muscle mass. In 
subsequent analyses, Brd4 was shown to bind active enhancers and to control differentiation 
of adipocytes but to be dispensable in maintaining terminally differentiated adipose tissue (Lee 
et al. 2017). Bao and colleagues targeted exon three to deplete Brd4 in myeloid-lineage cells 
and found Brd4 to modulate the innate immune response (Bao et al. 2017).  
However, in order to allow the examination of Brd4 functions in vivo, our group generated mice 
carrying a Brd4fl/fl allele. To disrupt Brd4 function in cardiomyocytes, mice carrying our 
conditional Brd4 allele with floxed exons six and seven were crossed to aMHC-Cre mice (Agah 
et al. 1997), which express a constitutively active Cre recombinase from early embryonic 
development throughout the animals lifespan (Davis et al. 2012). Mice with a heterozygous 
Brd4 knockout in cardiomyocytes were viable and showed no cardiac defects (data not shown). 
This suggests that a single copy of Brd4 is sufficient for its cardiac function and is consistent 
with previous reports that did not observe any cardiac phenotype in mice with a heterozygous 
global Brd4 knockout (Houzelstein et al. 2002). However, progeny of the F2 generation showed 
non-Mendelian genotype distribution as only one out of almost 100 pups was Cre-positive and 
carried two copies of the floxed allele (Cre+ ; Brd4fl/fl) (Figure 3.19) but died prematurely at 
postnatal week six. This suggests embryonic lethality upon homozygous Brd4 deletion in 




homozygous Brd4 knockout that died shortly after implantation at about embryonic day 5.5 
(E5.5) (Houzelstein et al. 2002; Gyuris et al. 2009).  
The heart is the first organ formed during organogenesis and the main steps of its development 
are the establishment of the cardiac mesoderm at E7.5, the development of the heart tube at 
E8, looping of the heart at E8.5, the formation of the heart chambers at E10.8, and the 
formation of the four-chambered heart at E14.5 (Nandi and Mishra 2015). Impaired expression 
of genes involved in cardiac differentiation and development leads to fetal heart failure, cardiac 
arrest and in-utero death by E14.5 (Nandi and Mishra 2015). The dysregulation of genes 
crucial for proper cardiogenesis after deletion of Brd4 is the most likely explanation for the 
observed embryonic lethality as BRD4 has been previously described to be essential for cell 
differentiation (Houzelstein et al. 2002; Lee et al. 2017). The birth of the only Cre+ ; Brd4fl/fl 
mouse might be due to later onset of Cre-expression, incomplete Cre-dependent 
recombination during embryogenesis or an unknown genetic factor. The role of Brd4 in 
cardiogenesis has not been further examined as this work focused on BET protein function in 
the adult heart.  
Therefore, the Tamoxifen-inducible αMHC-MerCreMer mouse line (Sohal et al. 2001) was 
used to allow Brd4 disruption at a later timepoint (Figure 3.20). Lexow and colleagues 
previously demonstrated that Tamoxifen itself has no effect in MerCreMer-negative animals 
and that cytosolic MerCreMer alone is not toxic (Lexow et al. 2013). However, MerCreMer 
translocation into the nucleus and, thus, activity increases dependent on the dose of Tamoxifen 
and may induce cardiomyocyte apoptosis, myocardial fibrosis, and cardiac dysfunction (Bersell 
et al. 2013). To achieve efficient Cre-mediated recombination on one hand but to minimize 
cardiotoxic effects of nuclear Cre recombinase on the other hand, Tamoxifen has been 
administered at the previously proposed optimal concentration of 30 mg/kg/day on three 
consecutive days (Bersell et al. 2013). Tamoxifen administration caused 10-20% mortality 
within the first two weeks after injection (data not shown), which is a known limitation of the 
inducible Cre-loxP-system and has been previously described as a loxP independent DNA 
damage response that leads to myocardial dysfunction and death (Bersell et al. 2013). 
However, the remaining Tamoxifen-induced animals were viable and lived for over one year. 
Further, to account for this acute mortality and to allow the reversion of any transient effects of 
Tamoxifen-induced MerCreMer activation (Higashi et al. 2009; Hougen et al. 2010) animals 
were administered to Tamoxifen at postnatal week five and thus at least three weeks prior to 
further interventions or measurements.  
The breeding of mice carrying our conditional Brd4 allele to αMHC-MerCreMer mice resulted 
in progeny with Mendelian genotype frequencies. All mice hetero- or homozygous for the 
conditional Brd4 allele and positive for the inducible Cre recombinase were viable and bred 




induced MerCreMer-mediated deletion of exons 6 and 7 of Brd4 led to an extremely significant 
depletion of Brd4 mRNA (Figure 3.21) demonstrating the successful knockout of Brd4 in 
cardiomyocytes. However, Brd4 knockout could not be demonstrated on protein level. Western 
blot analysis showed no BRD4 reduction in left ventricular protein fractions, whereas nuclear 
protein from isolated cardiomyocytes of Brd4 KO animals showed only a slight reduction of 
BRD4 protein levels (Figure 3.22). This might be due to limitations such as the overall low 
abundance of BRD4 in the heart, BRD4 from residual non-cardiomyocytes in nuclear protein 
from isolated cardiomyocytes, and residual BRD4 expression in 10-20% of cardiomyocytes 
without Cre-mediated recombination. The western blot conditions and, thus, the proof of BRD4 
depletion might be improved in the future by optimizing the purity of isolated cardiomyocytes 
or performing immune precipitation prior to western blotting. 
Nevertheless, the extremely decreased Brd4 mRNA levels in cardiomyocytes demonstrate 
successful and complete Brd4 disruption and were convincing enough to proceed with the first 
in vivo study of Brd4 loss-of-function in the mouse heart. 
4.3.4 BRD4 is necessary to suppress hypertrophic genes in the healthy heart 
The newly generated Brd4 KO mice were characterized using morphometric and 
echocardiographic methods, to investigate if the loss of Brd4 in cardiomyocytes alters cardiac 
morphology or function, and, thus, to determine if Brd4 is involved in maintaining the adult 
heart. The deletion of Brd4 was induced by tamoxifen injection at postnatal week five. The 
resulting knockout mice were viable and usually lived for more than 12 months. Brd4 KO mice 
showed left ventricular wall thickening, increased left ventricular to body weight ratios, and 
increased cardiomyocyte diameters in three and six months old animals, whereas left 
ventricles were non-dilated (Figure 3.23 -Figure 3.24). However, the systolic function of Brd4 
KO, which is presented as ejection fraction (EF), was not altered in comparison to controls. 
Furthermore, echocardiographic examination of tamoxifen-induced MerCreMer+ control 
animals demonstrated that the left ventricular wall thickening in Brd4 KO mice is not attributed 
to tamoxifen or Cre-activity (Figure 3.24). Thus, mice lacking BRD4 in cardiomyocytes develop 
a basal concentric hypertrophy with preserved ejection fraction and no adverse effect on 
survival.  
These findings suggest a basal growth-regulating function for BRD4 in the adult heart. On the 
one hand, this is consistent with previous studies that demonstrated the association of BRD4 
with enhancer and promoter regions of pro-hypertrophic genes (Anand et al. 2013; Spiltoir et 
al. 2013; Haldar and McKinsey 2014; Duan et al. 2017). On the other hand, these studies 
proposed BRD4-dependent transcriptional activation of pro-hypertrophic genes in response to 
cardiac stress, whereas my data suggest a basal suppression of hypertrophy genes by BRD4. 
Together these findings point towards two distinct roles of BRD4 in the heart, a basal negative 




expression that might be implemented by a shift from the short to the long BRD4 isoform upon 
cardiac stress as previously discussed (4.1).  
A basal negative regulation of target genes in the healthy heart might be conveyed through 
recruitment of transcriptional repressors by BRD4 as recently reported in pancreatic cells, in 
which a complex of the Euchromatic Histone Lysine Methyltransferase 2 (EHMT2) with BRD4 
represses autophagy and lysosome genes (Sakamaki et al. 2017). Furthermore, the short 
isoform of BRD4 has been described to co-repress HIV transcription through interaction with 
SWI/SNF nucleosome remodelers (Conrad et al. 2017). Very recently, Lambert and colleagues 
also reported a repressive function of BRD4 possibly through interaction with negative 
transcriptional regulators such as nucleosome remodeling and deacetylase (NuRD) or 
negative elongation factor (NELF) (Lambert et al. 2018). 
In the heart, a basal negative regulatory BRD4 function is further supported by molecular and 
histologic analyses of Sham Brd4 KO mice, which showed that the disruption of Brd4 in 
cardiomyocytes leads to the basal expression of cardiac stress markers (Figure 3.27C) and the 
development of a mild fibrosis (Figure 3.29). In addition, transcriptome analysis revealed that 
Brd4 KO leads to differential expression of a wide range of genes involved in biological 
processes such as cell cycle, ECM organization, energy metabolism, oxidative 
phosphorylation, cardiac muscle contraction, and dilated cardiomyopathy (Figure 3.31). 
Consistent with these findings, BRD4 was demonstrated to bind promoters of genes involved 
in mitochondrial bioenergetics and oxidative phosphorylation in vitro using human cytoplasmic 
hybrid cells (Barrow et al. 2016). In contrast to this work, Barrow and colleagues demonstrated 
the induction of the according genes upon Brd4 depletion, but the difference might be due to 
tissue-specific function of BRD4. Moreover, Brd4 KO mice show the reactivation of fetal genes 
such as the fetal myosin heavy chain 7 (Myh7), atrial natriuretic peptide (Nppa), or actin alpha 
1 (Acta1) (Figure 3.31E), which are common markers for cardiac remodeling and hypertrophy 
(Hill and Olson 2008; van Berlo et al. 2013; Nakamura and Sadoshima 2018). 
Nevertheless, it remains unclear which factors activate the transcription of Brd4 target genes 
in Brd4 KO mice. One can speculate that the remaining BET members BRD2 and BRD3 
occupy BRD4 binding sites in its absence and promote transcription of the Brd4 target genes. 
Indeed, no left ventricular wall thickening or cardiomyocyte hypertrophy was observed after 
displacement of all BET members from chromatin by JQ1 in Sham animals neither in this work 
nor in previous studies (Anand et al. 2013; Duan et al. 2017). A future study could address this 
open question by JQ1 administration in Brd4 KO mice to test if BET inhibition might rescue the 
basal concentric hypertrophy phenotype.  
Furthermore, pathway analysis of the Sham Brd4 KO expression data showed regulation of 
genes encoding for sarcomere proteins (Myh7, Mybpc3, Tnnt2, Tnni3, Actc1) and ion channels 




sensitivity of myofilaments, abnormal Ca2+ levels and an energy deficit (Fatkin and Graham 
2002). The analysis further revealed altered expression of integrins, intermediate filaments 
(Dystrophin and Desmin) as well as the activation of factors like IGF-1, TGF-ß, TNF-α, and IL-
6. Such dysregulation might lead to left ventricular diastolic dysfunction, hypertrophy and 
eventually to heart failure (Fatkin and Graham 2002).  
Altogether, the observed Brd4 KO effects in the adult murine heart resemble characteristics of 
hypertrophic cardiomyopathy (HCM). HCM is an inheritable cardiac condition that is 
characterized by concentric hypertrophy of the left ventricle without any stimulant pressure or 
volume overload, a non-dilated left ventricle, and normal or increased ejection fraction (Marian 
and Braunwald 2017). HCM is caused by mutations in genes encoding sarcomere proteins 
and is mostly inherited (Marian and Roberts 1998; Marian and Braunwald 2017). However, 
HCM shows a broad spectrum of phenotypic expression even in patients with mutations in the 
same gene, which is likely due to differences in genetic background and epigenetic factors 
(Marian 2002; Zhao et al. 2015; Marian and Braunwald 2017). As the Brd4 KO mouse 
presented in this work develops basal HCM without any known sarcomeric mutation, one could 
speculate that a certain sarcomere protein composition or expression of certain isoforms might 
induce HCM. Therefore, our Brd4 KO mice could be used in future studies to identify specific 
factors that drive development or lead to phenotypic variations of HCM. 
An example for another mouse that spontaneously develops a concentric hypertrophy is the 
mitogen-activated protein kinase kinase 1 (MEK1) transgenic mouse, which expresses an 
activated form of MEK1 under the control of the α-MHC promoter. The MEK1 mouse was 
reported to sustain the hypertrophic phenotype with increased heart function, and survival for 
over 12 months, and to show increased Nppa, Nppb, Actc1 as well as Myh7 mRNA levels 
(Bueno et al. 2000). In contrast to our Brd4 KO mouse, however, MEK1 does not show signs 
of interstitial fibrosis. Nevertheless, it is possible that the deletion of Brd4 somehow leads to 
activation of the MEK1-ERK1/2 pathway, which in turn might drive the development of a 
concentric hypertrophy observed in Brd4 KO animals. This possible explanation could be 
examined in the future by e.g. immunoblotting and quantification of total and phosphorylated 
ERK. 
4.3.5 Brd4 is necessary for the PO-induced remodeling and hypertrophy 
I further investigated if Brd4 depletion from cardiomyocytes influences cardiac remodeling in 
response to PO to challenge previous findings on cardio protective effects of JQ1-mediated 
BET inhibition (Anand et al. 2013; Spiltoir et al. 2013). Therefore, eight to ten weeks old Brd4 
KO mice were subjected to TAC, analyzed by echocardiography one and five weeks after 
surgery and either sacrificed for subsequent histological and molecular testing or received 





Consistent with the basal characterization, BRD4 KO mice subjected to Sham showed 
concentric hypertrophy but, in addition, significantly higher Nppa levels (Figure 3.27) and mild 
interstitial fibrosis (Figure 3.29) when compared to Sham control. In comparison, five weeks 
after TAC Brd4 KO and control mice showed no significant differences in Nppa/Nppb levels, 
cardiomyocyte diameters, and fibrosis although hearts of control animals were significantly 
larger (Figure 3.27). However, Brd4KO mice showed significantly higher mortality within the 
first 40 days after TAC (Figure 3.26). Nevertheless, heart function seems to be partially 
preserved in surviving Brd4 KO animals after PO or progression of HF slowed as ejection 
fraction decrease was not as dramatic as in the control group (Figure 3.30). These findings 
demonstrate that Brd4 KO animals have a limited capacity for cardiac remodeling after PO as 
well as a decreased compensatory potential in the acute phase after TAC. This suggests that 
Brd4 is necessary for the response to hemodynamic stress, which is consistent with previous 
reports (Anand et al. 2013; Spiltoir et al. 2013).  
Interestingly, similar observations were reported for the chromatin remodeling protein Brg1, 
which plays an important role in gene regulation, differentiation and growth of cardiac cells in 
embryos (Hang et al. 2010). Brg1 is silenced in adults but gets re-expressed upon cardiac 
stress to drive hypertrophy and isoform switch from adult (Myh6) to embryonic myosin heavy 
chain (Myh7) in complex with HDAC and poly (ADP ribose) polymerase (PARP) (Hang et al. 
2010). However, a knockout of Brg1 prevents hypertrophy and the myosin isoform switch 
demonstrating that Brg1 is essential for the response to cardiac stress (Hang et al. 2010). In 
comparison to Brd4 KO, depletion of Brg1 shows no basal cardiac phenotype (Hang et al. 
2010).  
HCM is associated with diastolic dysfunction, arrythmias, and even sudden cardiac death 
(Marian and Braunwald 2017), which might be possible explanations for the increased TAC-
mediated mortality of Brd4 KO animals. Diastolic dysfunction is manifested by left ventricular 
stiffening due to thickened ventricular walls with interstitial fibrosis, which leads to decreased 
left ventricular relaxation reducing the ventricle’s ability to fill with blood and contributes to the 
development of heart failure with preserved ejection fraction (HFpEF) (LeWinter and Meyer 
2013; Marian and Braunwald 2017). As Brd4 KO mice show a basal concentric hypertrophy 
and interstitial fibrosis, the development of a diastolic dysfunction is likely. This could be 
validated by measuring the left ventricular pressure and -volume via cardiac catheterization 
(Zhang et al. 2015) in future experiments. Furthermore, cellular disarray that occurs in the 
damaged heart can disrupt the normal electrical conduction in the heart and lead to arrythmias, 
which in turn can cause sudden cardiac death (Farza and Watkins 1999; Marian and 
Braunwald 2017). Electrocardiography (ECG) could be performed to analyze if Brd4 KO mice 
show heart rate variability or arrythmias. The surgical implantation of ECG telemeters is a well-




used to monitor multiple mice over several weeks (McCauley and Wehrens 2010). Both cardiac 
catheterization and implantation of ECG telemeters are additional interventions that have to 
be approved by the authorities and will be conducted thereafter to examine the causes of 
increased TAC-mediated mortality of Brd4 KO animals in the future. 
Consistent with previous observations, mRNA sequencing of Brd4 KO hearts showed that 
BRD4 controls genes associated with cardiac remodeling. However, in contrast to the reported 
stress-induced activation, my findings suggest that BRD4 suppresses these genes in the 
healthy adult murine heart (Figure 3.31E). Those opposing functions do not have to be mutually 
exclusive but rather point towards two distinct roles of Brd4, one in the healthy and the other 
in the stressed heart.  
To further examine the effect of cardiomyocyte-specific Brd4 disruption on stress-response, 
DEGs from the comparison of TAC Brd4 KO and TAC vehicle mice were used for KEGG 
pathway analysis. The analysis for TAC Brd4 KO specific DEGs revealed an enrichment of 
genes associated with metabolism, cellular respiration, and various human diseases such as 
HCM, dilated cardiomyopathy, Parkinson’s, Alzheimer’s, and Huntington’s disease (Figure 
3.33D), which share features such as mitochondrial dysfunction, oxidative stress, endoplasmic 
reticulum stress as well as immune response. These findings show that Brd4 depletion leads 
to metabolic remodeling, deficient energy metabolism, production of reactive oxygen species, 
and inflammation, which are known to promote pathologic hypertrophy, fibrosis, and heart 
failure (Nakamura and Sadoshima 2018).  
Interestingly, at our cutoff (padj<0.05, log2FC±0.5) only 34 genes were differentially expressed 
in Brd4 KO mice after TAC versus Sham and showed no enrichment for KEGG pathways 
(Figure 3.33C). This shows that gene expression of BRD4 KO mice is mostly unaffected by 
TAC-induced stress and vice versa suggests that BRD4 is essential for the response to such 
cardiac stress, although basal remodeling is already induced by the Brd4 disruption itself 
(Figure 3.31E). This is consistent with our experimental results as histologic, morphometric, 
and echocardiographic analyses showed only slight differences between Brd4 KO mice after 
Sham or TAC surgery (3.4.5 - 3.4.7). 
Furthermore, I identified genes that are regulated only upon Brd4 deletion and independent of 
the surgery and found them associated with mitochondrial membrane organization (Figure 
3.34), energy metabolism, the response to mechanical stimulus, and cardiac muscle 
contraction (Appendix Figure 5.4) suggesting that BRD4 regulates these processes in 
cardiomyocytes. Moreover, analysis of genes differentially regulated in Brd4 KO mice in 
comparison to TAC control showed their involvement in biological processes such as ion 
transport, membrane repolarization, and muscle contraction (Figure 3.34). This is consistent 
with the observed HCM phenotype, which can be induced by impairments in the sarcomere 




Future studies could compare my transcriptome data to the chromatin occupation of BRD4 in 
order to determine if the observed expression changes are due to direct regulation by BRD4 
or rather secondary effects. Moreover, ATAC (Assay for Transposase-Accessible Chromatin) 
sequencing (Buenrostro et al. 2015) could be performed to analyze if the overall chromatin 
structure in Brd4 KO mice is changed. 
The here described genetic approach was used to investigate the functions of individual BET 
members specifically in cardiomyocytes to challenge findings of cardio-protective effects 
previously described with systemic BET inhibition. However, the comparison of findings from 
my Brd4 KO experiments to JQ1-mediated BET inhibition is limited. Beside the intended cell-
specificity and targeting of one BET member at a time, the general difference between 
depletion and inhibition as well as the different timepoints of knockout induction and reported 
BET inhibition need to be considered. Recently Winter and colleagues demonstrated that in 
contrast to BET inhibition, BET degradation by a small-molecule degrader of BET family 
proteins (dBET6) impairs the assembly of a transcription elongation complex without affecting 
CDK9 recruitment. This study proposed BET proteins as master regulators of productive 
transcription elongation (Winter et al. 2017). The different effects might be due to BET functions 
apart from chromatin such as competitive interactions with nuclear factors that are lost after 
degradation but remain with BET inhibitors or by residual chromatin-binding despite inhibition. 
Furthermore, the here presented Cre-mediated Brd4 knockout was induced three weeks 
before TAC, whereas BET protein inhibition via JQ1 started one day after TAC in previous 
studies.  
These different timepoints for loss or inhibition of Brd4 function might lead to distinct effects 
after PO. As an example, inhibition of the long non-coding RNA cardiac hypertrophy associated 
epigenetic regulator (Chaer1), which is necessary for the development of cardiac hypertrophy, 
was shown to attenuate cardiac hypertrophy and dysfunction when performed before but not 
after PO (Wang et al. 2016). To investigate the influence of timing on the effect of Brd4 deletion, 
the Cre-mediated recombination could be induced after the onset of PO in future studies and 
compared to this work. 
4.4 Conclusions 
To complement existing data on cardiac effects after BET inhibition I have analyzed the 
survival of JQ1-treated mice after TAC but could not find any significant difference to vehicle 
treated animals. Indeed, the previously described cardio-protective effects could not be 
reproduced in this work, possibly due to factors such as gender and genetic background of the 
examined mice. Therefore, further investigation is needed for clarification. 
Next, to explore the potential of targeting BET proteins as treatment of HF and to overcome 




of Brd2 and the complete loss of Brd4 in cardiomyocytes in healthy mice as well as after 
induction of PO. The deletion of the first bromodomain of Brd2 did not elicit any substantial 
phenotype during development, in the adult heart, or after induction of pressure overload 
leading to the conclusion that the first bromodomain of BRD2 or the full length BRD2 is not 
essential in murine cardiomyocytes. These findings are relevant in regard to therapeutic BET 
inhibition, as directed inhibition of the first BET bromodomain in a non-cardiac context most 
probably would not affect cardiac cells in terms of BRD2 function. 
However, a cardiomyocyte-specific knockout of Brd4 was lethal if induced during early 
embryonic development but a knockout during adolescence led to the development of a 
hypertrophic cardiomyopathy (HCM) with the animals surviving for over twelve months. In 
conclusion, BRD4 is essential during cardiac development and necessary for negative 
regulation of genes promoting cardiac remodeling and hypertrophy in differentiated 
cardiomyocytes. Furthermore, Brd4 KO mice showed an increased mortality within the first 
four weeks after TAC, which is most likely due to diastolic dysfunction, arrythmias, and sudden 
cardiac death common for HCM. Nevertheless, surviving Brd4 KO mice showed better heart 
function than TAC control animals, which might point towards some cardio-protective effect of 
cardiomyocyte-specific Brd4 depletion. In addition, cardiac stress had almost no impact on 
gene expression as only 34 DEGs were detected (padj<0.05, log2FC±0.5) for Brd4 KO mice 
after TAC compared to Sham (Figure 3.33C). A likely explanation based on previous reports of 
BRD4 being integral for the response to hemodynamic stress (Anand et al. 2013; Spiltoir et al. 
2013; Haldar and McKinsey 2014) is that our Brd4 KO mice lose the ability to integrate such 
stress due to the absence of BRD4 from cardiomyocytes. A second, more speculative, 
explanation might be that a BRD4-independent response to TAC is somehow blunted or 
inhibited due to Brd4 KO mediated expression changes preceding the surgery such as the 
induction of HCM. 
Based on the findings of this thesis complemented with relevant literature I propose two distinct 
cardiac functions for BRD4: first, the negative regulation of e.g. pro-hypertrophic genes in the 
healthy heart and, second, the activation of pro-hypertrophic and other pathologic genes after 
pressure overload (Figure 4.1). BRD4 has recently been proposed as co-repressor in non-
cardiac tissues and cells (Conrad et al. 2017; Sakamaki et al. 2017; Lambert et al. 2018) but 
the underlying mechanisms remain elusive. The dual BRD4 function could be mediated by its 
interaction with negative transcriptional regulators such as EHMT2 (Sakamaki et al. 2017), 
NuRD (Lambert et al. 2018), SWI/SNF nucleosome remodelers (Conrad et al. 2017) or with 
positive transcriptional regulators like P-TEFb (Jang et al. 2005; Yang et al. 2005, p. 200). The 
functional shift could also be mediated by the switch from the short BRD4 to its long isoform 
after stress-induction as demonstrated in 3.1.2 hence enabling interaction with either an 





Figure 4.1: A model of BRD4 function in cardiomyocytes including relevant literature. 
BRD4 has possibly two distinct functions in cardiomyocytes of the adult murine heart. After pressure 
overload BRD4 and active P-TEFb (CDK9, CyclinT) induce transcription of the stress response gene 
program. Findings from this work suggest that in the healthy heart BRD4 co-represses target genes 
involved in energy metabolism, Ca2+ handling, cardiac muscle contraction, ECM coupling, and cell 
growth as the knockout of Brd4 leads to their induction. In its absence BRD4 target genes get probably 
activated by another chromatin reader or a different mechanism. The negative gene regulation might be 
mediated through chromatin occupation by BRD4 in interaction with e.g. an inactive P-TEFb (HEXIM1-
7SK-bound) complex or other negative transcriptional regulators. However, the functional shift from 
transcriptional repression to activation upon pressure overload could be mediated by a stress-induced 
isoform switch from short to long BRD4, which prevents the association of the inhibitory HEXIM1-7SK 
complex to P-TEFb thus promoting the transcription of stress response genes. 
 
Although the underlying mechanisms must be elucidated in future studies, my findings 
underscore the therapeutic potential of BRD4 for heart failure and depending on the condition 
might allow two distinct strategies. As the knockout of Brd4 induced HCM in healthy mice it 
would be interesting to test if e.g. an AAV-mediated overexpression of the short BRD4 isoform 
would rescue the phenotype in these mice. If successful, this approach could be tested in an 
independent HCM model. Furthermore, I concluded that the stress response might be 
mediated by the long BRD4 isoform. To challenge this hypothesis and to test if an isoform shift 
could be therapeutically exploited, the long but not the short BRD4 isoform could be silenced 







































Table 5.1: LV M-Mode – Calculation Definitions 
Name Description Units Formula 
LV Vol;d Left ventricle volume 
diastole 
µl ((7.0 / 2.4 + LVID;d)) * LVID;d3 
LV Vol;s Left ventricle volume 
systole 
µl ((7.0 / 2.4 + LVID;s)) * LVID;s3 
%EF LV ejection fraction % 100 * ((LV Vol;d – LV Vol;s) / LV Vol;d) 
%FS LV Fractional 
Shortening 
% 100 * ((LVID;d – LVID;s) / LVID;d) 
LV Mass LV Mass Uncorrected mg 1.053 * ((LVID;d + PWTh;d + AWTh;d)3 – LVID;d3) 
LV Mass Cor LV Mass corrected mg LV Mass * 0.8 
LV-W/BW LV weight to 
bodyweight 
mg/g LV Mass / body weight 
(adapted from Vevo instruction manual) 
 
Table 5.2: ImageJ script - Minimal Fiber diameter 
1. run("Gaussian Weighted Median", "radius=2");   
2. run("Subtract Background...", "rolling=15 sliding");   
3. run("Enhance Contrast...", "saturated=0.01 normalize");   
4. run("Threshold Regional Gradient", "circularity=0.3 minimum=300 maximum=15000 fill_phase fill_detected
 method=Fast");   
5. run("Adjustable Watershed", "tolerance=5");   
6. run("BinaryDilateNoMerge4 ", "iterations=3 white");   
7. run("Invert");   
8. run("Dilate");   
9. run("Invert");   
10. run("Fill Holes");   
11. run("Analyze Particles...", "size=50-Infinity circularity=0.30-1.00 show=Outlines display exclude add");  
 
Table 5.3: ImageJ script – Fibrotic area 
1. run("RGB Stack");   
2. run("Next Slice [>]");   
3. run("Next Slice [>]");   
4. run("Auto Threshold", "method=Minimum");   
5. run("Measure");   
6. run("Previous Slice [<]");   
7. run("Auto Threshold", "method=MaxEntropy");   






Figure 5.1: Power calculation to determine sample size for animal experiments. 
Distribution plot generated with G*Power (v. 3.1.9.2) (Faul et al. 2007) using the depicted parameters 
for calculation. Effect size was calculated as Cohen’s d (Cohen 1988) using previous ejection fraction 




Figure 5.2: Knockdown validation of the BRD2 and BRD4 antibodies used in this thesis. 
Protein from wildtype human pancreatic cancer cell line BxPC3 was compared to that of cells after gene 
silencing of Brd2, Brd3, or Brd4 by immunoblotting against BRD2 (A) or BRD4 (B). Western blot analysis 
and figures in A-B were performed and kindly provided by Ana Kutschat and Feda Hamdan (Johnsen 
lab). 
 
 - Means: Difference between two independent means (two groups)
A priori: Compute required sample size
Tail(s) = Two
Effect size d = 1.4293820
α err prob = 0.05
Power (1-β err prob) = 0.95
Allocation ratio N2/N1 = 1
Noncentrality parameter δ = 3.7817893
Critical t = 2.0555294
Df = 26
Sample size group 1 = 14
Sample size group 2 = 14
Total sample size = 28
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Figure 5.3: Gene set enrichment analysis reveals BET-mediated regulation of RNA processing, 
translation initiation, biosynthesis, and transport in TAC JQ1 mice. 
Gene set enrichment analysis (GSEA, Broad Institute) in TAC vehicle versus TAC JQ1 revealed 49 
positively enriched GO gene sets (padj<0.05, FDR<0.25). The GO categories were manually clustered 
into ‘Transport’, ‘Translation initiation’, ‘Splicing’, ‘RNA processing’, ‘Ribonucleoprotein complex’, 
‘Biosynthesis’ (A). GSEA for TAC vehicle and TAC JQ1 against exemplary GO gene sets from three of 















Macromolecule Transmembrane Transporter Activity
Monoamine Transport
Protein Targeting to Mitochondrion






SMN Sm Protein Complex
Precatalytic Spliceosome
U12 Type Spliceosomal Complex
Spliceosomal Complex
U5 snRNP
RNA Splicing via Transesterification Reactions
Spliceosomal snRNP Assembly
Regulation of mRNA Splicing via Spliceosome









Termination of RNA Polymerase II Transcription
tRNA Methylation
RNA Processing
Nuclear Transcribed mRNA Catabolic Process Exonucleolytic
ncRNA Processing
Maturation of 5.8S rRNA
tRNA Modification
ncRNA 3'-end Processing
Regulation of Telomerase RNA Localization to Cajal Body
Ribonucleoprotein Complex Localization




Ubiquitin-like Protein Conjugating Enzyme Activity
Histone mRNA Metabolic Process
Hsp70 Protein Binding
Cellular Protein Complex Disassembly
Nucleoside Triphosphate Biosynthetic Process
Macromolecular Complex Disassembly






















































































Table 5.4: Sequence alignment of truncated Brd2 mRNA 
cDNA of the truncated Brd2 mRNA was sequenced and aligned to the annotated main Mus musculus 
Brd2 transcript “CCDS28641.1”. Original translation start codon (ATG) in exon 2 is highlighted in yellow. 
The intended premature stop codon (TAA) in exon 5 is underscored. An internal in-frame ATG in exon 
5 (green) can act as alternative start codon and lead to the translation of a truncated BRD2 (amino acid 
sequence provided). 
                    <exon 2-----------------------------------------------><exon 3---------------------------- 
'Brd2 mRNA'         CTGAGCGGCGGCGGTTCCCTGAGGTCAAGATGCTGCAAAACGTGACTCCCCACAAGCTCCCTGGGGAAGGGAATGCAGGGTTACTGGGGC 
                                                                                                               
'mutant Brd2 mRNA'  CTGAGCGGCGGCGGTTCCCTGAGGTCAAGATGCTGCAAAACGTGACTCCCCACAA----------------------------------- 
 
                    ------------------------------------------------------------------------------------------ 
'Brd2 mRNA'         TGGGCCCAGAGGCAGCAGCACCAGGGAAAAGGATTCGAAAGCCTTCTCTGCTGTATGAGGGATTTGAGAGCCCCACAATGGCTTCTGTAC 
                                                                                                               
'mutant Brd2 mRNA'  ------------------------------------------------------------------------------------------ 
 
                    ------------------------------------------------------------------------------------------ 
'Brd2 mRNA'         CAGCTTTACAACTGGCCCCTGCCAATCCACCACCCCCTGAGGTGTCCAATCCCAAAAAGCCAGGACGGGTAACAAACCAACTGCAGTACC 
                                                                                                               
'mutant Brd2 mRNA'  ------------------------------------------------------------------------------------------ 
 
                    ---------------------------------------------------------------------------------------->< 
'Brd2 mRNA'         TGCACAAGGTAGTGATGAAGGCTCTGTGGAAGCATCAGTTTGCATGGCCATTCCGGCAGCCTGTGGACGCTGTGAAGCTGGGTTTGCCGG 
                                                                                                               
'mutant Brd2 mRNA'  ------------------------------------------------------------------------------------------ 
 
                    exon 4------------------------------------------------------------------------------------ 
'Brd2 mRNA'         ATTATCACAAAATTATAAAACAGCCTATGGACATGGGTACTATCAAGAGGAGACTTGAAAACAATTACTACTGGGCTGCCTCAGAATGTA 
                                                                                                               
'mutant Brd2 mRNA'  ------------------------------------------------------------------------------------------ 
 
                    ----------------------------------------------><exon 5------------------------------------ 
'Brd2 mRNA'         TGCAGGATTTTAATACTATGTTTACCAACTGTTACATTTATAACAAGCCCACCGATGATATTGTCCTAATGGCACAGACACTGGAAAAGA 
                                                                                        <M><A><Q><T><L><E><K>< 
'mutant Brd2 mRNA'  -----------------------------------------------CCCACCGATGATATTGTCCTAATGGCACAGACACTGGAAAAGA 
 
                    ------------------------------------------------------------------------------------------ 
'Brd2 mRNA'         TCTTCCTACAGAAAGTAGCATCCATGCCACAAGAGGAGCAAGAGCTTGTGGTGACCATCCCTAAAAACAGCCATAAGAAGGGGGCCAAGT 
                    I><F><L><Q><K><V><A><S><M><P><Q><E><E><Q><E><L><V><V><T><I><P><K><N><S><H><K><K><G><A><K>< 
'mutant Brd2 mRNA'  TCTTCCTACAGAAAGTAGCATCCATGCCACAAGAGGAGCAAGAGCTTGTGGTGACCATCCCTAAAAACAGCCATAAGAAGGGGGCCAAGT 
 
                    -----><exon 6----------------------------------------------------------------------------- 
'Brd2 mRNA'         TAGCAGCACTCCAGGGCAGTATTACCAGTGCCCATCAGGTGCCTGCTGTCTCTTCTGTGTCGCATACAGCCCTGTATACACCACCACCTG 
                    L><A><A><L><Q><G><S><I><T><S><A><H><Q><V><P><A><V><S><S><V><S><H><T><A><L><Y><T><P><P><P>< 
'mutant Brd2 mRNA'  TAGCAGCACTCCAGGGCAGTATTACCAGTGCCCATCAGGTGCCTGCTGTCTCTTCTGTGTCGCATACAGCCCTGTATACACCACCACCTG 
 
                    ------------------------------------------------------------------------------------------ 
'Brd2 mRNA'         AAATACCTACCACTGTCCTCAACATTCCCCACCCATCAGTCATCTCTTCTCCTCTTCTTAAGTCCCTGCATTCTGCTGGACCCCCACTCC 
                    E><I><P><T><T><V><L><N><I><P><H><P><S><V><I><S><S><P><L><L><K><S><L><H><S><A><G><P><P><L>< 
'mutant Brd2 mRNA'  AAATACCTACCACTGTCCTCAACATTCCCCACCCATCAGTCATCTCTTCTCCTCTTCTTAAGTCCCTGCATTCTGCTGGACCCCCACTCC 
 
                    ----------------------------------------><exon 7------------------------------------------ 
'Brd2 mRNA'         TTGCTGTATCAGCAGCGCCTCCAGCTCAGCCCCTTGCCAAGAAAAAAGGCGTTAAACGGAAAGCGGATACTACCACCCCTACACCCACAG 
                    L><A><V><S><A><A><P><P><A><Q><P><L><A><K><K><K><G><V><K><R><K><A><D><T><T><T><P><T><P><T>< 
'mutant Brd2 mRNA'  TTGCTGTATCAGCAGCGCCTCCAGCTCAGCCCCTTGCCAAGAAAAAAGGCGTTAAACGGAAAGCGGATACTACCACCCCTACACCCACAG 
 
                    ------------------------------------------------------------------------------------------ 
'Brd2 mRNA'         CCATCCTGGCTCCTGGTTCCCCAGCTAGTCCTCCTGGGAGTCTTGAGCCAAAGGCAGCAAGGCTCCCTCCTATGCGCAGAGAGAGTGGCC 
                    A><I><L><A><P><G><S><P><A><S><P><P><G><S><L><E><P><K><A><A><R><L><P><P><M><R><R><E><S><G>< 
'mutant Brd2 mRNA'  CCATCCTGGCTCCTGGTTCCCCAGCTAGTCCTCCTGGGAGTCTTGAGCCAAAGGCAGCAAGGCTCCCTCCTATGCGCAGAGAGAGTGGCC 
 
                    ------------------------------------------------------------------------------------------ 
'Brd2 mRNA'         GCCCAATCAAACCCCCACGAAAAGACTTGCCTGACTCGCAACAGCAACACCAGAGCTCTAAGAAAGGGAAGCTGTCAGAGCAGTTAAAGC 
                    R><P><I><K><P><P><R><K><D><L><P><D><S><Q><Q><Q><H><Q><S><S><K><K><G><K><L><S><E><Q><L><K>< 







                    ------------------------------------------------------------------------------------------ 
'Brd2 mRNA'         ACTGCAACGGCATCCTGAAGGAACTGCTCTCAAAGAAGCACGCTGCCTACGCCTGGCCCTTCTATAAGCCAGTGGACGCTTCTGCTCTTG 
                    H><C><N><G><I><L><K><E><L><L><S><K><K><H><A><A><Y><A><W><P><F><Y><K><P><V><D><A><S><A><L>< 
'mutant Brd2 mRNA'  ACTGCAACGGCATCCTGAAGGAACTGCTCTCAAAGAAGCACGCTGCCTACGCCTGGCCCTTCTATAAGCCAGTGGACGCTTCTGCTCTTG 
 
                    -------------------------------------------------------><exon 8--------------------------- 
'Brd2 mRNA'         GCCTTCATGATTACCATGACATCATTAAACACCCCATGGACCTCAGCACTGTCAAGCGGAAGATGGAGAACCGTGACTACCGGGATGCAC 
                    G><L><H><D><Y><H><D><I><I><K><H><P><M><D><L><S><T><V><K><R><K><M><E><N><R><D><Y><R><D><A>< 
'mutant Brd2 mRNA'  GCCTTCATGATTACCATGACATCATTAAACACCCCATGGACCTCAGCACTGTCAAGCGGAAGATGGAGAACCGTGACTACCGGGATGCAC 
 
                    ------------------------------------------------------------------------------------------ 
'Brd2 mRNA'         AGGAGTTTGCTGCTGATGTACGGCTTATGTTCTCCAACTGCTATAAGTACAATCCTCCAGACCACGATGTTGTGGCTATGGCACGAAAGT 
                    Q><E><F><A><A><D><V><R><L><M><F><S><N><C><Y><K><Y><N><P><P><D><H><D><V><V><A><M><A><R><K>< 
'mutant Brd2 mRNA'  AGGAGTTTGCTGCTGATGTACGGCTTATGTTCTCCAACTGCTATAAGTACAATCCTCCAGACCACGATGTTGTGGCTATGGCACGAAAGT 
 
                    ----><exon 9------------------------------------------------------------------------------ 
'Brd2 mRNA'         TGCAGGATGTGTTTGAGTTTCGCTATGCCAAGATGCCAGATGAGCCACTGGAACCAGGACCTCTACCAGTCTCTACTGCCTTGCCTCCTG 
                    L><Q><D><V><F><E><F><R><Y><A><K><M><P><D><E><P><L><E><P><G><P><L><P><V><S><T><A><L><P><P>< 
'mutant Brd2 mRNA'  TGCAGGATGTGTTTGAGTTTCGCTATGCCAAGATGCCAGATGAGCCACTGGAACCAGGACCTCTACCAGTCTCTACTGCCTTGCCTCCTG 
 
                    ------------------------------------------------------------------------------------------ 
'Brd2 mRNA'         GGTTGACCAAATCCTCTTCAGAGTCCTCCAGTGAGGAAAGTAGCAGTGAGAGTTCCTCTGAGGAAGAGGAGGAGGAGGAAGAAGATGAGG 
                    G><L><T><K><S><S><S><E><S><S><S><E><E><S><S><S><E><S><S><S><E><E><E><E><E><E><E><E><D><E>< 
'mutant Brd2 mRNA'  GGTTGACCAAATCCTCTTCAGAGTCCTCCAGTGAGGAAAGTAGCAGTGAGAGTTCCTCTGAGGAAGAGGAGGAGGAGGAAGAAGATGAGG 
 
                    ----------------------------------------------------------------------><exon 10----------- 
'Brd2 mRNA'         ACGAGGAGGAGAGTGAAAGCTCAGACTCTGAGGAGGAAAGGGCTCATCGCCTAGCAGAGCTGCAGGAGCAGCTTCGGGCAGTTCATGAAC 
                    D><E><E><E><S><E><S><S><D><S><E><E><E><R><A><H><R><L><A><E><L><Q><E><Q><L><R><A><V><H><E>< 
'mutant Brd2 mRNA'  ACGAGGAGGAGAGTGAAAGCTCAGACTCTGAGGAGGAAAGGGCTCATCGCCTAGCAGAGCTGCAGGAGCAGCTTCGGGCAGTTCATGAAC 
 
                    ------------------------------------------------------------------------------------------ 
'Brd2 mRNA'         AACTGGCTGCCCTGTCCCAGGGCCCAATATCTAAGCCCAAGCGGAAGAGAGAGAAAAAGGAAAAAAAGAAGAAACGGAAGGCAGAGAAAC 
                    Q><L><A><A><L><S><Q><G><P><I><S><K><P><K><R><K><R><E><K><K><E><K><K><K><K><R><K><A><E><K>< 
'mutant Brd2 mRNA'  AACTGGCTGCCCTGTCCCAGGGCCCAATATCTAAGCCCAAGCGGAAGAGAGAGAAAAAGGAAAAAAAGAAGAAACGGAAGGCAGAGAAAC 
 
                    ------------------------------------------------------------------------------------------ 
'Brd2 mRNA'         ATCGTGGCCGAATTGGGATCGATGAAGATGATAAGGGGCCTAGGGCACCTCGCCCACCTCAGCCCAAGAAATCTAAGAAAGCAGGTGGTG 
                    H><R><G><R><I><G><I><D><E><D><D><K><G><P><R><A><P><R><P><P><Q><P><K><K><S><K><K><A><G><G>< 
'mutant Brd2 mRNA'  ATCGTGGCCGAATTGGGATCGATGAAGATGATAAGGGGCCTAGGGCACCTCGCCCACCTCAGCCCAAGAAATCTAAGAAAGCAGGTGGTG 
 
                    ---------------------------------------------------------------><exon 11------------------ 
'Brd2 mRNA'         GGGGTAGCAATGCTACTACACTCAGCCATCCTGGCTTTGGGACTTCCGGAGGAAGTAGCAACAAGCTACCTAAAAAGTCTCAAAAGACAG 
                    G><G><S><N><A><T><T><L><S><H><P><G><F><G><T><S><G><G><S><S><N><K><L><P><K><K><S><Q><K><T>< 
'mutant Brd2 mRNA'  GGGGTAGCAATGCTACTACACTCAGCCATCCTGGCTTTGGGACTTCCGGAGGAAGTAGCAACAAGCTACCTAAAAAGTCTCAAAAGACAG 
 
                    ------------------------------------------------------------------------------------------ 
'Brd2 mRNA'         CTCCACCTGTCCTTCCCACTGGCTATGATTCTGAGGAGGAGGAAGAAAGCAGGCCCATGAGTTATGATGAGAAGAGACAGTTAAGCCTGG 
                    A><P><P><V><L><P><T><G><Y><D><S><E><E><E><E><E><S><R><P><M><S><Y><D><E><K><R><Q><L><S><L>< 
'mutant Brd2 mRNA'  CTCCACCTGTCCTTCCCACTGGCTATGATTCTGAGGAGGAGGAAGAAAGCAGGCCCATGAGTTATGATGAGAAGAGACAGTTAAGCCTGG 
 
                    ------------------------------------------------------------------------------------------ 
'Brd2 mRNA'         ATATCAATAAGTTACCTGGGGAAAAGCTGGGTCGAGTAGTACATATCATCCAAGCCAGGGAACCCTCTCTACGTGATTCAAATCCAGAAG 
                    D><I><N><K><L><P><G><E><K><L><G><R><V><V><H><I><I><Q><A><R><E><P><S><L><R><D><S><N><P><E>< 
'mutant Brd2 mRNA'  ATATCAATAAGTTACCTGGGGAAAAGCTGGGTCGAGTAGTACATATCATCCAAGCCAGGGAACCCTCTCTACGTGATTCAAATCCAGAAG 
 
                    ------------------------------------------------------------------------------------------ 
'Brd2 mRNA'         AAATTGAGATTGATTTTGAAACACTCAAGCCGTCCACACTTAGAGAGCTTGAGCGATATGTTTTATCCTGCCTTCGAAAGAAACCCCGGA 
                    E><I><E><I><D><F><E><T><L><K><P><S><T><L><R><E><L><E><R><Y><V><L><S><C><L><R><K><K><P><R>< 
'mutant Brd2 mRNA'  AAATTGAGATTGATTTTGAAACACTCAAGCCGTCCACACTTAGAGAGCTTGAGCGATATGTTTTATCCTGCCTTCGAAAGAAACCCCGGA 
 
                    --------><exon 12------------------------------------------------------------------------- 
'Brd2 mRNA'         AGCCCTACACTATTAGGAAACCTGTGGGAAAAACAAAGGAGGAACTGGCTTTGGAGAAGAAGCGGGAGCTAGAGAAGCGGTTGCAGGATG 
                    K><P><Y><T><I><R><K><P><V><G><K><T><K><E><E><L><A><L><E><K><K><R><E><L><E><K><R><L><Q><D>< 
'mutant Brd2 mRNA'  AGCCCTACACTATTAGGAAACCTGTGGGAAAAACAAAGGAGGAACTGGCTTTGGAGAAGAAGCGGGAGCTAGAGAAGCGGTTGCAGGATG 
 
                    -----------------------------------------><exon 13---------------------------------------- 
'Brd2 mRNA'         TCAGTGGACAGCTCAACTCCACCAAAAAGCCTCCCAAGAAAGCGAGTGAGAAGACAGAGTCATCTGCACAGCAAGTGGCAGTGTCCCGTC 
                    V><S><G><Q><L><N><S><T><K><K><P><P><K><K><A><S><E><K><T><E><S><S><A><Q><Q><V><A><V><S><R>< 





                    ------------------------------------------------------------------------------------------ 
'Brd2 mRNA'         TCAGTGCTTCTAGTTCCAGCTCAGATTCCAGCTCCTCGTCGTCATCTTCCTCTTCTTCAGACACCAGCGATTCAGACTCGGGCTAAGGGG 
                    L><S><A><S><S><S><S><S><D><S><S><S><S><S><S><S><S><S><S><S><D><T><S><D><S><D><S><G><Z>     
'mutant Brd2 mRNA'  TCAGTGCTTCTAGTTCCAGCTCAGATTCCAGCTCCTCGTCGTCATCTTCCTCTTCTTCAGACACCAGCGATTCAGACTCGGGCTAAGGGG 
 
                    --------------------------- 
'Brd2 mRNA'         CCAGGCCAGATGGGGCAGGAAGGCTCC 
                                                









Figure 5.4: Brd4 KO-specific DEGs regulate metabolic processes, cellular response to stimuli 
and cardiac muscle contraction. 
ClueGO pathway analysis of 742 Brd4 KO specific DEGs from (Figure 3.34B) (padj<0.05, log2FC±0.5) 
showed GO terms enriched for energy metabolism, response to stimulus, and cardiac muscle 
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